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 “Get tested, get vaccinated; eliminate hepatitis B!” 
The liver is the largest solid organ of the body, generally weighing between 1200 and 1800 
gram in adults.1 As a metabolic centre, the liver’s main function is to filter the blood coming 
from the entire digestive tract, before passing it to the rest of the body.1 The liver also 
operates as a manufacturer of plasma proteins and it has the capacity to detoxify many 
harmful substances.1 Another important function is the role in defense as it harbors innate 
immunological cells. In light of these important functions, it is not surprising that liver 
dysfunction is associated with extensive consequences for the entire body.2 
The number of liver-related deaths in the World Health Organization (WHO) European 
region (n=53 countries) are estimated to be 120,377 in the year 2015, and those are mainly 
attributable to complications such as cirrhosis and hepatocellular carcinoma (HCC).3, 4 The 
burden of liver disease in Europe is expected to continue growing.4 Besides an increased 
risk of mortality, economic impact is high and quality of life is low in patients with chronic 
liver disease.5, 6  
The burden of liver disease in Europe is a reflection of the three most common causes of 
chronic liver disease: alcohol-related liver disease, non-alcoholic fatty liver disease and viral 
hepatitis.7-11 Many patients with chronic liver disease may remain undiagnosed, since there 
may be no signs or symptoms until the complications of cirrhosis and HCC has developed.11 
In this thesis, we focus on hepatitis B virus (HBV) infection that accounts for a substantial 
proportion (29.9%) of liver-related deaths in Europe. 3, 12, 13 Though there is a similar silent 
liver disease progression in HBV infection as in other chronic liver diseases, the availability 
of hepatitis B vaccines since 1982 and antiviral treatment since 1992 represents an 
important opportunity to eliminate hepatitis B by 2030 as advocated by the WHO.14, 15 In 
general, elimination of infectious diseases is defined as a reduction to zero disease incidence. 
For hepatitis B in particular, elimination by 2030 is defined as a 90% reduction in the 
incidence of chronic HBV infection and a 65% reduction in mortality with the rates in year 
2015 as baseline.14 This thesis will address the past, present and future directions of HBV 
infection and control. The general introduction describes our research in this context and 
illustrates the evidence in relation to scientific knowledge at the start of our studies.  
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HEPATITIS B VIRUS  
The observation of the Australia antigen in the serum of an Australian aboriginal was the 
most important exploration to the discovery of HBV in 1967.16, 17  For a brief period, 20 nm 
spheres and filaments with the so-called Australia antigen on their surfaces were mistakenly 
considered to be the infectious virus.18, 19 Soon thereafter, however, electron microscopy 
evaluations revealed 42 nm particles which have a structure more consistent with that of a 
virus.18, 20, 21 The 42 nm particles are now known as Dane particles and the infectious virion 
of HBV with an outer envelope comprised of three related envelope glycoproteins (or 
hepatitis B surface antigen (HBsAg) also known as Australia antigen).18, 22 Within the 
envelope is the nucleocapsid or core, known as hepatitis B core antigen (HBcAg).18, 22 
Internal to this is the viral genome, a partially double-stranded, relaxed-circular DNA, and a 
polymerase that is responsible for the replication of viral DNA in infected cells (Figure 1).18, 
22  
 
Figure 1: The structure of hepatitis B virus. Abbreviations: HBcAg: hepatitis B core antigen; HBsAg: 
hepatitis B surface antigen; S: small, M: medium; L: large; HBeAg: hepatitis B e antigen. (Reprinted 
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Aside from HBsAg and HBcAg, a third antigen, the hepatitis B e antigen (HBeAg), was 
described in 1972.24-26 The development of assays for HBsAg, HBeAg and HBV DNA analysis 
in the early 1980s further allowed a better understanding of the natural history of HBV 
infection.26-29  
In 1985, McMahon et al30 described the relation between age and the likelihood of 
developing icteric hepatitis during acute HBV infection. An estimated 7 – 17% developed 
clinically apparent hepatitis after acute HBV infection at the age of one to four years as 
compared with 29 – 35% for adults.30 The rate of progression from acute to chronic HBV 
infection was also determined by the age at infection. The risk of developing chronic HBV 
infection was estimated at approximately 80 – 90% among infants infected perinatally in 
case of a HBeAg positive mother and less than 5% for an adult-acquired infection.30  
For chronic HBV infection, the natural course was initially divided into a replicative HBeAg-
positive phase and a non-replicative HBeAg-negative phase considering the close relation 
between HBeAg status and viral replication.31, 32 However, the absence of significant liver 
disease in a considerable amount of HBeAg-positive patients in Taiwan re-conceptualised 
chronic HBV infection in three phases: immune-tolerant phase (phase 1), immune-
clearance phase (phase 2) and inactive carrier phase (phase 3).31 33 On the other hand, the 
delineation of patients with signs of liver damage and viral replication in the absence of 
serum HBeAg, advocated the introduction of a fourth phase, i.e. HBeAg-negative chronic 
hepatitis (phase 4).26, 34 Figure 2 illustrates the natural history and new terminology for the 
four chronic HBV infection phases with their characteristic HBeAg status, HBV DNA levels 
and alanine aminotransferase (ALT) levels.7 The new nomenclature is based on the 
description of the two main characteristics of chronicity: infection versus hepatitis. 




Figure 2: Natural history of chronic hepatitis B virus infection divided into four phases. 
Abbreviation: HBV: hepatitis B virus; HBsAg: hepatitis B surface antigen; ALT: alanine aminotransferase; 
HBeAg: hepatitis B e antigen; anti-HBe: antibodies against HBeAg. (Reprinted from: EASL, J Hepatol, 
20177; Copyright: open access article, non-commercial use permitted)  
An ongoing debate in the natural history of chronic HBV infection is the predetermined none 
or minimal liver disease progression in HBeAg-negative chronic infection state (previously 
termed inactive carrier). In the year 2000, the arbitrary cutoff HBV DNA level at 20,000 
IU/mL was chosen for the differentiation between HBeAg-negative chronic infection and the 
progressive HBeAg-negative chronic hepatitis phase because, at that time, hybridization-
based assays could not detect HBV DNA levels < 20,000 IU/mL.35 However, Asian studies 
using high sensitive PCR-based HBV DNA assays in HBeAg-negative patients have 
contributed to our understanding that even low HBV DNA levels (< 20,000 IU/mL) might 
still be associated with the risk of liver disease progression.36-39 Nevertheless,  the risk of 
disease progression and its predictors in the Caucasian population living in Europe are 
unclear. The concept of a favourable long-term prognosis is critically reviewed in chapter 
1. Based on historical data from 1987 onwards, we assessed the long-term outcome of 
HBeAg-negative Caucasian patients with serum HBV DNA level < 20,000 IU/mL and 
persistently normal ALT levels.  
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HEPATITIS B EPIDEMIOLOGY 
Besides an adequate understanding of the natural disease history among the Caucasian 
population living in Europe, it is imperative to elucidate the preceding epidemiological trends 
of HBV infection in furtherance of accurately estimating the current and future disease 
burden. Between 1990 and 2013, global HBV-related deaths increased from 0.5 to 0.7 
million; there was also an increase in disability-adjusted life years (DALY) from 18.1 million  
to 20.6 million13 (Figure 3). This increase might in part be explained by demographic 
changes (e.g. aging, global population increase) and the fact that the vast majority of people  
remain undiagnosed, and many who are diagnosed have advanced liver disease.40 The most 
recent data from WHO indicate that globally 257 million people are living with chronic HBV 
infection and hepatitis B has resulted in 0.9 million deaths in 2015, mostly from serious 
sequelae cirrhosis and HCC.41 In the WHO European Region, hepatitis B causes 36,000 
deaths per year and an estimated 13.3 million individuals live with chronic HBV infection.12 
Although the epidemiological numbers of increasing global hepatitis B-related deaths over 
the years are sobering, they emphasize a crucial opportunity to improve public health given 
that hepatitis B is preventable by means of vaccination.7, 14, 41 Safe and effective hepatitis 
B vaccines are available since 1982 and it is now more than 27 years since the WHO 
recommended all countries to implement universal infant vaccination by 1997.42-44 As of 
2019, 48 of the 53 WHO European countries conduct universal hepatitis B vaccination.45, 46 
The most recent countries to follow the WHO recommendation were Ireland (in 2008), the 
Netherlands (in 2011) and the UK (in 2017).45, 46 Nonetheless, Denmark, Finland, Iceland, 
Norway and Sweden still implement a selective vaccination program targeting groups at risk 
of HBV infection only, instead of adding a universal vaccination program.45  




Figure 3: The absolute number global hepatitis B-related deaths (A) and DALYs (B), by year, 
with 95% uncertainty intervals. Continuous lines represent the mean with dotted lines depicting 2.5th 
percentile and dotted dash lines depicting 97.5th percentile. Abbreviations: DALYs: disability-adjusted life 
years. (Adapted from: Stanaway JD et al, Lancet, 201613; Copyright: open access article, non-
commercial use permitted) 
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The impact of hepatitis B vaccination on acute HBV notification rates in Europe was 
demonstrated by Miglietta et al44: a decrease from 1.6 per 100 thousand persons in 2006 
to 0.7 in 2017, with the most significant decrease in countries with a universal HBV 
vaccination program before 1995 and a vaccine coverage of > 95%.  Of the European 
countries, Belgium, Croatia and Italy were excluded from the study because a distinction 
between acute or chronic HBV cases was not possible.44 As Belgian data before the year 
2009 could not distinguish between acute or chronic hepatitis, in chapter 2 we assessed 
the impact of HBV vaccination and other prevention strategies on surveillance data of the 
acute HBV notification rates in Flanders, Belgium, from 2009 to 2017. 
HEPATITIS B SCREENING 
Considering the fact that universal infant HBV vaccination in most European countries 
started after 1995, an appreciable number of the exposed population may at present 
already been infected with HBV and may remain undiagnosed due to the asymptomatic 
nature of chronic HBV infection until progression to cirrhosis and HCC.44, 47  
Accordingly, the central idea of hepatitis B screening is early disease detection and antiviral 
treatment of undiagnosed eligible patients to prevent HBV-related deaths, prevent the 
onward transmission of HBV and reduce the economic burden of HBV-related complications 
in Europe.48-50 Although the central idea is simple, the path to its successful achievement on 
a national level may be far from simple. For this reason, Wilson and Jungner formulated 
several criteria for a suitable screening which have been revisited in 2008.51 The modified 
criteria are among others: 1) the disease should be an important health problem, 2) there 
should be a suitable test, 3) the availability of treatment, 4) the detection approach should 
be acceptable to the population and 5) the costs of diagnosis and treatment must be in an 
acceptable proportion to the costs of health care as a whole.51  
With regard to the first criterium, hepatitis B is currently acknowledged as an important 
public health problem in the WHO European Region with approximately 13.3 million people 
living with chronic HBV infection and causing about 36,000 deaths per year.12 Considering 
the silent liver disease progression of HBV infection, only 15 – 60% of the patients with 
chronic HBV infection are diagnosed.52, 53 Increasing testing offer and uptake, particularly 
among those at risk, is essential to abide to WHO elimination goals for hepatitis B.14 The 
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WHO stimulates action towards diagnosing 90% of the patients with chronic HBV infection 
and treating 80% of the eligible patients.14  
The prevalence of chronic HBV infection varies depending upon the geographic area from 
<2% in low-prevalence areas (e.g. Western Europe) to 2-8% in intermediate-prevalence 
areas (e.g. Mediterranean region) to >8% in high-prevalence areas (e.g. Sub-Saharan 
Africa) .54-56 The burden of hepatitis B also differs within Europe with a higher prevalence of 
chronic HBV infection in eastern and southern Europe than in countries in the northern and 
western parts.53 Figure 4 illustrates the geographic distribution of HBsAg prevalence 
worldwide. 
 
Figure 4: Geographic distribution of hepatitis B surface antigen prevalence worldwide. 
(Reprinted from: Schweitzer et al, Lancet, 201555; Copyright 2019, with permission from Elsevier)  
Although most countries in Europe have a low prevalence of HBsAg (<2%) in the general 
population, several risk groups for HBV infection have been identified (Table 1). HBV can be 
found in the blood and to a lesser extent in body fluids (e.g. saliva, menstrual, vaginal, 
seminal fluids) of an infected person.57 In low-prevalence areas, HBV is most commonly 
spread in adulthood through sexual contact and injecting drug use.58 In areas with 
intermediate and high prevalence for hepatitis B, HBV infection occurs either from mother 
to child at birth (perinatal transmission), or from horizontal transmission through non-sexual 
close contact, especially from an infected child to an uninfected child during the first five 
years of life.57 Hepatitis B is also spread by needlestick injury, tattooing and body piercing.57  
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Table 1: Groups at risk for hepatitis B virus infection  
Individuals born in intermediate- or high-prevalence areas for HBV infection  
People who have ever injected drugs 
Men who have sex with men, sex workers and other individuals with multiple unsafe sexual 
contacts 
Individuals with abnormal liver blood test results (ALT or AST) of unknown aetiology  
Individuals who received blood, organ or surgery before 1992 or in the setting of suboptimal 
infection control standards 
Predialysis and haemodialysis patients 
Infants born to HBsAg-positive mothers 
Persons with chronic liver disease 
Persons with HIV 
Household, needle-sharing, and sexual contacts of people diagnosed with HBV 
Persons seeking evaluation or treatment for a sexually transmitted infection 
Residents and staff of facilities for intellectual disabled people 
People who were ever incarcerated 
Abbreviations: HBV: hepatitis B virus; ALT: alanine aminotransferase; AST: aspartate aminotransferase; 
HBsAg: hepatitis B surface antigen. (Adapted from: Terrault NA et al, Hepatology, 201859 and European 
Centre for Disease Prevention and Control. Public health guidance on HIV, hepatitis B and C testing in 
the EU/EEA – An integrated approach. Stockholm: ECDC; 201850) 
Serological markers used for screening of HBV infection include HBsAg, hepatitis B surface 
antibody (anti-HBs) and hepatitis B core antibody (anti-HBc).60-62 Serum HBsAg is the 
primary marker of infection.60-62 Chronic HBV infection is defined as the presence of HBsAg 
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Table 2: Interpretation of hepatitis B serologic test results 
HBsAg Anti-HBc Anti-HBs Interpretation 
Negative Negative Negative Uninfected and not immune 
Negative Positive Positive Immune due to past HBV infection 
Negative Negative Positive Immune due to HBV vaccination 
Positive Positive Negative Acute or chronic HBV infection based on the presence 
of HBsAg for at least six months. 
Anti-HBc IgM is a marker of acute infection but may 
also be raised in acute exacerbation of chronic HBV 
infection. 
Anti-HBc IgG is a marker of chronic infection 
Negative Positive Negative Four possibilities: 
Past HBV infection (most common) 
False-positive anti-HBc 
Resolving acute infection 
Low grade chronic infection 
Abbreviations: HBsAg: hepatitis B surface antigen; anti-HBc: hepatitis B core antibody; anti-HBs: 
hepatitis B surface antibody; HBV: hepatitis B virus; IgM: immunoglobulin M; IgG: immunoglobulin G. 
(Adapted from: Terrault NA et al, Hepatology, 201859 and Mast EE, MMWR Recomm Rep, 200562) 
At present, we have serological assays that detect HBsAg at a relatively low cost and are 
therefore suitable for hepatitis B screening conform the second criterium by Wilson and 
Jungner.50, 63 They are available in the form of laboratory-based immunoassay (e.g.  enzyme 
immunoassays) or  rapid diagnostic tests.50, 63 Laboratory-based immunoassays have a 
superior sensitivity and specificity for HBsAg compared to rapid diagnostic tests but require 
laboratory infrastructure and can only be performed on specimen obtained by 
venipuncture.50 On the other hand rapid diagnostic tests do not need laboratory facilities, 
trained laboratory technician and can be performed with blood collected by fingerprick.50, 63 
Disadvantages include the lower sensitivity and specificity, and the current necessity of 





General introduction | 17 
 
 
For a screening program aimed at secondary prevention, the availability of effective 
treatment is inevitable, i.e. the third criterium. At this time, there are two main options for 
the treatment of adults with chronic HBV infection: nucleos(t)ide analogues and pegylated 
interferon-alpha. The nucleos(t)ide analogues include those with high barrier against HBV 
resistance (entecavir, tenofovir disoproxil fumarate and tenofovir alafenamide) and those 
with low barrier to HBV resistance (lamivudine, adefovir dipivoxil and telbivudine).7, 64, 65 The 
long-term administration of a potent nucleos(t)ide analogue with high barrier to resistance 
is the treatment of choice for naïve patients with chronic HBV infection.7 After 5 years of 
treatment with antivirals with high barrier against HBV resistance, undetectable HBV DNA 
is achieved in 97 – 99% of HBeAg-positive persons and 92 – 100% of HBeAg-negative 
persons with a favourable safety profile.7, 64, 65 Long-term viral suppression is associated with 
a significant lower incidence of cirrhotic complications, HCC and liver-related deaths.66, 67 In 
a lower proportion, namely 3.2 – 11.8% of HBeAg-positive patients and in 0.1 – 1.0% of 
HBeAg-negative patients, HBsAg loss, i.e. functional cure, occurs after long-term antiviral 
treatment with potent nucleos(t)ide analogues, thereby preventing HBV transmission.7, 68-70 
In addition to antiviral treatment, newly diagnosed patients with chronic HBV infection are 
advised to inform all first degree relatives and sexual partners to be tested for HBV infection 
and to be vaccinated if they are uninfected and not immune.7, 59, 65 This strategy facilitates 
the prevention of onward transmission. 
With regards to the fourth criterium of Wilson and Jungner ‘the detection approach should 
be acceptable to the population’, several testing strategies have been postulated: testing in 
health care settings (e.g. primary health care settings, hospital settings, other practices), 
community settings and other settings, i.e. self-sampling and self-testing.50 Routine testing 
for HBV infection in health care settings can reduce stigmatisation and can improve testing 
rates in groups at risk for HBV infection.50 Moreover, as patients are generally undergoing 
venipuncture in the health care setting, the additional costs for HBV testing are reduced.50 
However, testing rates are generally low and linkage to care may be inadequate due to lack 
of knowledge and limited time of health care professionals.50, 71-74 In contrast, community-
based hepatitis B testing are offered outside health care facilities and available data suggest 
that community-based testing services may result in high testing rates, high HBsAg positive 
rates in undiagnosed patients and may be effective at reaching groups at risk of HBV 
infection such as migrants from intermediate or high endemic countries.50 
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Regarding the fifth criterium and specifically for migrants originating from intermediate and 
high prevalence areas, it is shown that the costs of diagnosis and treatment of hepatitis B 
are in an acceptable proportion to the costs of health care as a whole.49, 75 However, before 
defining specific target groups for hepatitis B screening, it is advisable to assess HBV risk 
factors on recent national and local epidemiological data. Although recent data are available 
for the neighbouring countries (i.e. the Netherlands, France and Germany), the last 
epidemiological assessment for HBV infection in the general Belgian population dates from 
2002 – 2003.76-78 Since there is also no information on the predominant risk factors for HBV 
infection in Belgium, in chapter 3 we assessed the current prevalence and risk factors of 
HBV infection in a multi-ethnic region situated in Middle Limburg Belgium in 2017.  
Furthermore, in view of the lack of a current national screening program for HBV infection 
in migrants from intermediate or high endemic countries living in Europe, in chapter 4 we 
propose a protocol for community-based hepatitis B testing in the Turkish migrant 
population. After all, Turkey is an intermediate prevalence area with HBsAg prevalence 
ranging from 2 – 8% and with an estimated 97,255 chronic HBV cases among Turkish 
migrants in Europe, they form the third largest migrant population with the highest number 
of chronic HBV cases in Europe.79, 80 Moreover, limited data are available as to the Turkish 
migrant population in Europe since prior studies on hepatitis B testing in the migrant 
population generally involve Asians in the USA, Canada and Australia.81-90 The results of the 
outreach hepatitis B testing in Turkish migrants are subsequently presented in chapter 5. 
In addition to the early detection of patients with chronic HBV infection, the current 
screening program could identify persons who are susceptible to infection and would benefit 
from vaccination.48 
UNRESOLVED PROBLEM IN HEPATITIS B VACCINATION  
Hepatitis B vaccination is recommended within universal vaccination of infants as well as for 
all unvaccinated adults at risk for HBV infection and all adults requesting protection from 
HBV infection.91 Currently licensed hepatitis B vaccines in Europe are safe.92 Primary 
vaccination generally consists of three vaccinations at 0, 1 and 6 months and elicits 
seroprotection (anti-HBs levels > 10 mIU/mL) in 88 – 95% of the general adult 
population.93-95 However, the remaining 5 – 12% of the population with an inadequate 
immune response (anti-HBs level < 10 mIU/mL) are called hepatitis B vaccine non-
responders, remain susceptible for HBV infection and are an unresolved problem in hepatitis 
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B vaccination to reach elimination of hepatitis B. The standard of care for hepatitis B vaccine 
non-responders usually consists of revaccination with licensed hepatitis B vaccines in a  0, 
1, 2 months schedule or a schedule of two co-administered doses followed by another two 
doses after 2 months, which is associated with a seroprotection rate of approximately 50 – 
69%.96-100 Risk factors for non-response include age above 40 years, smoking, obesity, male 
sex, chronic medical condition, genetic factors and immune suppression.91, 101, 102 
In view of these matters, there is a medical need for new more immunogenic hepatitis B 
vaccines that will induce adequate antibody response in this hepatitis B vaccine non-
responder population. Recently, various strategies have been developed to elicit protective 
anti-HBs levels in these hepatitis B vaccine non-responders: increased antigen dose and 
alternative adjuvants, among others (Figure 5).103, 104 In a double-blind, randomized 
controlled trial among healthy Chinese adult non-responders, increasing the antigen dose 
to 60µg HBsAg is associated with a higher seroprotection rate of 92.1% compared to 83.0% 
after three revaccination doses of 10µg HBsAg.104 Compared to standard hepatitis B 
vaccines, higher immunogenic responses are attained in healthy non-responders with 
adjuvanted hepatitis B vaccines Fendrix® and Heplisav-B®.97, 98 However, in Europe, 
Fendrix® is currently only licensed (authorised in 2005) for patients with renal dysfunction 
and not for the healthy non-responder population.105 One should also acknowledge that the 
higher immunogenic response with Fendrix® is not only linked to the adjuvant 3-O-desacyl-
4'-monophosphoryl lipid A but also to the higher antigen content.98 The second adjuvanted 
vaccine Heplisav-B® is for the moment not licensed in Europe.106 
As the currently licensed hepatitis B vaccines in Europe all have an aluminium-based 
adjuvant, we tried to enhance the immune response by adding a cytokine-based adjuvant. 
The new HBAI20 vaccine consists of the standard HBVaxPro©-10 μg vaccine and the AI20 
adjuvant, containing 20 μg recombinant human IL-2 adsorbed to 20 μg aluminium 
hydroxide. In chapter 6, we determined the safety and immunogenicity of this new HBAI20 
hepatitis B vaccine in a phase 1 study in healthy naïve and non-responder population. As 
reported under chapter 7, we further evaluated the immunogenicity and safety of the new 
HBAI20 hepatitis B vaccine among healthy non-responders in a well-designed double-blind, 
randomized controlled phase 2 trial.  
 




Figure 5: Attempts to improve efficacy of hepatitis B vaccine in non-responders. Abbreviations: 
AS04: adjuvant system 04 consisting of aluminium hydroxide and the adjuvant 3-O-desacyl-4'-
monophosphoryl lipid A; CpG: cytidine-phosphate-guanosine oligodeoxynucleotide; AI20: 20 μg 
recombinant human IL-2 adsorbed to 20 μg aluminium hydroxide. 
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RESEARCH OBJECTIVES  
This PhD thesis focuses on the past, the present and future directions in viral hepatitis B in 
Europe. 
In chapter 1, we critically reviewed the expected long-term prognosis in patients with  
HBeAg-negative chronic infection. In a large historical cohort of Caucasian patients living in 
Europe, we specifically assessed whether there is a cut-off value of HBV DNA level that can 
predict those patients who would benefit from a strict follow-up program and those who do 
not require a stringent monitoring.  
To estimate the current HBV disease burden, we further evaluated the effect of prevention 
and control strategies on acute hepatitis B notification rates in Flanders, Belgium, using prior 
data from 2009 – 2017 in chapter 2. 
In chapter 3, we assessed the current prevalence and risk factors of HBV infection in a 
multi-ethnic region situated in Middle-Limburg, Belgium.  
Chapter 4 describes the design of a study to assess the present HBV prevalence in the 
Turkish population living in Belgium.  
In chapter 5, we subsequently report the results of the community-based hepatitis B 
testing in the Turkish population. We also determined the risk factors of HBV infection, 
uptake of HBV screening, vaccination and antiviral treatment in this Turkish migrant 
population.  
Considering the medical need for a more immunogenic vaccine in non-responders, in 
chapter 6 & 7 we determined the safety and immunogenicity of a new HBAI20 hepatitis B 
vaccine in non-responders in respectively a phase 1 and phase 2 study.  
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ABSTRACT  
Background: Sensitive PCR assays to measure HBV DNA became only available the last 
decade. Hence, the long-term outcome of Caucasian patients in Western Europe with 
hepatitis B e antigen (HBeAg)-negative chronic infection, especially with a baseline HBV DNA 
level > 2,000 IU/mL, is still unclear.  
Methods: Out of a cohort of 1,936 chronic HBV patients, 413 Caucasian patients were 
identified with HBeAg-negative chronic infection, defined as persistently normal alanine 
aminotransferase (ALT) levels and HBV DNA levels < 20,000 IU/mL. 
Results: During a mean follow-up of 12 years, 366 (88.6%) maintained a HBeAg-negative 
chronic infection status, whereas 25 (6.1%) developed chronic active hepatitis (CAH). Nine 
of these 25 CAH cases were related to  immunosuppression. Twenty-two (5.3%) individuals 
had ALT > 2 x ULN due to non-HBV related causes.  The cumulative probability of 
spontaneous developing CAH after 10 years was almost exclusively seen in patients with 
baseline HBV DNA level > 2,000 IU/mL (11.7% vs 1.2%, p < 0.001). Advanced liver disease 
developed significantly more in patients with baseline HBV DNA level > 2,000 IU/mL (5.2% 
vs 1.5%, p = 0.018) and occurred especially in patients with obesity (16.7% vs 4.2% p = 
0.049). The incidence of  hepatocellular carcinoma was 0.0%. 
Conclusion: Caucasian patients with HBeAg-negative chronic infection and baseline HBV 
DNA level of < 2,000 IU/mL have an excellent long-term prognosis in the absence of 
immunosuppressive therapy. However, patients with baseline HBV DNA level > 2,000 
IU/mL are at risk to develop advanced liver disease.  
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INTRODUCTION 
Infection with hepatitis B virus (HBV) remains a global health challenge with approximately 
257 million people living with chronic HBV infection, of whom 887,000 die annually from 
HBV-related complications such as cirrhosis and hepatocellular carcinoma (HCC).57 The 
natural history of chronic HBV infection can be divided in four phases, taking into account 
the presence of hepatitis B e antigen (HBeAg), serum HBV DNA levels and serum alanine 
aminotransferase (ALT) values.7, 59, 65  
One of these phases is the HBeAg-negative chronic infection state.7 This stage was 
previously called ‘inactive carrier’ phase, but this terminology was abandoned since previous 
studies indicated that some of these patients develop advanced liver disease.7  
According to current management guidelines on hepatitis B, therapy is not indicated in 
patients with HBeAg-negative chronic infection but follow-up for risk of HBV reactivation, 
advanced liver disease and HCC is recommended.7, 59, 65 Most evidence on the natural history 
of HBeAg-negative chronic infection is based on studies in Asian patients, wherein the high 
sensitivity of polymerase chain reaction (PCR)-based HBV DNA assays have contributed to 
our understanding that even low HBV DNA levels may still be associated with the risk of liver 
disease progression.36, 107, 108 However, only a limited number of studies have assessed the 
risk of disease progression and its predictors in Caucasian patients. Previous European 
studies on the natural history of patients in the chronic infection phase were limited by the 
short duration of follow-up (less than 10 year follow-up), small groups of patients  (< 200 
subjects), poorly defined criteria for HBeAg-negative chronic infection and the use of the low 
sensitivity branched HBV DNA assays for quantification.109-119  
Recent sensitive PCR assays to measure HBV DNA have demonstrated that in general, 
patients with HBeAg-negative chronic infection have HBV DNA levels < 2,000 IU/mL. 
However, some patients in this phase have HBV DNA levels between 2,000 and 20,000 
IU/mL.7, 59 The risk of liver disease progression is unclear in this subgroup of Caucasian 
patients with baseline HBV DNA levels > 2,000 IU/mL.  
This is the first long-term follow-up study of more than 10 years in HBeAg-negative 
Caucasian patients making use of the high sensitive PCR-based assays. The main objectives 
were to investigate the disease outcome of those with HBV DNA levels > 2,000 IU/mL and 
to find out whether a cut-off value of serum HBV DNA level of 2,000 IU/mL can predict those 
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PATIENTS AND METHODS 
The study involved three large educational hospitals, two in Belgium and one in the 
Netherlands. The data were to be collected according to a protocol that followed the 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement 
with clear definitions of the study population, follow-up and outcome data. 
STUDY POPULATION 
The study identified all consecutive chronic HBV patients of the participating centres between 
1 January 1987 and 31 July 2018 who fulfilled the following inclusion criteria: (1) Caucasian 
race, (2) persistence of HBsAg for at least one year, (3) the presence of antibodies to HBeAg 
(anti-HBe) without HBeAg, (4) low or undetectable HBV DNA (< 20,000 IU/mL), (5) 
persistently normal ALT levels, defined as > three ALT determinations (< 40 IU/L) at least 
two months apart over a period of at least 12 months and (6) follow-up at the enrolling 
centre for a minimum period of 12 months. Patients previously treated with HBV antiviral 
agents were excluded as well as HBsAg-positive patients with prophylactic administration of 
antiviral therapy. Other exclusion criteria were: (1) signs of significant fibrosis (F2 based on 
transient elastography values > 9.0 kPa or liver biopsy), (2) patients with hepatitis D or HIV 
co-infection, (3) a history of significant alcohol consumption based on a threshold of 14 units 
per week in men and 7 units per week in women8 and (4) evidence of coexisting liver disease 
(e.g. non-alcoholic steatohepatitis (NASH), autoimmune hepatitis). 
FOLLOW-UP 
The observation period was calculated from the date of presentation until death or the last 
visit at the outpatient clinic. At the first visit in the outpatient clinic, a complete history was 
taken, a physical examination was conducted, liver disease activity and severity were 
assessed including markers of HBV infection (e.g. HBeAg and anti-HBe, HBV DNA).7 
Biochemical parameters and an abdominal ultrasound were recommended in all patients. 
Patients were  monitored with periodical determinations of serum ALT and HBV DNA levels 
as well as for liver stiffness by transient elastography from 2006 onwards. Liver biopsy was 
not routinely advised and only performed in case of suspected advanced liver disease (based 
on laboratory results, abdominal ultrasound and/or transient elastography) and in the 
suspicion of a concomitant liver disease.7  Results from transient elastography and liver 
biopsies were evaluated according to the METAVIR classification.120  
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DEFINITION OF CLINICAL EVENTS 
The primary outcome was the development of chronic active hepatitis (CAH), defined by 
increased ALT levels to more than twice the upper limit of normal (ULN) on two occasions 
at least two weeks apart with HBV DNA levels > 2,000 IU/mL whether or not with HBeAg 
reversion.7, 59, 65 Increased ALT levels > 2 x ULN that could not be classified as CAH were 
designated as non-HBV related cause.121  
According to the report of the Baveno VI Consensus Workshop, advanced liver disease was 
suspected on transient elastography values > 10 kPa.122 The development of cirrhosis was 
defined as a clinical syndrome consisting of either histological confirmation of cirrhosis or 
ultrasonographic findings of cirrhosis.115 Cirrhosis was further classified according to the 
Child-Pugh score.123 HCC diagnosis was based on non-invasive criteria (positive lesion 
detected by at least two different imaging techniques) or pathology.115 Additionally, this 
study evaluated the incidence of mortality and liver-related mortality. 
IMMUNOSUPPRESSIVE TREATMENT 
This study also assessed whether patients who developed a CAH were exposed to 
immunosuppressive or cancer chemotherapy. The immunosuppressive therapies were 
classified into those with low (e.g. azathioprine), moderate (cyclosporine) and high (e.g. 
rituximab, high-dose corticosteroids, infliximab) risk of reactivation as previously outlined 
by Loomba and Liang.124 CAH resulting from immunosuppressive therapy was considered 
up to 6 months after cessation of immunosuppression, and in the case of B-cell depleting 
drugs (e.g. rituximab) as late as 12 months post-treatment.125  
LABORATORY PROCEDURES 
ALT and viral markers (HBsAg, antibodies to HBsAg (anti-HBs), HBeAg, anti-HBe, hepatitis 
C and D virus antibodies, anti-HIV) were determined using conventional serological assays. 
Serum samples at baseline were stored at -20°C. Up to 2002, serum HBV DNA levels were 
analysed on stored serum samples with the branched DNA signal amplification assay 
(Chiron Diagnostics, Emeryville, CA) lower limit of detection of 0.7 mEq/mL (7.00 x 105 
IU/mL). Thereafter, HBV DNA quantification was performed by ABI Prism 7900HT (Applied 
Biosystems, Thermo Fisher Scientific, Waltham, MA) with a detection limit of 100 IU/mL and 
from 2015 on by a commercial PCR assay (Abbot RealTime HBV assay, Abbott Molecular 
Inc, Des Plaines, IL) with a sensitivity of 10 IU/mL. Serum qHBsAg was measured on the 
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Elecsys HBsAg II quant (Roche Diagnostics, Penzberg, Germany) or Architect HBsAg QT 
(Abbott Diagnostics, IL, USA) assay. 
STATISTICAL ANALYSIS 
Statistical analysis was performed with the SPSS software version 25 (IBM Corp, Armonk, 
NY).  Continuous variables are expressed as means + standard deviation (SD) or medians 
+ interquartile range (IQR) as appropriate. For the comparison of categorical variables, 
either the Chi-square test or the Fisher’s exact test was used. The Student’s t test or Mann-
Whitney U nonparametric test was used to analyse continuous variables between two 
independent groups. The level of statistical significance was set at p < 0.05 in two-tailed 
tests. 
Estimates on the rate of CAH and advanced liver disease were calculated using the Kaplan-
Meier method, and the difference was determined using the log-rank test. Univariate 
analyses (log-rank tests) to identify variables associated with CAH or advanced liver disease 
included age at diagnosis (< 40 vs > 40 years), sex (male vs female), obesity (yes vs no), 
baseline ALT level (low-normal < 0.5 x ULN vs high-normal 0.5 – 1 x ULN), baseline 
quantitative HBsAg (qHBsAg) level (< 1,000 IU/mL vs > 1,000 IU/mL) and baseline HBV 
DNA level (< 2,000 IU/mL vs > 2,000 IU/mL).  
ETHICAL APPROVAL 
Following the Belgian law of the 7th of May 2004, an approval of an ethics committee is not 
necessary for a retrospective non-interventional study. 
 
  
30 | Chapter 1   
 
RESULTS 
Out of 1,936 patients with chronic HBV infection at baseline, we identified 413 Caucasians 
with HBeAg-negative chronic infection according to in- and exclusion criteria of this study 
(Figure 1.1). The baseline characteristics of the 413 included Caucasian patients are 
presented in Table 1.1. The mean age at presentation was 34 + 13.6 years; 210 (50.8%) 
were males and 81 (19.6%) had a baseline HBV DNA level > 2,000 IU/mL. Additional 
information on qHBsAg level was available in 146/413 (35.4%) patients. In patients with 
detectable viremia in which genotyping could be performed: 36/61 (59.0%) had a genotype 
A and 25/61 (41.0%) a genotype D.  
 
Figure 1.1: Study flowchart. Abbreviations: ALT: alanine aminotransferase; ULN: upper limit of 
normal; HBV: hepatitis B virus; HBeAg: hepatitis B e antigen; CAH: chronic active hepatitis; ALD: 
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Table 1.1: Baseline Characteristics of 413 Caucasian patients with hepatitis B e antigen 
negative chronic infection. A total of 366 individuals remained HBeAg-negative chronic infection, 25 
















Baseline Age (years) 34 + 13.6 36 + 12.2 33 + 14.2 0.866 
Sex, males (%) 210 (50.8) 181 (49.5) 15 (60.0) 0.308 
Obesity†, (%) 32 (7.7) 27 (7.4) 1 (4.0) 0.711 
Baseline ALT, (IU/L) 24 + 8.1 23 + 8.4 26 + 7.1 0.214 
Baseline qHBsAg 
level, (IU/mL)‡,§ 
360 + 1,667.0 362 + 1,613.9 291 + 3,350.0 0.617 
Baseline HBV DNA, 
(log IU/mL) ‡ 
   HBV DNA > 2,000                     
IU/mL, (%) 
2.5 + 3.12 
 
81 (19.6) 
2.5 + 3.10 
 
64 (17.5) 






Values shown as mean + standard deviation or as n (%). Abbreviations: HBeAg: hepatitis B e antigen; 
CAH: chronic active hepatitis B; ALT: alanine aminotransferase; ULN: upper limit of normal; qHBsAg: 
quantification of hepatitis B surface antigen; HBV: hepatitis B virus. †Obesity was defined as BMI > 30 
kg/m2. ‡Mann-Whitney U nonparametric test was used instead and medians + interquartile range (IQR) 
were shown as appropriate.  §Information on qHBsAg was available in 151/413 (36.6%), 130/366 
(35.5%) and 11/25 (44.0%) among all study patients, patients who remained HBeAg-negative chronic 
infection and those with CAH development, respectively. 
CHRONIC ACTIVE HEPATITIS 
During a mean follow-up of 12 + 8.3 years, 366 (88.6%) of the 413 patients maintained 
HBeAg-negative chronic infection, whereas 25 (6.1%) developed CAH. The remaining 22 
(5.3%) individuals had ALT level > 2 x ULN of non-HBV related cause (e.g. nonalcoholic 
fatty liver disease (NAFLD), medication use, malignant infiltration). Out of the 25 patients 
with CAH, 9 were considered to be the result from immunosuppressive therapy or cancer 
chemotherapy. Five patients received immunosuppressive therapy with a moderate risk of 
hepatitis B reactivation, i.e. two patients were the result from post-kidney transplant 
immunosuppression and three were in the setting of cancer treatment. In addition, three 
patients with lymphoma received rituximab containing regimens and one subject was 
treated with high-dose (> 20 mg orally daily) corticosteroids for rheumatic disease. Thus, 
the prevalence of spontaneous development to CAH in the study population was 16/404 
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(4.0%) (Figure 1.1). The cumulative probabilities of CAH development were 1/283 (0.4%), 
7/196 (3.6%) and  8/131 (6.1%) at 5, 10, and 15 years follow-up, respectively.  
In univariate analyses (log-rank tests) among the 404 Caucasian patients, baseline HBV 
DNA level > 2,000 IU/mL (11.7% vs 1.2%, p < 0.001) and qHBsAg level > 1,000 IU/mL 
(7.1% vs 1.0%, p = 0.015) were the only factors significantly associated with the 
occurrence of CAH.  Figure 1.2 shows the cumulative probabilities of spontaneous CAH 
development in two groups, i.e. baseline HBV DNA levels < 2,000 IU/mL and those with 
baseline HBV DNA levels > 2,000 IU/mL. Among patients with baseline HBV DNA level > 
2,000 IU/mL (n = 77),  qHBsAg level > 1,000 IU/mL identified patients with a higher risk 
to develop CAH (p = 0.002): it was 28.6% for patients with a qHBsAg level > 1 000 IU/mL 
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Time (years)  0 1 2 3 5 10 15 20 
Baseline HBV DNA  level  77 75 65 59 52 27 18 13 
> 2,000 IU/mL  
CAH development - 0 0 0 1 4 1 2 
Censored  - 2 10 6 6 21 8 3 
Time (years)  0 1 2 3 5 10 15 20 
Baseline HBV DNA level  327 326 294 272 229 161 104 57 
< 2,000 IU/mL  
CAH development - 0 0 0 0 1 0 2 
Censored  - 1 32 22 43 67 57 45 
Figure 1.2: Cumulative probabilities of spontaneous chronic active hepatitis development by 
baseline hepatitis B virus DNA level (n = 404). A total of 404 Caucasian patients with HBeAg-
negative chronic infection were analysed after excluding 9 individuals with immunosuppression-related 
CAH occurrence. Among this group, progression to CAH was higher in patients with baseline HBV DNA 
level > 2,000 IU/mL than in patients with baseline HBV DNA level < 2,000 IU/mL (p < .001, log-rank 
test). Cumulative probabilities of CAH were 1/53 (1.9%) vs 0/229 (0.0%), 5/32 (15.6%) vs 1/162 
(0.6%), 6/24 (25.0%) vs 1/105 (1.0%) at 5, 10, and 15 years follow-up, respectively. Abbreviations: 
HBV: hepatitis B virus; CAH: chronic active hepatitis; HBeAg: hepatitis B e antigen. †Patients were 
censored on the date of last outpatient clinic visit. 
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FOLLOW-UP OF SERUM HBV DNA LEVELS AND HBSAG 
Longitudinal follow-up of serum HBV DNA levels revealed that HBV DNA levels exceeded 
2,000 IU/mL in 151/404 (37.4%) Caucasian patients during follow-up versus 77/404 
(19.1%) at baseline and that 35/404 (8.7%) patients developed a HBV DNA level > 20,000 
IU/ml. Spontaneous HBsAg loss occurred in 0.94 per 100 persons-years. The cumulative 
incidences of HBsAg loss were 9/291 (3.1%), 19/206 (9.2%) and 32/145 (22.1%) at 5, 10, 
and 15 years follow-up, respectively. HBsAg loss was 11.5% in the group with HBV DNA 
level < 2,000 IU/mL and 4.9% in those with HBV DNA > 2,000 IU/mL, p = 0.080. In the 
group of patients with HBsAg loss (n = 42), anti-HBs appeared in 29 (69.0%) patients. The 
cumulative appearances of anti-HBs for 1, 2, 5 and 10 years were 5.1% (2/39), 13.2% 
(5/38), 40.0% (14/35) and 59.4% (19/32). 
CLINICAL OUTCOME 
A total of 73 (18.1%) out of the 404 Caucasian patients underwent percutaneous liver 
biopsy during follow-up on suspicion of progressive liver disease. Histologically proven 
advanced liver disease was present in 5/73 (6.8%) patients. Overall, the cumulative 
probabilities of advanced liver disease were 0/285 (0.0%), 2/195 (1.0%) and 4/127 (3.1%) 
at 5, 10 and 15 years of follow-up, respectively. 
Risk predictors for advanced liver disease in the univariate analyses (log-rank tests) among 
the 404 patients were male sex (3.9% vs 0.5%, p = 0.029) and baseline HBV DNA level > 
2,000 IU/mL (5.2% vs 1.5%, p = 0.018). Among patients with baseline HBV DNA level > 
2,000 IU/mL (n = 77), obesity was associated with a higher risk of advanced liver disease 
(16.7% vs 4.2% p = 0.049). In the group of patients with baseline HBV DNA level < 2,000 
IU/mL (n = 327), none of the variables were significantly associated with a lower risk of 
progression to advanced liver disease. Figure 1.3 illustrates the progression to advanced 
liver disease in patients with baseline HBV DNA level < 2,000 IU/mL against those with 
baseline HBV DNA levels > 2,000 IU/mL. 
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Time (years)  0 1 2 3 5 10 15 20 
Baseline HBV DNA level  77 76 66 60 53 29 17 11 
> 2,000 IU/mL  
Advanced liver disease - 0 0 0 0 2 1 1 
Censored  - 1 10 6 7 22 11 5 
Time (years)  0 1 2 3 5 10 15 20 
Baseline HBV DNA level  327 326 296 274 231 163 105 58 
< 2,000 IU/mL  
Advanced liver disease - 0 0 0 0 0 1 2 
Censored  - 1 30 22 42 68 57 45 
Figure 1.3: Cumulative probabilities of progression to advanced liver disease by baseline 
hepatitis B virus DNA level (n=404). After excluding 9 individuals with HBV reactivation due to 
immunosuppressive therapy, progression to advanced liver disease was higher in patients with baseline 
HBV DNA level > 2,000 IU/mL than in patients with baseline HBV DNA level < 2,000 IU/mL (p = .018, 
log-rank test). Cumulative probabilities of advanced liver disease were 0/53 (0.0%) vs 0/231 (0.0%), 
2/31 (6.5%) vs 0/163 (0.0%), 3/20 (15.0%) vs 1/106 (0.9%) at 5, 10 and 15 years follow-up, 
respectively. Abbreviations: HBV: hepatitis B virus; HBeAg: hepatitis B e antigen. †Patients were 
censored on the date of last outpatient clinic visit. 
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Six out of 404 patients (1.5%) developed cirrhosis. Five had Child-Pugh score A and one 
died due to acute-on-chronic liver failure. There were no reports of HCC. The mean age of 
the patients with cirrhosis was 39 + 10.3 years. The mean time to cirrhosis development 
was 17 + 4.5 years.  
A total of 381/404 (94.3%) were alive at the end of follow-up. Death occurred in 23 (5.7%) 
patients and among four of them reason of death was unknown. In the remaining 19 
patients, there was one liver-related mortality reported. Malignant neoplasms were the 
leading cause of death, accounting for nine cases of death. Chronic obstructive pulmonary 
disease, myocardial infarction, pneumonia, end-stage renal disease and enteric fever 
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DISCUSSION 
The term ‘inactive carrier’ for patients with HBeAg-negative chronic infection was abandoned 
as Asian studies demonstrated that even low HBV DNA levels may still be associated with 
the risk of liver disease progression.36, 107, 108 The introduction of sensitive PCR-based HBV 
DNA assays over the last decade have demonstrated that most patients with HBeAg-
negative chronic infection have HBV DNA levels < 2,000 IU/mL. However, some patients in 
this phase might  have HBV DNA levels between 2,000 and 20,000 IU/mL. 7, 59 Considering 
the fact that sensitive PCR to measure HBV DNA levels only became available the last 
decade, this is the first study to assess the 10 years or more disease outcome of Caucasian 
patients in Western Europe with HBeAg-negative chronic infection based on stringent criteria 
and the use of sensitive PCR-based HBV DNA assays. 
Only few other studies in the past have addressed the follow-up of HBeAg-negative 
Caucasian patients with persistently normal ALT levels and HBV DNA levels < 20,000 IU/mL 
based on sensitive PCR assay.109, 111, 112, 117, 118 Limited by a short follow-up time varying 
from 1 to 5 years, none had developed cirrhosis and no HCC or liver-related mortality was 
reported in these studies. These studies were also hampered by the small number of study 
participants (n = 35 - 195).  
In studies with a longer follow-up, the prevalence of cirrhosis varied widely from 0.4-
17.5%.113-116 Correlation between baseline HBV DNA level and worse prognosis was not 
evaluated in these studies.113-116 Moreover, in the prior studies patients’ serum HBV DNA 
level was quantified by an insensitive hybridization method. Hence, some patients may have 
been misclassified as HBeAg-negative chronic infection without use of PCR-based assays.  
That the level of viremia can be important has been illustrated in the REVEAL study in Asian 
patients. There was an increased risk of cirrhosis, HCC and liver-related mortality in HBeAg-
negative patients with baseline normal ALT level and HBV DNA level > 2,000 IU/mL.36  
There are only a few studies that have addressed the issue of CAH development in 
Caucasian HBeAg-negative patients with persistently normal ALT values and HBV DNA 
levels below 20,000 IU/mL on sensitive PCR-based assays.109, 110, 112, 118 With a limited 
follow-up between 1 – 5 years, the overall prevalence of progression to CAH in these studies 
was 0.0% in patients with HBV DNA level < 2,000 IU/mL and varied widely from 0.0% to 
50.0% in those with HBV DNA level > 2,000 IU/mL. Our finding of spontaneous progression 
to CAH over 10 years was 1.2% and 11.7% in those patients with baseline HBV DNA level 
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< 2,000 IU/mL and HBV DNA level > 2,000 IU/mL, respectively. This is lower than 
previously reported and could be ascribed to differences in study population, follow-up 
duration and the use of different criteria for CAH.109, 110, 112, 118 Moreover, the number of 
patients with baseline HBV DNA level > 2,000 IU/mL in the previous studies was small (n 
= 4 – 46). 109, 110, 112, 118 In the current cohort, 81 patients had a baseline HBV DNA level > 
2,000 IU/mL.  In line with our findings, Papatheodoridis et al110 confirmed the relation 
between baseline HBV DNA level > 2,000 IU/mL and the risk of HBV reactivation in patients 
in Greece. 
Recent data have shown that hepatitis B surface antigen quantification might be helpful in 
the decision on the frequency of follow-up in such patients.7, 59, 65, 126 However, this test is 
not routinely available in daily practice. In line with prior studies, our patients - in which we 
could do this test - had a median qHBsAg level < 1,000 IU/mL and qHBsAg level could 
identify patients at higher risk of progression in the subgroup with baseline HBV DNA level 
> 2,000 IU/mL.112, 126  
As a consequence of the growing obesity epidemic, more and more chronic HBV patients 
with co-existing NASH are expected.127 NASH is an independent risk factor for cirrhosis and 
HCC, and in our study obesity was also a risk factor for advanced liver disease among those 
patients with baseline HBV DNA level > 2,000 IU/mL.127  
We could also confirm that CAH was triggered by immunosuppressive therapy or cancer 
chemotherapy. In that respect, we found that immunosuppression was associated with the 
development of CAH in more than one third of the patients, underlying the importance of 
screening for hepatitis B prior to starting immunosuppressive therapies.7, 59, 65   
CONCLUSION 
In conclusion, Caucasian patients from Western Europe with HBeAg-negative chronic 
infection and baseline HBV DNA levels < 2,000 IU/mL have a favourable condition without 
any risk of HCC and with a cumulative incidence of HBsAg loss of approximately 10% they 
can be considered as inactive carriers. This in contrast to patients with baseline HBV DNA 
levels > 2,000 IU/mL who are, especially in the presence of obesity, at  risk for  advanced 
liver disease.  
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ABSTRACT  
Background: Belgium is a low-endemic country for hepatitis B. Universal hepatitis B 
vaccination in infants with catch-up in the age cohort of 10-13 year-olds began in 1999. Our 
objective was to evaluate the effect of prevention and control strategies on acute hepatitis 
B notification rates in Flanders (Belgium) from 2009 to 2017. 
Methods: This observational study collected demographic data and risk factors for acute 
hepatitis B from mandatory notifications to the Agency for Care and Health. 
Results: In Flanders, acute hepatitis B notification rates per 100,000 population decreased 
from 1.6 in 2009 to 0.7 in 2017. These rates declined in all age groups: 0-4-year-olds: 0.6 
to 0.0, 5-14-year-olds: 0.2 to 0.0, 15-24-year-olds: 0.8 to 0.7, 25-34-year-olds: 3.4 to 1.1 
and ≥ 35-year-olds: 1.59 to 0.7. There was also a downward trend in acute hepatitis B 
notification rates in native Belgians and first-generation migrants. Among 15-24-year-olds 
and 25-34-year-olds, a possible reversal of the decreasing trend was observed in 2016 and 
2015, respectively. Among 548 acute hepatitis B cases, the main route of transmission was 
sexual activity (30.7%), and the pattern of transmission routes over time showed an 
increasing proportion of sexual transmission in men who have sex with men (MSM) after 
2014. During the period from 2009 to 2017, five mother-to-child transmissions were 
reported. 
Conclusion: Prevention and control strategies were effective in reducing the acute hepatitis 
B notification rate. However, stronger prevention and control measures are needed in adult 
risk groups, particularly MSM.  
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INTRODUCTION 
Hepatitis B is caused by the hepatitis B virus (HBV), a member of the Hepadnaviridae family 
that infects liver cells, potentially causing liver cirrhosis and hepatocellular carcinoma.128 
Although most acute HBV infections are self-limiting, ca 0.1–0.5% of patients will develop 
fulminant hepatitis. Only 7–17% of 0–4-year-olds develop clinically apparent hepatitis after 
acute infection with HBV, compared with 29–35% for adults 30 years or older.30, 129 In 
addition to the relation between age and clinical hepatitis, there is a relation between age at 
infection and the likelihood of subsequently becoming a chronic hepatitis B patient. The risk 
of developing chronic HBV infection is estimated at 80–90% among infants infected 
perinatally if the mother is positive for hepatitis B e antigen, and this risk decreases with 
increasing age at infection.30, 129  
HBV is widely prevalent and it is estimated that ca 2,000 million people have been exposed 
to the virus, with 257 million people living with chronic HBV infection worldwide.128 In 2015, 
up to 887,000 deaths resulted from complications of hepatitis B, making it together with 
hepatitis C virus infection the 7th leading cause of mortality globally.13, 128 In Europe, the 
burden of hepatitis B differs by geographical region. Countries in eastern and southern 
Europe have a higher prevalence of chronic HBV infection than countries in the northern and 
western parts.53 Belgium is classified as a country of low HBV endemicity, with ca 0.7% of 
the population positive for hepatitis B surface antigen (HBsAg).130-132  
In Belgium, hepatitis B vaccine has been on the market since the 1982, yet universal free-
of-charge vaccination only began in September 1999. Initially, infants received three 
consecutive doses from age 3 months, whereas adolescents received catch-up vaccination 
for the age cohort with the age range of 10–13 years. Since 2004, infants have been 
vaccinated with a hexavalent vaccine against diphtheria, tetanus, pertussis, hepatitis B, 
poliomyelitis and Haemophilus influenza type B at the ages of 8, 12 and 16 weeks and 15 
months.133, 134 The catch-up vaccination in adolescents was concluded in 2012, as infants 
vaccinated in 1999 reached target age for adolescent vaccination in 2011 and 2012. 
Reimbursement for hepatitis B vaccination in other birth cohorts is foreseen for certain 
patient groups (e.g. patients with haemophilia, pre-dialysis and dialysis patients, individuals 
with mental disabilities and first-degree relatives of a chronic hepatitis B patient), healthcare 
workers and employees who have an occupational risk for HBV infection. Hepatitis B 
vaccination is recommended but not reimbursed for the following groups: travellers to 
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countries with intermediate or high HBV endemicity and specific HBV risk groups (e.g. men 
who have sex with men (MSM), sex workers, illicit drug users, patients with sexually 
transmitted infections (STI), individuals with multiple sex partners and patients with chronic 
liver disease). 
In Belgium, there is endorsement for harm reduction programmes including peer support, 
opioid substitution therapy to reduce the frequency of injecting drugs and needle and 
syringe exchange programmes offering sterile injecting material for people who inject 
drugs.135 Both healthcare workers and patients are encouraged to adhere to universal 
preventive methods and standard precautions to avoid exposure with HBV. There is also 
general advice to avoid unsafe sexual contacts through the use of condoms. 
Strategies for screening have also been adopted. In Belgium, voluntary blood donors have 
been screened for HBV since 1972. Belgium has also had an antenatal HBV screening 
strategy since 2004 which is recommended during the first trimester of the pregnancy.136 
Children of HBsAg-positive mothers should receive the first hepatitis B vaccine together with 
a dose of 300 international units (IU) of hepatitis B immunoglobulins at birth.137 
The aim of the current study was to assess the impact of the above prevention and control 
strategies on acute hepatitis B notification rates in Flanders, Belgium. As the Belgian 
registration of hepatitis B did not make a distinction between acute or chronic hepatitis B 
until 2009, the main goal was to assess the trend in acute hepatitis B notifications from 
2009 to 2017.  
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METHODS 
STUDY DESIGN  
This observational study collected information on acute cases of viral hepatitis B in the period 
from 2009 to 2017 from the mandatory notifications to the Agency for Care and Health 
(Flanders). In Flanders, hepatitis B has been notifiable since 1971, and information collected 
by the Agency for Care and Health includes diagnosis, basic demographic data (e.g. age, 
sex and country of birth), clinical features, serological test results and risk factors for 
infection on the date of diagnosis. Before 2009, a differentiation between acute or chronic 
hepatitis B was not possible. Since then, only acute hepatitis B has been reported by 
mandatory notifications from both laboratories and physicians to the Agency for Care and 
Health (Flanders). 
OUTCOME MEASURES  
The primary study endpoint was the assessment of the overall trend in acute hepatitis B 
notification rates in Flanders from 2009 to 2017. Secondary and exploratory endpoints were 
the acute HBV notification rates by age, sex and country of birth. We also assessed the main 
routes of transmission among our study population of acute hepatitis B cases. 
CASE DEFINITION  
In our criteria for differentiating acute and chronic hepatitis B, patients with the appropriate 
symptoms and signs (e.g. jaundice, elevated serum aminotransferase levels, abdominal 
pain, loss of appetite, nausea, vomiting, fatigue or fever) and laboratory confirmation were 
identified as definite acute hepatitis B cases.138 Laboratory confirmation included (i) a 
positive test for HBsAg and anti-HBc IgM, (ii) detection of HBsAg and negative HBsAg in the 
6 months before presentation which are routinely reported if available or (iii) detection of 
HBV DNA and negative for HBV DNA in the 6 months before presentation which are routinely 
reported if available.138 In line with the European Union case definitions, unknown cases 
were identified as newly diagnosed HBsAg-positive individuals with the appropriate 
symptoms and signs but without IgM determination or previous markers for HBV 
infection.138 
NOTIFICATION RATES AND VACCINATION COVERAGE  
According to the population data from Statistics Belgium (StatBel), the total population in 
Flanders increased from 6,208,877 in 2009 to 6,516,011 in 2017.139 Acute hepatitis B 
notification rates from 2009 to 2017 were calculated per 100,000 population and were 
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based primarily on the total number of acute hepatitis B notifications, i.e. the sum of definite 
and unknown acute HBV cases. Age groups were categorised as 0–4, 5–14, 15–24, 25–34 
and ≥ 35 years on mid-decade to mid-decade. The ≥ 35-year-olds were individuals not 
covered by the universal hepatitis B vaccination with catch-up in children aged 10–13 year 
in Flanders. Based on the country of birth, infected persons were identified as Belgian or as 
first-generation migrants (FGM), i.e. born outside Belgium. FGM were grouped according to 
the six World Health Organization (WHO) regions: Africa, the Americas, the Eastern 
Mediterranean, Europe, South East Asia and the Western Pacific.55 
In this study, vaccination coverage data for infants and adolescents in Flanders were 
obtained from an extended programme of immunisation-based surveys.140-144 For 
calculating the influence of prevention and control strategies on the age distribution of acute 
hepatitis B patients over time, we stratified notification rates into two time periods, 2009–
12 and 2013–17. The cut-off was chosen to balance the time covered, and 2012 was the 
end of the catch-up period for adolescents. 
STATISTICAL ANALYSIS  
Binary data were analysed using chi-squared test or Fisher’s exact test. Comparison of two 
continuous variables was done with the independent t-test or Mann–Whitney U-test, 
depending on the presence of normality and homogeneity. Results are presented either as 
frequencies (%) or as means (standard error of mean (SEM)). The level of statistical 
significance was set at p < 0.05. 
ETHICAL STATEMENT  
Following Belgian regulation, ethical approval was waived because of the non-interventional 
character of our study.  
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RESULTS 
OVERALL TREND  
Acute hepatitis B notification rates decreased by 2017 to 42%, 40% and 55% of the 2009 
rate for, respectively, the total number of cases, definite cases and unknown cases (Figure 
2.1). The hepatitis B incidence for the total number of cases in Flanders declined from 1.56 
per 100,000 population in 2009 to 0.77 per 100,000 population in 2013 and 0.66 per 
100,000 population in 2017. For definite and unknown cases, the respective incidences were 
0.85 and 0.71 per 100,000 population in 2009, 0.58 and 0.19 per 100,000 population in 
2013, and, 0.34 and 0.32 per 100,000 population in 2017. Reported hepatitis B vaccination 
coverage among infants between 1999 and 2017 is also presented in Figure 2.1. In infants, 
coverage with three doses of hepatitis B vaccine exceeded 90% from the 2005 survey 
onwards in Flanders. In adolescents, the HBV vaccination coverage was below 90% up to 
2017 (Figure 2.1). 
 
Figure 2.1: Acute hepatitis B notification rates, 2009–2017 (n = 548) and coverage with a 
complete hepatitis B vaccine schedule, 1999–2017, Flanders. Definite cases were defined as 
patients with the appropriate symptoms/signs and laboratory confirmation, i.e. a positive test for HBsAg 
and anti-HBc IgM, detection of HBsAg and negative markers in the 6 months before presentation or 
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detection of HBV DNA and negative HBV markers in the 6 months before presentation. Unknown cases 
were defined as HBsAg-positive patients with the appropriate symptoms/signs without IgM 
determination or previous markers for HBV infection. Total cases are the sum of definite cases and 
unknown cases. Estimates on vaccination coverage in infants for the period 2000–2004 were based on 
survey results from 1999. Survey results from 2005, 2008, 2012 and 2016 were used to determine 
vaccination coverage in infants and adolescents for the periods 2006–07, 2009–11, 2013–15 and 2017. 
AGE AND SEX  
Notification rates by age groups from 2009 to 2017 are presented in Figure 2.2. The rates 
in 2009 for age groups 0–4, 5–14, 15–24, 25–34 and ≥ 35 years were 0.59, 0.15, 0.82, 
3.35 and 1.59 per 100,000, respectively. In the period 2009 to 2017, the data clearly show 
that the trend in hepatitis B notification rates was decreasing for all age groups. The 
notification rates in 2017 for the 0–4, 5–14, 15–24, 25–34 and ≥ 35 year-olds were 0.00, 
0.00, 0.68, 1.12 and 0.74 per 100,000, respectively. There was an increase in incidence 
among those aged 15–24 years and 25–34 years in 2016 and 2015, respectively. 
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Figure 2.3 shows the age distribution of acute hepatitis B notifications in the periods 2009 
to 2012 and 2013 to 2017. There was a decrease in the proportion of 15–24 year-olds from 
6.4% between 2009 and 2012 to 5.2% between 2013 and 2017 (p = 0.597). For the 25–
34 year-olds, this was 22.9% and 14.3%, respectively (p = 0.015). Moreover, the mean 
age of the acute hepatitis B cases in the period 2009 to 2012 was significantly lower than in 
the period 2013 to 2017 (43.0 ± 0.99 years vs 46.6 ± 0.96 years; p = 0.013).  
 
Figure 2.3: Proportion of acute hepatitis B cases by age group in 2009–2012 and 2013–2017, 
Flanders (n = 548) 
Notification rates for male and female cases in 2017 were 0.99 and 0.33 per 100,000, 
respectively. The rates in adolescents and young adults were slightly higher among women, 
whereas men had higher rates than women in the age groups 25 years and older. Acute 
hepatitis B notification rates in 2017 were highest among 25–34-year-old men (Figure 2.4). 
This age group had the highest rate difference between male and female cases (1.73 and 
0.50 per 100,000 in 2017, respectively). 
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Figure 2.4: Acute hepatitis B notification rate per 100,000 population by age group and sex, 
Flanders, 2017 (n = 43) 
The notification rates for male and female cases were, respectively, 2.14 and 0.86 per 
100,000 in 2009 and 1.05 and 0.50 per 100,000 in 2013. In the age group 25 years and 
older, the notification rates in men remained higher than in women throughout the study 
period (data not shown). 
COUNTRY OF BIRTH  
Country of birth data were available for 455 of 548 (83.0%) acute hepatitis B cases. Among 
those 455 individuals, 360 (79.1%) were born in Belgium. Among FGM, 51 (53.7%) 
originated from the WHO European Region (13 from Turkey, eight from Romania and 30 
from 16 other countries), 17 (17.9%) from the WHO African Region (three from Ghana and 
14 from 10 other countries), 15 (15.8%) from the WHO Eastern Mediterranean Region (five 
from Morocco, four from Afghanistan and six from six other countries), six (6.3%) from the 
WHO South East Asian Region (three from Indonesia and three from two other countries) 
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The age structure between native Belgians and FGM was different, namely 16 (4.4%) vs 16 
(16.8%) 0–24-year-olds (p < 0.001), 61 (16.9%) vs 31 (32.6%) 25–34-year-olds 
(p < 0.001) and 283 (78.6%) vs 48 (50.5%) ≥ 35-year-olds (p < 0.001). Figure 2.5 
illustrates a downward trend over time in acute hepatitis B notification rates in native 
Belgians as well as in FGM. The incidence of acute hepatitis B was higher among FGM and 
the gap between the two groups increased after 2013. 
 
Figure 2.5: Acute hepatitis B notification rate per 100,000 population by country of birth, 
Flanders, 2009–2017 (n = 455) 
ROUTES OF TRANSMISSION  
Information on routes of transmission was available in 213 (38.9%) of the 548 acute 
hepatitis B notifications. Over the time period from 2009 to 2017, the main route of 
transmission for acute hepatitis B was sexual activity in 168 cases (78.9%), of whom the 
majority did not specify sexual interest (78/168, 46.4%). Forty-nine (29.2%) of 168 
individuals reported heterosexual activity and 41 (24.4%) reported male homosexual 
activity. Intravenous drug use accounted for eight (3.8) of the 213 cases (Table 2.1). Table 
2.1 also illustrates the routes of transmission by country of birth. All five (2.3%) reported 
mother-to-child transmissions occurred in Belgium. Transmission through sexual activity 
was more common in men than in women (131/162 (80.9%) vs 37/51 (72.5%), 
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p = 0.300), and 41 (25.3%) were MSM. The routes of transmission for acute hepatitis B 
cases over time are illustrated in Figure 2.6. In particular, an increasing trend of male 
homosexual transmission was apparent from 2014 onwards. 
Table 2.1: Routes of transmission for acute hepatitis B cases, Flanders, 2009–2017 (n = 213) 









n % n % n %  
Intravenous drug use 8 3.8 5 2.9 3 12.5 0.067 
Sexual 16 78.9 13 79.4 16 66.7 0.097 
  Heterosexual 49 23.0 42 24.7 5 20.8 0.618 
  Male homosexual 41 19.2 35 20.6 2 8.3 0.176 
  Sexual, unspecified 78 36.6 58 34.1 9 37.5 0.838 
Mother-to-child 5 2.3 3 1.8 0 0.0 1.000 
Invasive healthcare 
procedure/dental 
7 3.2 5 2.9 2 8.3 0.220 
Blood 
transfusion/transplantation 
3 1.4 3 1.8 0 0.0 1.000 
Needle injury or other 
occupational exposure 
3 1.4 3 1.8 0 0.0 1.000 
Tattooing/body piercing 3 1.4 2 1.2 1 4.2 0.337 
Other 16 7.5 14 8.2 2 8.3 1.000 
FGM: first-generation migrants. Information on routes of transmission was not available in 335 of 548 
(61.1%) overall, in 190 of 360 (52.8%) native Belgians and 71 of 95 (74.7%) FGM. 
 




Figure 2.6: Pattern of transmission routes for acute hepatitis B notifications, Flanders, 2009–
2017 (n = 548) 
Compared with native Belgians, FGM were more frequently infected abroad (21/285 with 
known information on place of transmission and country of birth (7.4%) vs 20/61 (32.8%); 
p < 0.001). Among the 20 FGM infected abroad, 16 were infected while travelling in their 
country of birth. Among the individuals who acquired acute HBV infection abroad (44/398 
with known information on place of transmission; 11.1%), 36 acquired it in an intermediate 
or high HBV-endemic country: 15 in the WHO European Region, 11 in the WHO South East 
Asian Region, four in the WHO African Region, three in the WHO Western Pacific Region, 
two in the WHO Eastern Mediterranean Region and one in the WHO Region of the Americas. 
It was reported that 40 individuals acquired HBV infection by heterosexual transmission in 
Belgium and six abroad. For male homosexual and unspecified sexual transmission, the 
numbers were 32 vs four and 59 vs six, respectively.  
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DISCUSSION 
The acute hepatitis B notification rates in Flanders Belgium decreased from 2009 to 2017 in 
all age groups (0–4 years, 5–14 years, 15–24 years, 25–34 years and ≥ 35 years). Since 
universal infant vaccination started in 1999, notification rates for 5–14-year-olds from 2013 
onwards represent age groups that received universal infant vaccination, which may explain 
the decline in acute hepatitis B notification rates after 2013 in this age group. Moreover, the 
downward trend in 15–24- and 25–34-year-olds indicates the birth cohorts 1987 to 1998 
who were covered by universal catch-up vaccination in this low-prevalence country where 
sexual activity is recognised as the most important exposure for HBV infection.145 
The effects of a universal HBV vaccination programme in infants with catch-up in 
adolescents were also evaluated on serum samples collected in 2006 and 2007 from 
children aged 1–19 years by Theeten et al.134 They demonstrated that the prevalence of 
HBV infection remained low in Belgium and that overall high levels of vaccine-induced 
immunity were achieved in infants as well as in adolescents. 
Although the infant hepatitis B vaccination coverage for the three doses increased above 
90% after 2004, the continuing downward trend in acute hepatitis B notification rates in 
≥ 35-year-olds from 2009 to 2017 cannot be explained by universal infant and toddler 
vaccination with catch-up in adolescents. For this, an explanation should be explored in the 
vaccination and health behaviour of certain patient groups (e.g. dialysis patients), 
healthcare workers, those with occupational risk of HBV infection, travellers to intermediate 
or high HBV-endemic countries, patients with STI and sex workers in Belgium. However, 
there is no information on the uptake of vaccination in adults aside from Belgian studies in 
sex workers, healthcare workers, travellers to intermediate or high HBV-endemic countries 
and pregnant women.146-151 In order to eliminate hepatitis B as a public health threat by 
2030 as recommended by WHO, recent studies are warranted to evaluate hepatitis B 
prevention and control measures, particularly in adult risk groups such as MSM and patients 
with STI.152 
Moreover, relatively higher notification rates of acute hepatitis B were observed in adults 
than in children, emphasising the importance of raising the awareness of healthcare 
workers, policymakers and the general public about stronger prevention and control 
measures targeting the adult group. These numbers could be ascribed to (i) vaccination 
uptake and/or (ii) sexual transmission being the most important infection route for hepatitis 
B in a low-prevalence country and/or (iii) the relation between age and clinical hepatitis.129, 
134, 145  
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By 2018, 191 of 194 (98%) WHO member states had introduced universal infant or 
childhood hepatitis B vaccination. This is a substantial increase compared with the year 2000 
where only 129 (66%) countries had included hepatitis B vaccination in their national 
universal immunisation system.153 In this context, we found that acute hepatitis B 
notification rates declined also in FGM, not only in native Belgians. However, the reduction 
in acute hepatitis B cases among FGM was smaller than among native Belgians; therefore, 
the number of FGM with acute hepatitis B could have limited the overall decreasing trend of 
acute hepatitis B cases found in the current study. Our findings are in line with a previous 
study indicating that the estimated number of vaccinated people is lower for FGM than for 
native Belgians.130 In view of the increase in hepatitis B incidence among FGM in 2017, it 
should be noted that this trend could possibly continue after 2017. There is currently no 
screening programme targeting this group, although vaccination is recommended but not 
reimbursed for immigrants travelling back to their endemic country of birth. New infections 
among adult FGM and their relatives could be prevented. 
After 2013, the decline in hepatitis B incidence was less pronounced. This could possibly be 
related to the bimodal pattern of immunisation coverage with the highest proportion of 
vaccinated individuals in the birth cohorts targeted by the vaccination programme (1999–
2002 and 1987–1989) with a clear dip in between.134 Moreover, there was a possible 
reversal of the decreasing trend for 15–24-year-olds and 25–34-year-olds in 2016 and 
2015, respectively. This could in part be ascribed to a rise in the number of cases among 
MSM. Notification rates by sex indicated that rates were higher in men with the highest rate 
difference in 25–34-year-olds, i.e. 1.23 per 100,000 population. Higher rates of HBsAg 
positivity among men have been described in several European countries.154-156 Sex 
differences could be attributed to higher risk behaviour among men, particularly MSM. In 
the current study, male homosexual activity was reported as route of transmission in 25% 
of men.  
Sexual activity as the most important exposure and source of transmission is well 
recognised in other low-prevalence countries.145 The observed low proportion of people who 
inject drugs (PWID) among the cases might be a result of decrease in heroin users in the 
country, needle and syringe exchange programmes or vaccination of PWID and their close 
contacts. Unfortunately, these data are not available in Belgium. During study follow-up, 
five mother-to-child infections were reported despite the recommendation of antenatal HBV 
screening in pregnant women, highlighting the need to strengthen their registration for HBV 
infection. A study conducted in Antwerp, Belgium indicated that HBsAg screening results 
were available at the moment of delivery for only 28% of the women who gave birth in 
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2010.146 It is crucial to be aware of the hepatitis B status of the mother as the child, in case 
of HBsAg positivity of the mother, will very likely be infected perinatally and with high risk 
of developing chronic hepatitis.137, 157 In line with the WHO recommendation, hepatitis B 
vaccination and immunoglobulins should be provided to the newborn within 24 hours if 
antenatal screening detects HBV infection, which in 94% is effective in preventing mother-
to-child transmission.137, 158  
Limitations of our study are intrinsic to the surveillance system in Flanders, i.e. the number 
of actual acute hepatitis B rates could be underestimated because of under-reporting and 
underdiagnosis. However, the acute hepatitis B notification rates from 2009 to 2017 in 
Flanders showed a downward trend. In the European Union, the average annual acute 
hepatitis B notification rate between 2006 and 2014 was 1.0 per 100,000 population.44 The 
surveillance data for acute hepatitis B notification rates in Flanders were therefore 
comparable with other European countries, although direct comparison between countries 
is not possible considering the heterogeneity in acute hepatitis B case definitions and 
reporting systems. It should also be noted that the available surveillance data do not permit 
comparison of hepatitis B incidence before and after the introduction of universal hepatitis 
B vaccination. It is indeed not possible to distinguish the specific impact of hepatitis B 
vaccination from that of other prevention and control measures. Data on transmission 
routes were missing in 61% and in 17%, country of birth was unknown. The absence of 
these data could reduce statistical power and as missing data are random, we could consider 
randomness as not producing bias. 
CONCLUSION 
Acute hepatitis B notification rates decreased in all age groups and declined from 1.56 per 
100,000 population in 2009 to 0.66 in 2017. This may in part be explained by the universal 
vaccination in infants with catch-up in 10–13-year-olds, which can have a positive impact 
among adolescents and adults. The possible reversal of the decreasing trend for 15–24- and 
25–34-year-olds in 2016 and 2015, respectively, could largely be explained by an increase 
in cases in MSM, demanding stronger prevention and control measures in adult risk-group.  
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ABSTRACT 
Background: The hepatitis B virus (HBV) prevalence study performed in 2003 in Belgium 
is believed  to be underestimating HBV prevalence due to underrepresentation of the non-
Belgian population. Therefore, we assessed the prevalence and risk factors of HBV infection 
in a multi-ethnic region situated in Middle-Limburg Belgium, in 2017. 
Methods: Between May and November 2017, blood samples and questionnaires were 
taken from patients who presented at the emergency department of a large educational 
hospital. Blood samples were tested for hepatitis B surface antigen (HBsAg) and hepatitis B 
core antibodies (anti-HBc). A sample size of 1,000 persons was required to obtain a 
representative sample of the general Middle-Limburg population.  
Results: Of the 1,131 patients screened, the overall HBsAg prevalence was 0.97% with 
differences between Belgians (0.67%) and first-generation-migrants (2.55%), (p = .015). 
Five (45.5%) out of 11 HBsAg positive individuals were not aware of their HBV status.  All 
five (100%) newly diagnosed HBsAg positive patients had further clinical evaluation and all 
had a normal level of alanine-aminotransferase. The prevalence of anti-HBc was 8.4%, and 
was significantly associated with age-gender-ethnicity interaction, presence of HBV infected 
household member, hepatitis C virus infection, men who have sex with men, and 
haemodialysis. 
Conclusions: In this area with large immigrant populations, we found a higher prevalence 
of HBV infection compared to the nationwide study of 2003.  National HBV screening for 
first-generation migrants is needed as this high-risk group will go unnoticed due to the 
possible incorrect interpretation of normal alanine-aminotransferase values.   
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INTRODUCTION 
Hepatitis B virus (HBV) remains a global health problem given that an estimated two billion 
people have been exposed to this virus and 257 million people live with chronic HBV infection 
worldwide in the year 2017.41 Since the onset of HBV infection is generally asymptomatic, 
many of the HBV infected patients may not be aware of their infection status, thereby 
increasing the likelihood of infecting others.159 Chronic HBV infection was also responsible 
for up to 887,000 deaths in 2015, making it together with hepatitis C virus (HCV) infection 
the 7th leading cause of mortality worldwide.13, 41 
The prevalence of chronic HBV varies upon the geographic distribution, from high-
prevalence areas (>8% hepatitis B surface antigen (HBsAg) positive), to intermediate-
prevalence areas (2-7% HBsAg positive) and low-prevalence areas (<2% HBsAg 
positive).160 Western Europe is among the low-prevalence areas, but subgroups of higher 
HBV prevalence may exist in regions with large immigrant populations. Even though 
migrants comprise only one in 20 European citizens, they account for one in four of all 
chronic HBV infections. In Belgium, 52% of chronic HBV cases are estimated to be among 
migrants from intermediate- and high-prevalence areas. This number is even >70% in 
countries such as Austria, Ireland, the Netherlands and United Kingdom.79 
Both prevalence studies in Flanders (Belgium), one in 1993-1994 and one in 2003, showed 
that 0.7% of the population was HBsAg positive.130, 131 However, the prevalence of chronic 
HBV infection in the population-based study in 2003 is believed to be an underestimation 
due to underrepresentation of the non-Belgian population.  Moreover, there are no data 
regarding the predominant risk factors for HBV infection in the Belgian general population. 
The recognized risk factors of HBV infection include having an HBsAg positive mother, 
HBsAg positive close family member, HBsAg positive sex partner, multiple (unsafe) 
heterosexual contacts, men who have sex with men (MSM), intravenous drug use (IDU), 
blood or blood-product transfusion, haemodialysis, invasive healthcare procedure or dental 
treatment and tattooing or body piercing.161  
Even in low-prevalence areas such as Belgium, HBV prevention and control is a public health 
priority, particularly since safe and effective vaccines are available. In addition to primary 
prevention, recent advancements in the treatment of chronic HBV infection now allow 
secondary prevention.162, 163  
Since chronic HBV infections are often asymptomatic, sero-epidemiological studies are 
needed (1) to understand the extent and importance of this public health problem, (2) to 
identify population subgroups with an increased prevalence of infection and (3) to foresee 
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its future impact on the health system and ensure an adequate allocation of financial 
resources. 
The aim of the present study was to evaluate the current prevalence and risk factors of HBV 
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METHODS 
STUDY POPULATION AND SAMPLE DESIGN  
This epidemiological study was conducted in a multi-ethnic region of about 240,803 
inhabitants in the region of Middle-Limburg between May and November 2017. All patients 
between the age of 18 and 70 who presented at the emergency department of a large 
educational hospital were eligible for this study. Upon written informed consent, a blood 
sample was taken and a face-to-face questionnaire, assessing demographics (age, gender, 
country of birth, mother’s country of birth), known viral hepatitis status (HBV positive, HCV 
positive, HIV positive), and risk factors was performed. These risk factors included having 
an HBsAg positive close family member, multiple (unsafe) sexual contacts, MSM, IDU, blood 
or blood-product transfusion, haemodialysis, invasive healthcare procedure or dental 
treatment (i.e. surgery), healthcare worker, cultural or ritual intervention, and tattooing or 
body piercing. Immigrants who were not born in Belgium were considered first-generation 
migrants (FGMs). 
Trained personnel collected a blood sample for serological testing for each patient. The 
Ziekenhuis Oost-Limburg laboratories tested all blood samples for HBsAg and hepatitis B 
core antibodies (anti-HBc) using an electrochemiluminescence assay (Cobas 8000 e602, 
Roche, Germany). The interpretation of positive and negative results was carried out as 
recommended by the test producer. 
The culturally targeted, multilingual (Dutch-, English- and Turkish-speaking) first author 
attempted to contact persons with HBsAg positive results via telephone one week after their 
screening. At least six attempts at three different times of the day were made. Persons not 
reached within six months were considered lost to follow-up.  The first author encouraged 
and invited all newly diagnosed HBsAg positive patients to enter an Outpatient Hepatology 
Department. A clinical work-up and treatment program was proposed for newly diagnosed 
patients based on European Association for the Study of the Liver (EASL) guidelines.7  
ETHICAL APPROVAL AND TRIAL REGISTRATION  
The study was approved by the local Medical Ethical Committees (16/072U), and was 
conducted in accordance with the provisions of the Declaration of Helsinki and its 
amendments. Good clinical practice guidelines were followed throughout the study. The 
study is registered at clinicaltrials.gov (NCT03425513).  
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STATISTICAL ANALYSES  
Sample size calculation was performed with the aid of Epi Info (Version 7.2.1.0, Atlanta, 
GA). The number of patients needed per ethnicity was calculated so that the results of the 
sample group agreed with those of the Middle-Limburg population with a confidence interval 
of 95%.  The expected frequency for FGMs was 21% (Limburg in cijfers, personal 
communication). The sample size calculation suggested a total of 1,000 tested persons 
would need to be included. 
Survey data were entered bed-side into a secure electronic database Castor EDC (Castor 
Electronic Data Capture, Ciwit Bv, Amsterdam, the Netherlands). Analysis of variance 
(ANOVA) was used to test for differences in mean age and prevalence between different 
ethnic groups.  
For calculating the effect of universal HBV vaccination in Belgium, we stratified HBsAg and/or 
anti-HBc prevalence into two birth cohorts (born before 1987 and born after 1987). The 
cutoff was chosen as the vaccination program since September 1999 with catch-up 
vaccination for one age cohort with the age range of 10-13 years covered children born after 
1987.133  
In order to correct for differences between the sample and the Middle-Limburg population, 
weighted tests were conducted. Weighting was done based on the combination of age and 
ethnicity (Belgian vs. non-Belgian (i.e. FGM)).164 Weighted chi squared tests were used to 
assess significant associations between the evaluated risk factors and HBsAg or anti-HBc 
prevalence. Risk factors that were shown to be significantly associated (p < .10) to HBsAg 
or anti-HBc in these univariate analyses were included in a weighted multiple logistic 
regression model. In these models, Firth’s bias adjustment was used to account for data 
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Several classification methods were also applied to the data on anti-HBc positivity for 
prediction purposes. First, a simple classification tree was constructed based on an almost 
completely balanced training dataset (i.e. 40% of the subjects were anti-HBc positive) to 
identify characteristics that explain the outcome in the best way. Bagging and random 
forests were then used in an attempt to improve the error rate of this classification tree. 
Since the predictions based on (almost) balanced data overestimated the true proportion of 
anti-HBc positives, a correction was made.166 The classification models were then compared 
to the weighted logistic regression model in terms of prediction accuracy. Data analyses 
were performed using RStudio (Version 1.0.136, Boston, MA). 
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RESULTS 
CHARACTERISTICS OF THE STUDY POPULATION  
Of the 1,537 individuals invited, 1,131 (73.6%) completed the questionnaire and donated 
blood. The study included 605 men (53.5%) and 526 women (46.5%), with a mean age of 
46 years (95% CI 45.2-46.9 years). FGMs comprised 20.8% of the study population. FGMs 
were mainly born in the Netherlands (32.8%), Turkey (18.7%), and Italy (12.3%). Gender 
distribution was similar in both ethnic groups (Belgian and FGM, p = .629). When compared 
to the Belgian patients (mean age of 46 years, 95% CI 45.0-46.9 years), FGMs (mean age 
of 47 years, 95% CI 44.8-48.3 years) were not significantly older (p = .536). 
Patients who refused participation had a mean age of 48 years (95% CI 43.3-46.3 years) 
and 52.1% were male. This did not significantly differ from patients willing to participate (p 
= .135 and p = .699 for age and gender, respectively). Reasons for not participating were: 
fear of needles (14.5%), too sick (26.9%), other worries than testing (27.3%), does not 
want to know viral hepatitis status (8.1%), already participating in a lot of studies (0.3%), 
and other (22.9%). 
PREVALENCE OF ANTI-HBC ANTIBODIES 
In two patients, blood sample volumes were insufficient for testing and in 22 patients, no 
anti-HBc blood sample was taken. Anti-HBc positivity was 8.4% among the remaining 1,107 
participants. Anti-HBc prevalence in Belgian individuals born after 1987 was 1.6%. This 
number was higher for those born before 1987 (7.0%, p = .001). Current or past HBV 
infection in FGMs was apparent in 49/231 (21.2%) with differences in those born in the 
Netherlands (5/75, 6.7%), Turkey (16/44, 36.4%), Italy (8/28, 28.6%), other low endemic 
countries (2/30, 6.7%) and other intermediate or high endemic countries (18/54, 33.3%), 
p < .001. In the weighted chi squared tests, age-gender-ethnicity interaction (p < .001), 
not shown in table), living with an HBV infected person (p < .001), HCV infection (p = .004), 
MSM (p = .001), blood transfusion before 1972 (p = .026), haemodialysis (p < .001), 
cultural or ritual intervention (p = .015) and having a tattoo or body piercing (p = .041) 
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Table 3.1:  Prevalence of anti-HBc by different risk factors (weighted chi squared test) 






Overall 93 1107 8.40 -- -- 
Gender 
   Men 










.659 0.94 (0.62–1.44) 
Age group 
   18-39 years 










.015 2.16 (1.30–3.60) 
Ethnicity 
   Belgian 















   Yes  










<.001 4.24 (1.99–9.04) 
HCV infection 
   Yes  










.004 4.09  
(0.93-14.17) 
HIV infection 
   Yes  










.298 2.74  
(0.06-28.08) 
Multiple (unsafe) sexual contacts 
   Yes 










.203 0.70 (0.42–1.16) 
MSM 
   Yes 
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Abbreviations: anti-HBc: hepatitis B core antibodies; OR: odds ratio; CI: confidence interval; FGM: first-
generation migrants, i.e. foreign-born persons;; HBV: hepatitis B virus; HCV: hepatitis C virus; MSM: 
men who have sex with men; IDU: intravenous drug use. 
 
IDU 
   Yes  










.479 1.84  
(0.41–8.33) 
Blood transfusion before 1972 
   Yes  










.026 4.44  
(0.85–23.18) 
Haemodialysis 
   Yes 










<.001 6.72  
(2.74–16.48) 
Surgery  
   No 
   Yes, before 1990 
   Yes, in a non-Western country 























   Yes  










.478 0.75 (0.41–1.38) 
Cultural or ritual intervention 
   Yes 










.015 2.21 (1.24–3.96) 
Tattooing or body piercing 
   Yes 










.041 0.60 (0.37–0.98) 
Non-hygienic tattoo 
   Yes 










.415 1.49 (0.62–3.58) 
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Since only 2 out of 7 patients that have had a blood transfusion before 1972 were anti-HBc 
positive, this risk factor was not included in any further analyses. Parameter estimates of 
the weighted multiple logistic regression model are shown in Table 3.2. It can be seen that, 
compared to 18-39 years old Belgian females, there was a significantly increased risk of 
anti-HBc positivity in all FGMs, as well as in 40-70 years old Belgian females (p = .039). 
Young Belgian males had a lower risk of anti-HBc positivity, although not statistically 
significant. Furthermore, living with an HBV infected person (p < .001), reporting HCV 
infection (p = .005), being on haemodialysis treatment (p < .001), and being MSM (p = 
.002) appeared to be associated with a higher risk of anti-HBc positivity. 








(intercept)  -3.98 0.51 <.001 -- 
Female, 18-39yrs, FGM 44 (10) 2.60 0.71 <.001 13.41 (3.41 – 68.37) 
Male, 18-39yrs, Belgian 160 (2) -0.71 0.81 .380 0.49 (0.07 – 2.47) 
Male, 18-39yrs, FGM 34 (5) 1.91 0.84 .023 6.75 (1.06 – 38.55) 
Female, 40-70yrs, Belgian 245 (17) 1.15 0.56 .039 3.16 (1.17 – 13.36) 
Female, 40-70yrs, FGM 61 (14) 2.67 0.72 <.001 14.47 (3.64 – 74.29) 
Male, 40-70yrs, Belgian 312 (22) 1.08 0.55 .051 2.94 (1.10 – 12.33) 
Male, 40-70yrs, FGM 92 (20) 2.51 0.67 <.001 12.26 (3.45 – 59.72) 
Household HBV 38 (10) 1.84 0.46 <.001 6.30 (2.44 – 15.38) 
HCV infection 15 (4) 1.79 0.63 .005 5.96 (1.49 – 19.16) 
MSM 15 (5) 2.16 0.69 .002 8.69 (2.02 – 34.52) 
Haemodialysis 22 (8) 1.88 0.52 <.001 6.58 (2.15 – 17.60) 
Abbreviations: anti-HBc: hepatitis B core antibodies; S.E.: standard error around the coefficient for the 
constant; OR: odds ratio; CI: confidence interval; yrs: years; FGM: first-generation migrants, i.e. foreign-
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ANTI-HBC CLASSIFICATION MODELS  
In growing the classification tree, only the risk factors that were shown to be significantly 
associated (p < .10) to anti-HBc prevalence (in the weighted chi squared tests) were used 
as input (except for having received a blood transfusion before 1972, for the same reason 
mentioned above). The obtained classification tree is shown in Figure 3.1. The predictive 
accuracy of this tree was 73.0% based on the ROC curve (see solid line in Figure 3.2), with 
a sensitivity of 57.1% and specificity of 80.1%. The predictive accuracy was also calculated 
for the weighted logistic regression model, giving a predictive accuracy of 77.5% with a 
sensitivity and specificity of 68.8% and 77.8%, respectively. From Figure 4.2 it can be 
concluded that the weighted logistic regression model using Firth’s bias adjustment 
performed best in predicting anti-HBc prevalence in this study. 
 
Figure 3.1: Classification tree based on (almost) balanced training sample for anti-HBc.  A ‘0’ 
indicates anti-HBc negative, while a ‘1’ indicates anti-HBc positive. Abbreviation: anti-HBc: hepatitis B 
core antibodies; FGM: first-generation migrants, i.e. foreign-born persons; HCV: hepatitis C virus; HBV: 
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Figure 3.2: Comparison of different classification models for anti-HBc using ROC curves for 
which the AUC is used to quantify the predictive accuracy. In an attempt to reduce the tree 
misclassification error, bagging was applied. All risk factors were included and B=400 trees were grown. 
Class weights were used to correct for the (almost) balanced training sample. The predictive accuracy of 
this model however was only 55.7% (see dashed line).  For the random forest model, at each iteration 
12 randomly sampled risk factors were included and B=5000 trees were grown. Class weights were 
again used. The predictive accuracy of this model was slightly higher than for bagging, i.e. 55.9% (see 
dotted line). The six most important variables from the random forest (RF) analysis were included in a 
logistic regression model (see grey dotted line), which had a predictive accuracy of 73.6%, still lower 
than for the abovementioned weighted logistic regression model (77.5%, see dot-dashed line). 
Abbreviation: anti-HBc: hepatitis B core antibodies; ROC: receiver operating characteristic; AUC: area 
under the ROC curve; RF: random forest. 
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PREVALENCE OF HBSAG  
Of the 1,131 patients tested, 11 (1.0%) were HBsAg positive. Five (45.5%) HBsAg positive 
patients were born in Belgium, two (18.2%) in Italy, one (9.1%) in Turkey and three 
(27.2%) in other intermediate or high endemic countries (one in Saudi Arabia, Iran, and 
Kenya), p = .136. None of the HBsAg positive patients were younger than 30 years of age 
(born after 1987) compared to 11 HBsAg positive patients born before 1987, p = .282. The 
HBsAg prevalence in FGMs was 2.55% (6/235), with differences in those born in the 
Netherlands (0/77, 0.0%), Turkey (1/44, 2.27%), Italy (2/29, 6.9%), other low endemic 
countries (0/30, 0.0%) and other intermediate or high endemic countries (3/55, 5.5%), p 
= .285. 
Table 3.3 shows the prevalence of HBsAg by different risk factors. In the weighted chi 
squared tests, HBsAg positivity was significantly associated with ethnicity (p = .015), having 
an HBV infected household member (p = .036), MSM (p = .016), and tattooing or body 
piercing (p = .077). Logistic regression was not conducted for HBsAg due to the low number 
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Table 3.3: Prevalence of HBsAg by different risk factors (weighted chi squared test)                         






Overall 11 1131 0.97 -- -- 
Gender 
   Men 










.744 1.38 (0.42–4.56) 
Age group 
   18-39 years 










.581 1.53 (0.41–5.81) 
Ethnicity 
   Belgian 













   Yes  













   Yes  













   Yes  












Multiple (unsafe) sexual contacts 
   Yes 










.498 1.39 (0.40–4.77) 
MSM 
   Yes 
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IDU 
   Yes  











Blood transfusion before 1972 
   Yes  












   Yes 













   No 
   Yes, before 1990 
   Yes, in a non-Western country 




























   Yes  










.572 0.47 (0.06–3.73) 
Cultural or ritual intervention 











.846 1.00 (0.13–7.88) 
Tattooing or body piercing 
   Yes 










.077 0.20 (0.03–1.55) 
Non-hygienic tattoo 
   Yes 












Abbreviations: HBsAg: hepatitis B surface antigen; OR: odds ratio; CI: confidence interval; FGM: first-
generation migrants, i.e. foreign-born persons; HBV: hepatitis B virus; HCV: hepatitis C virus; MSM: men 
who have sex with men; IDU: intravenous drug use. 
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LINKAGE TO CARE  
Of the 11 HBsAg positive individuals, five (45.5%) were not aware of their HBV status and 
the other six (54.5%) were already linked to care.  Thus, the percentage of newly diagnosed 
HBsAg positive patients was 0.44% (5/1131). All five (100%) patients had further clinical 
evaluation which revealed that all had a normal level of alanine aminotransferase (ALT <40 
U/L), all were hepatitis B e antigen (HBeAg) negative, all had HBV DNA levels below 2,000 
IU/mL, all had fibrosis score F0-1 according to Metavir score, and none had evidence of liver 
cirrhosis on ultrasound. One of the five patients is currently being treated prophylactically in 
the Outpatient Hepatology Department before and during the administration of 

















76 | Chapter 3  
 
DISCUSSION 
This is the first study to assess the seroprevalence of HBV infection in a multi-ethnic Belgian 
region including a considerably large proportion of foreign-born individuals. Besides 
estimating the seroprevalence in a multi-ethnic region, risk factors associated to HBV 
infection were evaluated, which may assist physicians, public health practitioners and 
policymakers in eliminating hepatitis B as a public health threat by 2030.14 
The principal findings of the present study can be summarized as follows. First, there was 
an overall HBsAg seroprevalence of 1.0%, with higher prevalence in FGMs (2.55%) 
compared to Belgians (0.7%). Second, none of the HBsAg positive patients were born after 
1987. Third, an anti-HBc prevalence of 8.4% was found in the multi-ethnic region situated 
in Middle-Limburg with age-gender-ethnicity interaction, having an HBV infected household 
member, reporting HCV infection, being MSM, and ever having been on haemodialysis 
treatment being significantly associated with past or current HBV infection. Fourth, this study 
demonstrated an excellent linkage to care with five out of 11 (45.5%) HBsAg positive 
individuals not being aware of their HBV status and further clinical evaluation showing 
normal levels of alanine-aminotransferase in all five patients. 
In this study, about 1.0% of all patients appeared to be HBsAg positive and 8.4% showed 
evidence of HBV exposure. Until now, the overall prevalence in Belgium was estimated to 
be lower, i.e. 0.7% positive for HBsAg and 6.4% positive for anti-HBc.130, 131  This 
discrepancy can be explained by the fact that both of these previous epidemiological studies 
also included individuals aged 0-17 years. Moreover, selection bias can explain a possible 
underestimation in 2003 as the recruiting of participants in the general population by mail 
probably missed people from certain risk groups (e.g. migrants). In the present study, we 
included patients aged 18-70 years who presented at the emergency department of a large 
educational hospital in a multi-ethnic region situated in Middle-Limburg. Furthermore, the 
region of Middle-Limburg has a large immigrant population, with 20.8% of the study 
population being FGMs, in contrast to 8.0% in Flanders, Belgium. In this respect, we found 
a higher HBsAg prevalence in FGMs and especially in those born in intermediate or high 
endemic countries, highlighting the fact that migrants are an important risk group for chronic 
HBV infection.167, 168  
The HBsAg prevalence in the general population of the neighbouring countries ranges from 
0.1% in Ireland to 0.8% in Spain.53 In line with our findings, a higher HBV prevalence was 
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found in FGMs born in intermediate- or high-prevalence areas in comparison to the native 
population of countries such as France, Germany, the Netherlands and Spain.76, 77, 154, 155  
The impact of implementation of a universal free-of-charge hepatitis B vaccination in 
Belgium was also apparent from the results of the current study. None of the HBsAg positive 
patients were born after year 1987. Anti-HBc prevalence was also lower in Belgian 
individuals born after 1987, when compared to those born before 1987. After all, universal 
infant hepatitis B vaccination with catch-up in adolescents aged 10-13 years began in 
September 1999 in Belgium.133 Consequently, the vaccination program covered children 
born after 1987. To evaluate the effects of a universal HBV vaccination program in <20 
year-olds, prevalence of seroprotection and HBV infection were assessed by Theeten et al.134 
They demonstrated that the prevalence of HBV infection remained low in Belgium and that 
overall high levels of ‘vaccinated’ serostatus were achieved in infants as well as in 
adolescents. 
We also analysed the risk factors associated to anti-HBc positivity. The most prominent risk 
factors were being FGM and age between 40 and 70 years (except for Belgian males), 
having an HBV infected household member, reporting HCV infection, being MSM, and ever 
having received haemodialysis, with 22.22%, 26.32%, 26.67%, 33.33% and 36.36% 
testing positive for anti-HBc, respectively. A comparison of different classification methods 
revealed that the weighted logistic regression model performed best in classifying patients 
as either anti-HBc positive or negative, although the identified risk factors in this model were 
the same as those found in a classification tree analysis.  
The implementation of a culturally and linguistically appropriate health care provider in the 
present study could explain the high linkage to care of newly diagnosed HBsAg positive 
patients.169 Moreover, all newly diagnosed HBsAg positive patients underwent ALT 
determination and normal ALT levels were found in all of them. The Belgian nationwide 
epidemiological data support the findings of our study and emphasized that 80% of the 
newly diagnosed chronic HBV patients had normal ALT levels at diagnosis.170 A major 
limitation of ALT as a biochemical marker of liver disease is that its levels often fluctuate 
over time during the variable course of chronic HBV infection and may fail to identify patients 
with necro-inflammatory activity or fibrosis.171 
There are some limitations to the present study. First, by screening at the emergency 
department, a bias towards subjects in certain risk groups may occur. However, these risk 
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groups might have been underrepresented in the previous population-based study in 
Belgium.131 Inclusion of certain risk groups in our study also allowed us to determine the 
most prominent risk factors for HBV prevalence in Belgium for the first time. Second, due 
to logistical factors (e.g. limited daily enrolment time, limited study research team) not every 
eligible participant could be informed about the study. Third, a concern is that, even though 
the patients’ demographics, known viral hepatitis status and risk factors were recorded, 
certain risk behaviours could have been underreported as the questionnaire was performed 
using a face-to-face interview. Inferences from this study should also be drawn with caution 
since it is difficult to establish causal pathways from cross-sectional studies as our present 
study. Thus, we have attempted only to identify risk factors associated with HBV infection 
using odds ratios. This study could also be underpowered to find significant associations 
between certain risk factors and HBsAg or anti-HBc, as the study was powered in such a 
way that the distribution per ethnicity was similar to that of the Middle-Limburg population, 
and not to specific risk factors. However, good predictive accuracy was shown for the 
weighted multiple logistic regression model, providing evidence for the significant impact of 
abovementioned risk factors for anti-HBc.  
CONCLUSION 
In conclusion, this study shows that the HBsAg and anti-HBc seroprevalences in a multi-
ethnic region in Middle-Limburg are higher than those previously found nationwide, probably 
because high-risk groups such as FGMs are more present. Since all newly diagnosed HBsAg 
positive patients had normal levels of ALT, national HBV screening for individuals born in 
intermediate or high endemic countries is needed as this high-risk group will go unnoticed 
due to the possible incorrect interpretation of normal ALT values. In order to adapt or to 
adopt screening practices and preventive measures, sero-epidemiological studies should not 
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ABSTRACT 
Background: Hepatitis B virus (HBV) infection is an important public health problem in the 
Turkish population, ie one of the largest migrant populations in Europe. With the introduction 
of cost-effective antiviral treatments in the past decade, there is a need to identify HBV 
infected patients who may benefit from treatment. This paper describes the design of a 
study to assess the HBV prevalence in the Turkish population living in Belgium. Additionally, 
we will determine the risk factors of HBV infection and the uptake of screening, vaccination 
and antiviral treatment in this hard-to-reach Turkish population. 
Methods: A longitudinal, epidemiological study will be conducted in the region Middle 
Limburg Belgium, where the Turkish adult population, 18 years of age and older, will be 
screened for hepatitis B surface antigen (HBsAg), antibodies against HBsAg (anti-HBs) and 
antibodies against hepatitis B core antigen (anti-HBc). Educational meetings concerning viral 
hepatitis B will be organized and there will be three ways to be screened for HBV: (1) 
immediately after the educational meetings, (2) at the Outpatient Hepatology Department 
of Ziekenhuis Oost-Limburg (ZOL) and (3) at home visits. Subsequently, participants will be 
asked to fill in a questionnaire regarding sociodemographic factors, migration history, risk 
factors for HBV infection (eg sharing toothbrushes, HBV infected family member) and HBV 
vaccination status. Six months after screening, HBsAg positive patients will be assessed 
whether they are under follow-up at the general practitioner or hepatologist. We will also 
gather information regarding the uptake of vaccination in non-immunized subjects. 
Discussion: This study will provide information about the HBV prevalence and distribution 
of the stages of liver disease in the Turkish population in Belgium. By determining the risk 
factors for HBV infection, subgroups with an increased prevalence of HBV infection can be 
identified.   
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INTRODUCTION 
Hepatitis B virus (HBV) infection is an important public health problem. In the year 2017, 
approximately 257 million people are chronically infected worldwide and at risk of 
developing serious sequelae, such as cirrhosis and hepatocellular carcinoma.41, 172  
According to the World Health Organization, Turkey is one of the countries with intermediate 
endemicity for hepatitis B. The hepatitis B surface antigen (HBsAg) prevalence thereby 
changes from 2-3% in the Western part of the country to 7-8% in Eastern part.80 In 
intermediate endemic countries, such as Turkey, horizontal HBV transmission by non-sexual 
close contact besides perinatal, sexual and parenteral transmission is the main route of 
infection.173-176 Risk factors associated with horizontal transmission in childhood are poor 
socioeconomic conditions, the presence of a HBsAg-positive family member and the habit 
of sharing various personal and household articles within the home (eg contaminated 
toothbrush, contaminated towels).173, 177, 178  
In contrast, the HBsAg prevalence is low (<1%) in the general population of Belgium and 
many other Western European countries.55, 131 Sexual transmission of HBV in persons with 
high-risk sexual behaviour (eg men who sex with men, heterosexual persons with multiple 
sex partners) remains a common source of HBV transmission in these low endemic 
countries.41  
Starting in 1961, political, economic and social developments led Turkish people to migrate 
to Europe, Australia, Arab countries and former Soviet Union countries.179 According to 
Turkish government statistics, 5.5 million Turkish citizens live abroad, of whom around 4.6 
million live in Western European countries.180 Turkish citizens are therefore one of the largest 
migrant groups in Europe. Moreover, a recent study by Ahmad et al79 indicated that the 
Turkish population was ranked third as migrant group with the highest absolute number of 
chronic HBV cases in Europe. However, their estimates of HBsAg prevalence were based on 
prevalence studies conducted in Turkey. Another study conducted by a Dutch group showed  
that the Turkish population in the Netherlands had a low level of awareness and knowledge 
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Nonetheless, little is known about the true prevalence and risk factors of HBV infection 
among the Turkish population living in Western European countries. Considering the fact 
that (1) infection with HBV in children most often result in chronic infection137 and (2)  
universal HBV vaccination in Belgium and Turkey only started after, respectively, 1999134 
and 199880, an appreciable number of the Turkish population in Belgium may be infected 
with HBV. Many of the HBV infected Turkish patients may also remain undiagnosed, since 
the onset of HBV and progression to cirrhosis and hepatocellular carcinoma are generally 
asymptomatic and occur many years after exposure.47 As HBV treatment options have 
greatly improved over the past decades and have proven to be cost-effective, there is a 
need to identify chronic carriers who may benefit from treatment.7, 59, 65 Therefore, this study 
aims to assess the prevalence and risk factors of HBV infection in hard-to-reach Turkish 
population living in Belgium. The identification and early antiviral treatment of HBV infection 
in the Turkish population could prevent the development of end-stage liver disease and 
further spread, while the associated health cost burden in this group at risk can be reduced.  
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METHODS 
STUDY DESIGN  
The current study is a longitudinal, epidemiological study. 
STUDY POPULATION 
The study population consists of Turkish individuals, living in the region Middle Limburg in 
Belgium.  
Inclusion criteria:  
• 18 years and older of age 
• Turkish individuals (defined as persons who are born in Turkey or persons of whom 
one of the parents is born in Turkey) 
• All participants irrespective of being aware of having been tested and knowing their 
HBV status 
• All participants irrespective of being aware of having been fully vaccinated 
• Signed informed consent form 
Minors, incapacitated subjects and non-Turkish individuals were to be excluded from the 
study. 
PRE-SCREENING PHASE 
In the pre-screening phase, we developed a brochure, flyer, poster and video focusing on 
HBV infection (Supplementary file S4.1 and S4.2). The patient information and consent 
form, questionnaire, brochure, flyer,  poster and video were translated in the Turkish 
language by a certified translator. The final information in Dutch and Turkish language were 
then thoroughly checked by delegates of Turkish associations and the questionnaire was 
pilot tested by ten persons of Turkish origin, first- and second-generation migrants, males 
and females, from different age categories (age group 18-39 years, 40-59, 60-79 and 80+). 
During the study, participants will be able to contact the first author by phone or e-mail for 
Turkish/Dutch information and questions. This study will be communicated to the 
association of general practitioners (GPs) in Genk, a city in the region Middle Limburg, who 
will be kept well informed throughout the study. 
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RECRUITMENT  
An estimated 17,510 Turkish persons live in the region Middle Limburg, of whom 
approximately 11,540 are 18 years of age and older (Limburg in cijfers, personal 
communication). Before the start of the screening phase, focus group discussions were held 
with delegates of four mosques in Middle Limburg  (Waterschei, Winterslag, Kolderbos and 
Sledderlo) and two Turkish responsibles of the Genk city council. Group discussions included 
general information on hepatitis B (eg hepatitis B occurs more often in Turkey compared to 
Belgium, routes of transmission, asymptomatic nature of disease, disease outcome), 
prevention (eg screening, vaccination), design of this study, recruitment and conduct of the 
study. Being familiar with the stigma regarding hepatitis in the Turkish community, several 
motivating factors and barriers to go for HBV screening were identified during the group 
discussions. Table 4.1 and 4.2 illustrate the motivating factors and barriers by social-cultural, 
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Table 4.1: Motivating factors for hepatitis B virus screening identified during focus group 
discussions and actions taken in current study 
Motivating factors for HBV screening Actions taken in current study  
Social-cultural factors 
1. Stimulation by family members, 
friends and delegates of the Turkish 






















2. Engagement of Turkish study 
personnel 
Social-cultural factors 
1. Social support regarding HBV 
screening 
a. Recognizing the 
importance of social 
support, we will offer the 
possibility to get 
screened during home 
visits and educational 
meetings at Islamic 
mosques, Turkish 
organizations, etc. 
b. Key figures within 
Turkish organizations 
will be asked to 
distribute invitations for 
educational sessions 
using information flyers. 
c. Screened individuals will 
be asked to inform their 
family members and 
friends about the 
opportunity of HBV 
screening. 
 
2. We will involve Turkish medical 
doctors, nurses and volunteers for 
HBV screening and questionnaire. 
Religious factors 
1. Islamic belief towards doing your best 
to stay healthy.  
Religious factors 
1. In Islamic mosques, the imams 
(ie the person who leads prayers 
in a mosque) will be asked to 
invite his cemaat (ie community) 
for educational HBV meetings. 
Other 








2. Availability of information in Turkish 
and Dutch language. 
Other 
1. In addition to the possibility to get 
screened at the Outpatient 
Hepatology Department of the 
hospital, we will implement home 
visits and screenings immediately 
after educational meetings in 
Turkish organizations. 
 
2. All information materials will be 
available in Turkish and Dutch 
language. Educational meetings 
will be principally done in Turkish. 
Abbreviations: HBV: hepatitis B virus. 
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Table 4.2: Barriers for hepatitis B virus screening identified during focus group discussions 
and actions taken in current study 
Barriers for HBV screening Actions taken in current study 
Social-cultural factors 
1. Association of HBV infection with 












2. Confrontation with a male physician 
for some women. 
 
 
3. Some women and men might have a 
concern regarding joint educational 
meetings. 
Social-cultural factors 
1. In the questionnaire, we did not 
ask for intravenous drug use or 
sexual behavior. However, it was 
decided that the Turkish 
community should have 
knowledge about all the 
transmission routes of HBV 
infection but sexual behavior will 
be addressed in a subtle way by 
addressing the main route of 
transmission, ie transmission 
from mother to child. 
 
2. There will always be the 
opportunity of a female Turkish 
physician. 
 
3. We will organize educational 
meetings for (1) men only, (2) 
women only and (3) joint 
educational meetings for men and 
women. Before setting up 
educational meetings the type of 
audience will always be discussed 




1. Suspicion that blood samples will be 





















1. Blood sample storage and 
analysis 
a. It was decided not to 
store blood samples for 
future studies.  
b. We will involve 
delegates of the Turkish 
community during 
recruitment. 
c. During educational HBV 
screening meetings we 
will implicitly mention 
that blood samples will 
be analyzed for HBV in 
the hospital and will be 
destroyed afterwards.  
d. We will engage Turkish 
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3. Little/no knowledge about hepatitis B. 
2. Emphasis will be set on the 
importance of secondary 
prevention in HBV infection. “We 
do not want to make you sick, we 
just want you to know that 
effective treatment is available to 
prevent liver cancer.”  
 
3. Flyers, posters and video on HBV 
infection will be available in 
Turkish and Dutch language. The 
flyers, posters and name cards 
with link to the video will be 
disseminated among the Turkish 
community. Moreover, 
educational meetings will be 
planned before the actual HBV 
screening. 
Abbreviations: HBV: hepatitis B virus. 
As the Islamic mosques mainly consist of male members/visitors, we will also search for 
female Turkish organizations in the Middle Limburg area. From September 2017 until 
August 2019, with the support of key figures within these organizations, we will organize 
educational meetings with the possibility for immediate HBV screening afterwards. The 
educational and screening sessions will be scheduled after the regular meetings of each 
organization.  
The key figures within these organizations will distribute invitations for the sessions using 
information flyers, posters and name cards with a link to the hepatitis B video. The flyers, 
posters and video contain information about risk factors for horizontal transmission (sharing 
personal and household articles, such as toothbrushes) and vertical transmission in addition 
to general information such as HBV vaccination, consequences of unrecognized HBV and 
the possibility of antiviral treatment. Turkish persons who are unable to attend a session will 
be invited to visit additional educational meetings and screening sessions in Ziekenhuis 
Oost-Limburg (ZOL) or can make an appointment with Ö.M.K at the Hepatology Outpatient 
Department (OPD) of ZOL. In addition to the above mentioned methods, Turkish people 
can also contact the first author for home visits with the possibility to sign an informed 
consent and be screened for HBV. Figure 4.1 shows the flow chart of the study design. 
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Figure 4.1: Flow chart of the study design. Abbreviations: HBV: hepatitis B virus; HBsAg: hepatitis 
B surface antigen; anti-HBs: antibodies against hepatitis B surface antigen; anti-HBc: antibodies against 
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SCREENING PHASE 
The educational sessions will be held in Turkish by the first author who will address the risk 
factors, routes of transmission, the fact that screening is free of charge, consequences, 
prevention and HBV treatment. After the educational meetings, there will be the possibility 
to be screened for HBV. Those who opt for screening, will be given an informed consent 
form and a questionnaire, available in Dutch and Turkish. HBV screening will also be possible 
at home visits and at the OPD of ZOL. Blood specimens will be transported to and processed 
in the laboratory of ZOL. 
LABORATORY TESTING 
All blood samples will be tested for HBsAg, antibodies against HBsAg (anti-HBs) and 
antibodies against hepatitis B core antigen (anti-HBc) using an electrochemiluminescence 
assay (Cobas 8000 e602, Roche, Germany). The interpretation of positive and negative 
results will be carried out as recommended by the test producer. 
POST-SCREENING PHASE AND FOLLOW-UP ACTIONS   
Patients who test positive for HBsAg will have the opportunity to enter an OPD. HBV 
screening results will be sent by letter to the patients and to their GP. A clinical work-up and 
treatment program in the OPD will be proposed for newly diagnosed patients. No further 
action will be undertaken in previously registered HBsAg positive patients. 
Non-immunized subjects and their GP will be informed about the test results by a letter. 
Non-immunized subjects will additionally be asked to consult their GP for HBV vaccination. 
In case of immunization against HBV infection, only a letter regarding the HBV screening 
results will be sent to the participant as well as to the GP. 
SAMPLE SIZE 
Sample size calculation was performed with the aid of Epi Info® (version 7.2). Considering 
the lack of data on the number of first- and second-generation Turkish migrants living in 
Middle Limburg, the number of samples per age was calculated instead so that the results 
of the sample group agree with that of the Turkish population in Middle Limburg with a 
confidence interval of 95% and 3% as an acceptable margin of error. The expected 
frequencies for the different age categories 18-39, 40-59, 60-79 and 80+ are 54%, 35%, 
9% and 1%, respectively (Limburg in cijfers, personal communication). Our analysis would 
lead to a total of 1,000 tested persons.  
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MEASURES  
Questionnaire: we searched PubMed to identify articles on risk factors for HBV infection in 
the Turkish community using the following terms and keywords alone and/or in appropriate 
combinations: hepatitis B, Turkey, Turkish, Turks, risk factor. No publication date or 
language restrictions were set. In addition, reference lists of all identified articles were 
checked to identify additional material, including (grey) literature. The final questionnaire 
includes the following risk factors: blood transfusion (no, yes before 1974 in Turkey, yes 
before 1974 in Belgium, other), dental treatment (yes in Turkey, other), (if female) 
gynaecological examination (no, yes in Turkey, yes in Belgium, other), (if male) circumcision 
(no/yes), (if male) circumcision carried out by a doctor (no, yes, unknown), (if male) way 
of circumcision (alone, collective, unknown), surgery (no, yes in Turkey, yes in Belgium, 
other), treatment with needles (no, yes in Turkey, yes in Belgium, other), HBV infected 
mother (no/yes), HBV infected father (no/yes), HBV infected brother (no/yes), HBV infected 
sister (no/yes), HBV infected partner (no/yes), other infected family member (no/yes), 
sharing toothbrushes with other household members (no, yes once, yes on regular basis), 
sharing nail clippers with other household members (no/yes), sharing razors with other 
household members (no/yes), sharing used towels with other household members 
(no/yes), eating from the same plate as other household members (no/yes), 
tattoo/piercing/earlobe perforation (no, yes in Turkey, yes in Belgium, other), treatment 
with Fish spa (no, yes in Turkey, yes in another country than Turkey). Furthermore, the 
questionnaire will collect data on HBV vaccination (vaccinated no/yes/unknown, (if yes) 
number of vaccinations, (if no) reasons of not being vaccinated) and previous HBV test 
results. Data regarding sociodemographics (age, gender, educational status of mother, 
educational status of father), first language (Dutch/Turkish), migration history (country of 
birth, (if born in Turkey) year of migration to Belgium, mother’s country of birth, father’s 
country of birth, (if mother born in Turkey) region of birth from mother, (if father born in 
Turkey) region of birth from father) will be collected to characterize the study population. 
Regarding region of birth, Turkey will be divided in the seven geographical regions: (1) 
Marmara, (2) Aegean, (3) Mediterranean, (4) Central Anatolia, (5) Black Sea, (6) Eastern 
Anatolia and (7) Southeastern Anatolia (Figure 4.2).80 The questionnaire will not cover 
questions regarding intravenous drug use or sexual behaviour as (1) these questions could 
lead to a significant lower participation rate and (2) the answers to these questions are not 
reliable in this Turkish population with a majority being Muslim.  
 




Figure 4.2: Map of Turkey according to the geographical regions.  Map of Turkey according to 
regions: A: Marmara, B: Aegean, C: Mediterranean, D: Central Anatolia, E: Black Sea, F: Eastern 
Anatolian and G: Southeastern Anatolia. 
Clinical outcomes: within six months of a HBsAg positive test result, we will assess 
whether or not HBsAg positive patients are under follow-up at the GP or hepatologist. Clinical 
follow-up data will be collected: co-infection (hepatitis C virus, hepatitis delta virus, HIV); 
determination of liver disease stage (via fibroscan, ultrasonography abdomen, Magnetic 
Resonance Imaging of the liver, duodenoscopy, and, if necessary, liver biopsy); and 
treatment eligibility, initiation and outcomes. Outcomes of Fibroscan and/or liver biopsy will 
be scored according to the METAVIR classification system for fibrosis (F0: no fibrosis, F1: 
portal fibrosis without septa, F2: few septa, F3: numerous septa without cirrhosis, F4: 
cirrhosis).182 Within six months after HBV screening, we will also gather data regarding non-
immunized subjects, namely if they initiated HBV vaccination by the GP. 
Primary outcome measure 
The primary outcome variable is the prevalence of current infection with HBV in the Turkish 
population living in Middle Limburg. For this reason, one Li-heparin tube collection and 
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Secondary/Exploratory outcome measures 
The questionnaire will provide information on secondary outcomes by assessing the risk 
factors for recent or past HBV infection (anti-HBc positivity). We will also determine the 
willingness for HBV assessment in the Turkish population in Middle Limburg. This will be 
assessed by the number of persons who did go for HBV testing divided by the total 
population who attended one of the educational meetings, the OPD of ZOL or home visit. 
Other secondary outcome measures are (1) percentage of new HBsAg positive patients that 
are under follow-up at the GP or a hepatologist, (2) factors associated with HBsAg positive 
persons to be under follow-up at the GP/hepatologist six months after HBV screening test 
result, (3) distribution of stages of liver disease in HBsAg positive patients, (4) treatment 
eligibility, initiation and outcomes in HBsAg positive patients, (5) the percentage of Turkish 
population who are immune against HBV infection based on anti-HBs status and (6) 
percentage of Turkish population who are susceptible for HBV infection and (7) uptake of 
HBV vaccination in non-immunized Turkish subjects. 
STATISTICAL ANALYSES 
Survey data will be entered bed-side into a secure electronic database Castor EDC (Castor 
Electronic Data Capture, Ciwit Bv, Amsterdam, the Netherlands). Coded data analyses will 
be performed using SPSS (Release 25, Armonk, NY). Categorical data will be analysed with 
the Chi squared test or Fisher’s exact test. Differences in two and several continuous 
variables will be assessed by the independent t-test and one way-ANOVA test, respectively. 
The normality and homogeneity of variances will be verified, respectively, by Shapiro-Wilk 
and Levene values >0.05. In case the assumptions for parametric tests are violated, the 
equivalent Mann-Whitney test and Kruskal-Wallis test will be applied for comparing two and 
several continuous variables, respectively. A multivariate logistic regression model will be 
used to identify risk factors associated with anti-HBc total positivity. Risk factors that are 
found to be significantly associated (p<0.05) with anti-HBc total positivity in univariate 
analysis will be included as covariates in the logistic regression model. Since all included 
samples will be linked to questionnaires, corrections for over- or undersampling of certain 
groups will be performed. In order to do this poststratification, weights for age and gender 
will be created. This will be done for the two variables separately, and for their interaction. 
Chi-squared tests will then be performed again, this time including the poststratification 
weights. The same will be done for logistic regression. The level of statistical significance is 
set at p<0.05. 
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ETHICAL APPROVAL AND INFORMED CONSENT   
The Ethical Committee of ZOL Genk and Hasselt University approved this study with protocol 
version 1.0 dated 13 July 2017 (B371201732623) and written informed consent will be 
obtained from all study participants. 
AVAILABILITY OF DATA AND MATERIALS   
The datasets used during the current study will be available from the corresponding author 
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DISCUSSION 
Immigration to Western Europe has a long history, but increased at an unprecedented rate 
over the past decades. During this time period, the incidence and mortality of  hepatocellular 
carcinoma increased in Western Europe, likely in part due to the increased migration from 
countries with intermediate (HBsAg prevalence 2-7%) or  high (>8%) HBV prevalence.79, 
183  
Moreover, screening in migrants from countries with an intermediate HBV endemicity, such 
as the Turkish population in the Netherlands and Germany, has shown a 15-25 times higher 
HBsAg prevalence of 3-5% in comparison to the general population.184, 185 However, data 
on the real HBV prevalence in the Turkish population residing in Belgium and data on the 
risk factors and distribution of stages of liver disease in this Turkish population are not 
available. Nonetheless, knowledge on the HBV prevalence, risk factors and clinical evolution 
in Western Europe is necessary. 
Strengths and limitations 
This study will determine the prevalence and risk factors of HBV infection in a large panel of 
first- and second-generation Turkish migrants living in Middle Limburg, Belgium. It will show 
whether the HBV prevalence obtained from this Turkish population study is higher than the 
HBV prevalence found in previous studies conducted in the general population living in 
Belgium. The inclusion of a large number second-generation migrants will also provide 
information whether second-generation Turkish migrants are at risk for HBV infection in 
addition to first-generation migrants. In the Netherlands, a study on 103 second-generation 
Turkish migrants could not find a difference in HBsAg and anti-HBc seroprevalence from the 
native population.185 Considering the small sample size of the Dutch study, but also in view 
of variations in HBV prevention and control strategies between European countries, it is 
important to assess the issue of HBV infection in the second-generation migrants living in 
Belgium together with first-generation migrants.186  
In contrast to cross-sectional studies, this longitudinal follow-up study will be able to 
differentiate between acute/chronic HBV cases and false-positive HBsAg test results. It will 
also provide information on linkage to care and stages of liver disease which may assist 
physicians, public health practitioners and policymakers in eliminating hepatitis B.  The 
assessment of anti-HBs in addition to HBsAg and anti-HBc will give us insight in the 
proportion of individuals susceptible to HBV infection. Furthermore, this study will gather 
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information on risk factors for HBV infection, sociodemographics, migration history and 
clinical data (eg HBsAg positivity). Combined, this information could help identify how HBV 
infection in this Turkish population is spreading so that further spread can be stopped. This 
study will also provide information on the feasibility and acceptability of HBV screening in 
hard-to-reach migrant groups. 
There are some limitations to the present study. First, this study could be underpowered to 
find significant associations between certain risk factors and HBsAg or anti-HBc, as sample 
size calculation was performed on distribution of age categories and not on expected HBsAg 
or anti-HBc prevalence. Second, a concern is that, even though risk factors for HBV infection 
were recorded, certain risk behaviours could have been underreported due to social 
desirability bias. Third, it is unknown whether observations from Turkish population in Middle 
Limburg could be used as an estimate for Europe. However, collection of demographic 
factors allows subanalyses. Fourth, the questionnaire will not cover points regarding 
intravenous drug use or high-risk sexual behaviour as these questions could lead to a 
significant lower or biased participation rate and the answers to these questions are ought 
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SUPPLEMENTARY FILES 
Supplementary file S 4.1: Informative flyer on hepatitis B screening project in the Turkish 
migrant population (available in Dutch and Turkish language) 
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Supplementary file S 4.2: Educational poster on hepatitis B virus infection (available in Dutch 
and Turkish language) 
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ABSTRACT 
Background: Turkey is an intermediate hepatitis B virus (HBV) endemic country. However, 
prevalence among Turkish migrants in Belgium is unknown, especially in those born in 
Belgium with a foreign-born parent, i.e. second-generation migrants (SGM). 
Aims To evaluate the prevalence of HBV infection and associated risk factors in Turkish 
first-generation migrants (FGM), i.e. foreign-born, and SGM.  
Methods: Between September 2017 and May 2019, free outreach testing for hepatitis B 
surface antigen (HBsAg), hepatitis B core antibodies (anti-HBc), and antibodies against 
HBsAg was offered to Turkish migrants in Middle-Limburg, Belgium. Face-to-face 
questionnaire assessed HBV risk factors. HBsAg positive patients were referred and followed 
up. Turkish SGM were stratified into birth cohort born before and after 1987, since those 
born after 1987 should be covered by the universal infant vaccination program. 
Results: A total of 1,081/1,113 (97.1%) Turkish did go for HBV testing. Twenty-six (2.4%) 
were HBsAg positive; 11/26 were unaware of their status and 10/11 were successfully 
referred. HBsAg prevalence was 3.0% in FGM and 1.5% in SGM, p = .070. These numbers 
were 32.8% and 5.7% for anti-HBc, respectively, p < .001. Only one out of seven HBsAg 
positive SGM was born after 1987.  Anti-HBc positivity in Turkish SGM born after 1987 was 
1.1%, this was 9.1% for those born before 1987, p < .001. 
Conclusion: Outreach testing was well-accepted and referral to specialist care was 
generally successful. National HBV screening should be implemented in the Turkish FGM 
population and might be considered in SGM not covered by primary prevention strategies.  
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INTRODUCTION 
Hepatitis B virus (HBV) infection is one of the most common infectious diseases worldwide. 
Approximately one third of the world population has been exposed to the virus and an 
estimated 257 million people are chronically infected.57 Regardless of the asymptomatic 
nature of chronic HBV infection, patients remain infectious to others and are at risk of death 
from cirrhosis and hepatocellular carcinoma.57 In 2015, HBV-related complications 
accounted for 887,000 deaths globally.57  
The possibilities for antiviral treatment of chronic HBV infection have greatly improved over 
the past decades, and cost-effective drug therapies are now available.137, 187  However, due 
to  the asymptomatic course, most patients are unaware of their HBV infection and do not 
benefit from treatment. Screening for hepatitis B, aimed at early detection of chronic HBV 
infection with follow-up and antiviral treatment of eligible patients, is needed to reduce the 
economic burden of HBV-related complications and health-related suffering in Europe.48, 49 
In addition, screening could identify persons who are susceptible to infection and would 
benefit from vaccination.48 
In low endemic countries (< 2% hepatitis B surface antigen (HBsAg) positive), migrants 
born in intermediate (2 – 7.99% HBsAg positive) or high endemic (> 8% HBsAg positive) 
regions are an important risk group for chronic HBV infection.132 In Belgium, the prevalence 
of chronic HBV infection is estimated to be 0.67% in the general population and 4.69% in 
first-generation migrants (FGM) born in intermediate or high endemic countries.130-132 
Migrants from intermediate or high endemic countries account for more than half of the 
patients with chronic HBV infection in Belgium.79 Turkish individuals form the second largest 
FGM population in Europe and with a HBsAg prevalence in Turkey ranging from 2 – 3% in 
the Western part up to 7 – 8% in Eastern part, a substantial proportion of the Turkish 
migrant population may be infected with HBV.79, 80  
Most studies concerning hepatitis B testing in FGM involved southeast Asians in the USA, 
Canada and Australia.81 A cross-sectional study in Turkish FGM in Germany showed a 
prevalence of 5% for chronic HBV infection, and this was 3% in a study conducted in the 
Netherlands.184, 185 However, HBV risk factors and follow-up in Turkish FGM are mostly 
unclear. Furthermore, much less is known about infection prevalence, risk factors and 
follow-up in second-generation migrants (SGM), i.e. born in Belgium with a foreign-born 
parent. This is all the more important as the descendants of the FGM population grow. 
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Regarding acute hepatitis B notification rates, a Dutch study showed a higher rate of 
3.7/100,000 in SGM compared with 1.6/100,000 in native Dutch/Western persons.188  
We organized a hepatitis B testing and risk factor assessment campaign for the Turkish 
population in Middle Limburg, Belgium, a region with a relatively large Turkish population.189 
Here we report the prevalence of HBV infection in individuals with a Turkish background 
(FGM and SGM), the results of a questionnaire on risk factors, and the follow-up of patients 
referred to care.  
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PATIENTS AND METHODS 
From 1 September 2017 until 2 May 2019, we recruited > 18 year-old Turkish migrants 
living in the region Middle Limburg. Follow-up was concluded on 2 November 2019, 6 
months after the last inclusion. The study methods have been published previously.190 In 
brief, the free outreach hepatitis B testing campaign was combined with risk factor 
assessment by a face-to-face questionnaire. Blood samples were tested for HBsAg, 
antibodies against HBsAg (anti-HBs) and hepatitis B core antibodies (anti-HBc) with an 
electrochemiluminescence assay (Cobas 8000 e602, Roche, Germany). Both participants 
and their general practitioner received the test result by letter and, supplementary to this, 
the general practitioners were advised to contact the HBsAg positive participants by phone. 
All patients who tested positive for HBsAg were referred to a hepatologist for a clinical work-
up and treatment program according to the European clinical practice guidelines.7 HBsAg 
positive patients were divided in four phases, taking into account the presence of hepatitis 
B e antigen (HBeAg), serum HBV DNA levels and serum alanine aminotransferase (ALT) 
values.7 Persons susceptible to HBV infection were asked to consult their general practitioner 
for HBV vaccination.  
QUESTIONNAIRE 
Before hepatitis B testing, HBV risk factors were assessed through a face-to-face 
questionnaire (see Table 5.2). The questionnaire was available in the Dutch or Turkish 
language, and covered a total of 23 and 21 questions for males and females, respectively. 
The questionnaire did not cover information on intravenous drug use or sexual behaviour 
as these questions are sensitive and therefore socially censured;  pressure to conform to 
societal norms could cause self-reports to be fraught with bias.  
STATISTICAL ANALYSIS 
The sample size calculation was performed with the aid of Epi Info® (version 7.2). Since 
data on country of birth in Middle Limburg are unavailable and data on nationality do not 
represent country of birth, the number of study participants per age group was calculated 
so that the results of the study group agree with that of the Turkish population living in 
Middle Limburg with a significance level of 5%. This is important for the extrapolation of the 
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Table 5.1: Composition of the study group compared with the composition of the Turkish 
population living in Middle Limburg regarding age and gender 
Age (years) Total 18-39 40-59 > 60 Male Female 
Study group (N) 1,081 433 511 137 468 613 
Study group (%) 100 40.1 47.3 12.6 43.3 56.7 
Turkish Middle Limburg population 
(%) 
100 53.9 35.4 10.7 50.5 49.5 
 
To assess the impact of universal HBV vaccination in Belgium among Turkish SGM, we 
stratified HBsAg, anti-HBc and/or anti-HBs prevalence into two birth cohorts (1930 – 1986 
and 1987 – 2001). This cutoff was chosen as the free-of-charge HBV vaccination program 
in infants since September 1999 with catch-up vaccination for 10 – 13 year-olds covered 
children born after 1987 in Belgium.191  
Since participants could be part of the same household, resulting in violation of the 
assumption of independent observations for classical tests such as logistic regression, 
univariate generalized estimating equations (GEE) were used to investigate the influence of 
the different variables on the presence of past or current HBV infection (anti-HBc positive), 
chronic HBV infection (HBsAg positive) and vaccination status (solely anti-HBs positive). The 
correlation structure in these GEE is assumed to be of the ‘compound symmetry’ type, 
specifying that all observations within the same cluster are equally correlated. Although this 
might not be the correct assumption, GEE has been shown to be robust to misspecification 
of the working correlation structure.192  
Variables showing significant association (p < .20) in the univariate analyses were 
subsequently included in a multiple GEE model. As origin and educational level of mother 
and father were highly correlated, only maternal factors were included in the models. 
Backward selection was used to obtain a final model. In order to correct for differences 
between the sample and the Middle-Limburg population, weights were included in all GEE 
models. Weighting was done based on the combination of age and gender. 
ETHICAL APPROVAL 
The study was undertaken in accordance with Good Clinical Practice guidelines and the 
Declaration of Helsinki. The protocol was approved by the medical ethics committees of 
Hasselt University and Hospital East-Limburg (17-039U). 
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RESULTS 
In total 1,081 Turkish migrants were tested for HBV infection; 1,047 of the 1,079 (97.0%) 
persons present at the educational meetings in a Turkish organization and all  34 (100.0%) 
participants present at home visits did go for testing. Less than half of the study participants 
were male (43.3%), and the mean age was 44 + 13.7 years. The majority of the 
participants were born in Turkey (58.1%), 41.9% were born in Belgium.  
Blood samples were insufficient for anti-HBs testing in four participants. In 21.5% 
(232/1,081) there was evidence of a past or recent HBV infection (anti-HBc positive), 2.4% 
(26/1,081) had a chronic HBV infection (HBsAg positive), 22.9% (247/1,077) of the 
samples were solely anti-HBs positive (‘vaccinated’ serostatus) and 55.5% (598/1,077) 
appeared to be susceptible for HBV infection (negative HBV markers). 
PAST OR RECENT HBV INFECTION  
Past or recent HBV infection in FGM was apparent in 206/628 (32.8%) with differences 
between males and females, i.e. 40.4% (110/272) vs 27.0% (96/356), respectively, p = 
.001. Among FGM, anti-HBc prevalence in 18-39 year-olds, 40-59 year-olds and >60 year-
olds was 13.2% (14/106), 31.9% (123/385) and 50.4% (69/137), respectively, p < .001. 
Gender difference regarding anti-HBc prevalence was not seen in Turkish SGM, i.e. 5.6% 
(11/196) in males vs 5.8% (15/257) in females, p = 1.000. Anti-HBc prevalence in Turkish 
SGM born after 1987 was 1.1% (2/190), and was higher for those SGM born before 1987, 
i.e. 9.1% (24/263), p < .001. Older age was associated with past or recent HBV infection 
in SGM, i.e. 4.0% (13/327) in 18-39 year-olds vs 10.3% (13/126) in 40-59 year-olds, p = 
.018. There were no SGM 60 years or older. 
Factors associated with past or recent HBV infection in the weighted univariate GEE are 
shown in Table 5.2. From the weighted multiple GEE analyses as shown in Table 5.3, it can 
be seen that male gender (p = .021), older age (p < .001), FGM (p < .001), lower (i.e. 
none or primary) educational level of the mother (p = .003), HBV infected mother (p = 
.008), HBV infected siblings (p = .002), HBV infected other family member (p = .004), 
gynaecological examination in Turkey or unsafe male circumcision (p = .032), dental 
treatment in Turkey (p = .049), and treatment with needles in Turkey (p = .012) 
significantly increased the odds of anti-HBc positivity.  
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Table 5.2: Prevalence of past or recent hepatitis B virus infection by different risk factors 
among the total study population (n = 1,081) (weighted univariate GEE) 




Crude OR  
(95% CI) 
Overall  232 1,081 21.5% - - 
Gender 
   Male 











1.38 (1.02 – 1.86) 
(ref) 
Age group 
   18-39 years 
   40-59 years 

















5.73 (3.67 – 8.92) 
16.26 (9.55 – 27.67) 
Ethnicity 
   FGM 











8.84 (5.59 – 13.97) 
(ref) 
Year of immigration (if FGM) 
   Before 1987    











2.33 (1.58 – 3.42) 
(ref) 
Southeastern Anatolian 
origin of mother 
   Yes 















1.28 (0.68 – 2.42) 
(ref) 
Mother’s educational level 
   None 
   Primary school 
   Secondary school 

















7.65 (0.96 – 60.73) 
3.57 (0.45 – 28.64) 
0.37 (0.03 – 4.15) 
(ref) 
HBV infected partner 
   Yes 











1.23 (0.43 – 3.50) 
(ref) 
HBV infected mother 
   Yes 
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HBV infected father 
   Yes 











0.24 (0.05 – 1.17) 
(ref) 
HBV infected siblings 
   Yes 











3.77 (1.81 – 7.87) 
(ref) 
HBV infected other family 
member 
   Yes 



















   Yes  















2.35 (1.59 – 3.47) 
(ref) 
Sharing nail clippers 
   Yes 











0.74 (0.43 – 1.25) 
(ref) 
Sharing razors 
   Yes 











1.13 (0.73 – 1.75) 
(ref) 
Sharing used towels 
   Yes 











1.38 (0.85 – 2.24) 
(ref) 
Eating from the same plate 
  Yes 











1.19 (0.77 – 1.84) 
(ref) 
Gynaecological examination  
in Turkey (if female) 
  Yes  















2.73 (1.60 – 4.67) 
(ref) 
Circumcision (if male) 
   Collective 
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Circumcision not carried out 
by medical doctor (if male) 
   Yes 















5.24 (2.76 – 9.94) 
(ref) 
Gynaecological examination 
in Turkey or unsafe male 
circumcision 
   Yes 



















2.92 (2.12 – 4.02) 
(ref) 
Blood transfusion  
   Yes  











1.52 (1.01 – 2.27) 
(ref) 
Dental treatment in Turkey 
   Yes 











4.36 (3.17 – 5.98) 
(ref) 
Surgery in Turkey 
  Yes  











3.12 (2.05 – 4.76) 
(ref) 
Treatment with needles in 
Turkey 
   Yes  



















perforation in Turkey 
   Yes  



















1.58 (1.14 – 2.20) 
(ref) 
Fish spa treatment 
   Yes in Turkey 











0.54 (0.25 – 1.14) 
(ref) 
Abbreviation: GEE: generalized estimating equations; OR: odds ratio; CI: confidence interval; HBV: 
hepatitis B virus; FGM: first-generation migrants; SGM: second-generation migrants. First-generation 
migrants: foreign-born individuals; second-generation migrants: individuals born in Belgium with foreign-
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Table 5.3: Association of past or recent hepatitis B virus infection to different risk factors 
among the total study population (n = 1,081) (weighted GEE model) 
Parameter  Estimate 
(SE) 
P Value aOR (95% CI) 
(intercept)  -4.39 (0.79)   
Gender  





(1.08 – 2.31) 
Age group  
40 – 59 years (vs 18 – 
39 years) 
 









(1.36 – 3.62) 
 
4.50 
(2.39 – 8.47) 
Ethnicity  









None (vs High 
school/University) 
Primary (vs High 
school/University) 










(0.38 – 8.88) 
1.70  
(0.35 – 8.20) 
0.31  



























3.86 (1.80 – 8.30) 
Gynaecological 
examination in 
Turkey or unsafe 
 




1.51 (1.04 – 2.21) 
 











1.50 (1.01 – 2.21) 
Treatment with 
needles in Turkey 
 




1.63 (1.13 – 2.36) 
Abbreviations: GEE: generalized estimating equations; SE: standard error; aOR: adjusted odds ratio; 
CI: confidence interval; HBV: hepatitis B virus; FGM: first-generation migrants; SGM: second-generation 
migrants. First-generation migrants: foreign-born individuals; second-generation migrants: individuals 
born in Belgium with foreign-born parents; unsafe male circumcision: collective circumcision and/or 
circumcision not carried out by medical doctor. 
Multiple GEE analyses were also conducted for males and females separately as well as for 
FGM and SGM (Supplementary file S5.1 – 5.4). The final model for males and females 
included age (p = .006 and p < .001), FGM (p < .001 and p < .001) and treatment with 
needles in Turkey (p = .030 and p = .003). In males, HBV infected siblings (p  = .022) and 
circumcision not conducted by a medical doctor were additional independent risk factors.  
Independent risk factors for recent or past HBV infection among FGM included age (p < 
.001), HBV infected mother (p = .042), HBV infected siblings (p = .024), gynaecological 
examination in Turkey or unsafe male circumcision (p < .001), and treatment with needles 
in Turkey (p = .003). Among SGM, risk factors included HBV infected other family member 
(p = .010) and treatment with needles in Turkey (p  = .030). 
Sixty-five patients with past or recent HBV infection had a family member with HBV 
infection: among seven (10.8%) patients only the partner was infected, 14 (21.5%) with 
HBV infected mother only, one (1.5%) with HBV infected father only, 16 (24.6%) with HBV 
infected siblings only, 19 (29.2%) had another family member with HBV infection, three 
(4.6%) with HBV infection among mother and siblings, one (1.5%) with HBV infected father 
and siblings, and four (6.2%) with HBV infected siblings and other family member. 
Therefore HBV infected mother could potentially explain 17/65 (26.2%) anti-HBc positive 
cases with a positive family history of HBV infection. 
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CHRONIC HBV INFECTION  
Of the 26 HBsAg positive individuals, 19 were FGM, leading to a HBsAg prevalence of 3.0% 
(19/628) in FGM. Compared to females, male FGM had a higher prevalence of chronic HBV 
infection (5.5% (15/272) in males vs 1.1% (4/356) in females,  p = .002).  
Gender difference regarding chronic HBV infection was not seen in Turkish SGM, i.e. 1.5% 
(3/196) in males vs 1.6% (4/257) in females, p = 1.000. Overall, 1.5% (7/453) SGM were 
HBsAg positive; only one out of seven HBsAg positive SGM was born after 1987. This 
corresponds to a HBsAg positivity of 0.5% (1/190) and 2.3% (6/263) in those born after 
and before 1987, respectively, p = .135. All but one had HBV infection in the family: one 
with HBV infection in mother only, two with HBV infection in siblings only, one with HBV 
infection in another family member only and two with HBV infection in siblings and another 
family member. 
Supplementary file S5.5 shows factors associated with chronic HBV infection in the weighted 
univariate GEE. From the weighted multiple GEE analyses as shown in Table 5.4, it can be 
seen that older age (p = .022) and gynaecological examination in Turkey or unsafe male 
circumcision (p =.004) significantly increased the odds, while body 
piercing/tattooing/earlobe perforation in Turkey resulted in a lower odds of chronic HBV 
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Table 5.4: Association of chronic HBV infection to different risk factors among the total study 
population (n = 1,081) (weighted multiple GEE) 






(intercept)  -5.28 (0.65)   
Age group  
40 – 59 years (vs 18 – 39 
years) 








(1.03 – 12.48) 
4.45 
(0.90 – 21.92) 
Gynaecological 
examination in 
Turkey or unsafe 
male circumcision 
 




















(0.11 – 0.99) 
Abbreviations: GEE: generalized estimating equations; SE: standard error; aOR: adjusted odds ratio; 
CI: confidence interval. Unsafe male circumcision: collective circumcision and/or circumcision not carried 
out by medical doctor. 
FOLLOW-UP IN PATIENTS WITH CHRONIC HBV INFECTION  
Eleven of 26 chronically infected patients were unaware of their HBV status and the other 
15 were already linked to care (Figure 5.1). Thus, the percentage of newly diagnosed HBsAg 
positive patients was 1.02% (11/1,081). Two patients were referred to another hospital, 
one could not be linked to care due to incorrect contact details and the remaining eight 
patients were seen at the Department of Gastroenterology and Hepatology of Hospital East-
Limburg.  
Out of the 15 patients that were already linked to care, 11 were classified as HBeAg-negative 
chronic infection, three as HBeAg-negative chronic hepatitis and one with HBeAg-positive 
chronic hepatitis. Both patients referred to another hospital and the eight patients evaluated 
in our hospital were categorized into two groups according to the HBV DNA (> 2,000 IU/mL 
vs < 2,000 IU/mL) and ALT level (> 40 IU/L vs < 40 IU/L) at the first visit (Figure 5.1). 
There was no evidence of cirrhosis or HCC on abdominal ultrasound. Advanced liver disease 
was suspected in one patient based on transient elastography value > 10 kPa. However, 
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liver biopsy revealed F1 (portal fibrosis without septa) and the presence of nonalcoholic 
steatohepatitis (NASH). Within one year follow-up, none of the ten newly HBsAg positive 
patients had an indication for antiviral treatment. Two patients were lost to follow-up after 
the first visit for reasons unknown.   
 
 
Figure 5.1: Follow-up results in patients with chronic HBV infection. Abbreviations: HBV: 
hepatitis B virus; ALT: alanine aminotransferase. 
SOLELY ANTI-HBS POSITIVE  
Regarding our question on HBV vaccination, a total of 22.2% (239/1,076) indicated to be 
vaccinated, 26.9% (289/1,076) were not vaccinated and history of HBV vaccination was 
unknown in the remaining 50.9% (548/1,076) participants. Among those with a history of 
vaccination (n = 239), 29 (12.1%) and 1 (0.4%) were anti-HBc positive and HBsAg positive, 
respectively.  
Solely anti-HBs positivity in Turkish SGM born after 1987 was 72.1% (137/190), and was 
lower for those SGM born before 1987 (21.5%, 56/261), p < .001. Supplementary file S5.6 
shows factors associated with vaccination status in the weighted univariate GEE. For solely 
anti-HBs positivity (i.e. vaccination status), the final model included gender (p = .008), age 
group (p < .001), ethnicity (p < .001), mother’s educational level (p = .007) and vaccination 
history (p < .001) (Table 5.5). 
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Table 5.5: Association of vaccination status (solely anti-HBs positive) to different risk factors 
among the total study population with information on anti-HBs (n = 1,077) (weighted 
multiple GEE) 






(intercept)  1.50 (0.69)   
Gender  





(0.39 – 0.86) 
Age group  
40 – 59 years (vs 18 – 39 
years) 








(0.18 – 0.43) 
0.18  
(0.06 – 0.51) 
Ethnicity  









None (vs High 
school/University) 
Primary (vs High 
school/University) 










(0.06 – 0.83) 
0.29  
(0.08 – 1.11) 
0.54  
(0.14 – 2.11) 







(0.10 – 0.22) 
Abbreviations: GEE: generalized estimating equations; SE: standard error; aOR: adjusted odds ratio; 
CI: confidence interval; FGM: first-generation migrants; SGM: second-generation migrants. First-
generation migrants: foreign-born individuals; second-generation migrants: individuals born in Belgium 
with foreign-born parents; unsafe male circumcision: collective circumcision and/or circumcision not 
carried out by medical doctor. 
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SUSCEPTIBLE FOR HBV INFECTION  
Six months after the last inclusion, 19.1% (44/230 susceptible individuals with follow-up 
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DISCUSSION 
In addition to the screening of FGM, i.e. those born in Turkey, our study is one of the first 
hepatitis B screening projects in Europe targeting a substantial proportion of SGM, i.e. those 
born in Belgium with a foreign-born parent. First, we show that outreach testing was well-
accepted in Turkish migrants. Although Turkish migrants could opt for screening during 
home visits or at the hepatology outpatient clinic, the majority (97%) were tested 
immediately after educational sessions in Islamic mosques and Turkish organizations. 
Our finding of 3% HBsAg positivity in Turkish FGM is in line with previous findings reported 
in the Netherlands and Germany (HBsAg prevalence varying from 3 – 5%), and reflects the 
high prevalence in the country of origin.80, 184, 185, 193 However, the 1.5% prevalence of 
chronic HBV infection in Turkish SGM is higher than the reported 0.7% HBsAg prevalence 
in native Belgians.130-132 This finding is novel and might in part be explained by the 
interaction of high prevalence in the country of origin and suboptimal coverage by primary 
prevention strategies in the country of birth. None of the seven cases of SGM with chronic 
HBV infection in our study were born after 1999, which is the year universal HBV vaccination 
in infants was implemented in Belgium. However, although six HBsAg positive SGM were 
born before 1987, one was born between 1987 and 1999, a birth cohort that should have 
been covered by the catch-up vaccination in 10 – 13 year-olds since 1999. In this matter, 
lowest immunization coverage rates in Belgium were found in those born between 1990 
and 1998.134 Moreover, prior studies indicated that non-European origin and low educational 
level of the mother were associated with a decreased odds of vaccination coverage in 
children.144, 194 In our study, mother’s educational level was associated with vaccination 
coverage.  
In our Turkish migrant study population, HBV infection in the mother could potentially 
explain less than one third of the patients with past or recent HBV infection. HBV infection 
in siblings possibly accounted for another major part of past or recent HBV infection in our 
study. In Turkey, perinatal transmission of HBV infection is uncommon as HBeAg positivity 
in pregnant chronic HBV patients is very low.174 The infection is mostly acquired in childhood 
through horizontal transmission, i.e. that occurring through non-sexual and non-parenteral 
contact beyond six months of age, in childhood and pre-adolescent period.174, 189 In the 
Turkish families, most of the mothers are housewives and mostly stay at home as 
caretakers for the children. Although the mother is important for horizontal HBV 
transmission through non-sexual close contact, sibling-to-sibling horizontal transmission 
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might also be an important route of HBV infection.195-197  Siblings share the same 
environment, experience the same cultural and family traditions, which may be associated 
with increased risks of transmission. 
Physicians from countries with a selective vaccination program targeting groups at risk of 
HBV infection only, instead of adding a universal vaccination program, should be aware of 
horizontal transmission through non-sexual close contact.45 Children are more likely to have 
contact with each other’s body fluid and are therefore at risk of horizontal transmission 
through non-sexual close contact. Skin lesions or sharing contaminated material such as 
towels, toothbrushes or razor blades has been shown to play a role in horizontal 
transmission through non-sexual close contact.174 In this matter, sharing toothbrushes 
regularly was univariately associated with past or recent HBV infection in our study 
population. However, this association diminished when accounting for other risk factors. The 
most important independent risk factors for past or recent HBV infection found in our study 
were male gender, older age, being a FGM, low educational level of the mother, a family 
history of HBV infection, gynaecological examination in Turkey or unsafe male circumcision, 
dental treatment in Turkey and treatment with needles in Turkey. These findings are in line 
with previous studies conducted in Turkish migrants living in Europe and studies conducted 
in Turkey.174, 184, 185, 193, 195 
For a screening program aimed at secondary prevention of HBV infection, access to care is 
inevitable to reduce the economic burden of HBV-related complications. In Greece, it is 
estimated that less than half of the patients diagnosed with HBV were referred and received 
the appropriate care.198 This number was between 40% and 66% in the USA.199 Most 
screening projects provide data on the HBsAg prevalence but do not assess referral, disease 
stage and initiation of antiviral therapy. We showed a successful referral of more than 90% 
newly diagnosed patients with chronic HBV infection. The implementation of a pre-screening 
phase with awareness activities among general practitioners and delegates of Turkish 
organizations as well as the impact of educational meetings on the Turkish migrant 
population to make an informed decision to participate in screening, might explain the good 
compliance to referral.81 Within one year of follow-up, all newly diagnosed patients had 
HBeAg-negative chronic infection based on normal ALT levels, low HBV DNA levels, HBeAg 
negative status and no significant fibrosis.7 During follow-up, none had an indication for 
antiviral therapy, but continued monitoring was still recommended for risk of HBV 
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reactivation, advanced liver disease and HCC, especially those with HBV DNA levels > 2,000 
IU/mL.7, 59, 171  
Less than one in five susceptible individuals initiated hepatitis B vaccination. This is lower 
than the reported 52 – 89% among migrant populations in the USA and might be explained 
by 1) dissimilar populations, 2) free of charge vaccination or vaccination at a reduced price 
and 3) the use of a combination of letters, phone calls, e-mail and in-person appointments 
to contact susceptible individuals for vaccination in these studies.81, 83, 200-203 This is in 
contrast to our study, in which susceptible individuals were invited by a letter to consult their 
general practitioner for hepatitis B vaccination in accordance with standard practices in 
Belgium. The uptake of vaccination was also low (22%) in an outreach screening project 
among Chinese migrants in the Netherlands.204  
CONCLUSION 
In conclusion, we found that outreach testing and referral to specialist care was clinically 
effective in the Turkish migrant population. We confirmed that HBV prevalence among 
Turkish FGM reflects the high prevalence in the country of origin. An important finding was 
the relatively high infection prevalence in Turkish SGM compared with prevalence estimates 
for the general population in Belgium and other European countries.  Given WHO’s ambitious 
goal to eliminate viral hepatitis by 2030, national HBV screening for Turkish FGM should be 
implemented and might be considered in SGM not covered by primary prevention 
strategies, taking into account the asymptomatic nature of disease and misleading normal 
levels of ALT. Screening projects aimed at SGM are needed to further inform future 
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SUPPLEMENTARY FILES 
Table S 5.1: Association of past or recent hepatitis B virus infection to different risk factors 
among the male study population (n = 468) (weighted GEE model) 
Parameter  Estimate (SE) P 
Value 
aOR (95% CI) 
(intercept)  -2.38 (0.51)   
Age group  
40 – 59 years (vs 18 – 
39 years) 







2.53 (1.15 – 5.56) 
 
5.15 (1.96 – 13.58) 
Ethnicity  


































1.88 (1.08 – 3.28) 
Abbreviation: GEE: generalized estimating equations; SE: standard error; aOR: adjusted odds ratio; CI: 
confidence interval; HBV: hepatitis B virus FGM: first-generation migrants; SGM: second-generation 
migrants. First-generation migrants: foreign-born individuals; second-generation migrants: individuals 
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Table S 5.2: Association of past or recent hepatitis B virus infection to different risk factors 
among the female study population (n = 623) (weighted GEE model) 
Parameter  Estimate (SE) P 
Value 
aOR (95% CI) 
(intercept)  -3.45 (0.33)   
Age group  
40 – 59 years (vs 18 – 
39 years) 







2.83 (1.48 – 5.41) 
 
5.71 (2.58 – 12.65) 
Ethnicity  













2.11 (1.32 – 3.36) 
Abbreviation: GEE: generalized estimating equations; SE: standard error; aOR: adjusted odds ratio; CI: 
confidence interval; FGM: first-generation migrants; SGM: second-generation migrants. First-generation 
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Table S 5.3: Association of past or recent hepatitis B virus infection to different risk factors 
among first-generation migrants (n = 628) (weighted GEE model) 
Parameter  Estimate (SE) P 
Value 
aOR (95% CI) 
(intercept)  -2.42 (0.32)   
Age group  
40 – 59 years (vs 18 
– 39 years) 





1.77 (0.34 ) 
<.001  
2.99 (1.62 – 5.50) 
 




































1.77 (1.23 – 2.54) 
Abbreviation: GEE: generalized estimating equations; SE: standard error; aOR: adjusted odds ratio; CI: 
confidence interval; HBV: hepatitis B virus. First-generation migrants: foreign-born individuals; unsafe 
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Table S 5.4: Association of past or recent hepatitis B virus infection to different risk factors 
among second-generation migrants (n = 453) (weighted GEE model) 




aOR (95% CI) 


















3.38 (1.43 – 7.97) 
Abbreviation: GEE: generalized estimating equations; SE: standard error; aOR: adjusted odds ratio; CI: 
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Table S 5.5: Prevalence of chronic hepatitis B virus infection by different risk factors among 
the total population (n = 1,081) (weighted univariate GEE) 




Crude OR (95% CI) 
Overall  26 1,081 2.4% - - 
Gender 
   Male 











2.55 (1.02 – 6.38) 
(ref) 
Age group 
   18-39 years 
   40-59 years 

















4.28 (1.35 – 13.62) 
6.14 (1.63 – 23.19) 
Ethnicity 
   FGM 











2.15 (0.86 – 5.39) 
(ref) 
Year of immigration (if 
FGM) 
   Before 1987    















1.90 (0.86 – 5.39) 
(ref) 
Southeastern Anatolian 
origin of mother 
   Yes 















1.61 (0.37 – 7.00) 
(ref) 
Mother’s educational level 
   None 
   Primary school 
   Secondary school 



















HBV infected partner 
   Yes 













HBV infected mother 
   Yes 











1.12 (0.10 – 12.22) 
(ref) 
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HBV infected father 
   Yes 













HBV infected siblings 
   Yes 











10.57 (2.88 – 38.82) 
(ref) 
HBV infected other family 
member 
   Yes 



















   Yes  















2.52 (1.06 – 5.99) 
(ref) 
Sharing nail clippers  
   Yes 











1.04 (0.24 – 4.49) 
(ref) 
Sharing razors  
   Yes 











1.37 (0.46 – 4.06) 
(ref) 
Sharing used towels  
   Yes 











0.86 (0.28 – 2.69) 
(ref) 
Eating from the same 
plate at least once 
  Yes 















1.25 (0.36 – 4.34) 
(ref) 
Gynaecological 
examination in Turkey (if 
female) 
   Yes 






















1.10 (0.26 – 4.67) 
(ref) 
Circumcision (if male) 
   Collective 











2.62 (0.97 – 7.12) 
(ref) 
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Circumcision not carried 
out by medical doctor (if 
male) 
   Yes 


















examination in Turkey or 
unsafe circumcision 
   Yes 



















6.93 (2.71 – 17.75) 
(ref) 
Blood transfusion  
   Yes 











1.12 (0.35 – 3.58) 
(ref) 
Dental treatment in 
Turkey 
   Yes 















2.84 (1.23 – 6.60) 
(ref) 
Surgery in Turkey 
   Yes 











2.30 (0.91 – 5.81) 
(ref) 
Treatment with needles in 
Turkey 
   Yes  



















perforation in Turkey 
   Yes  



















0.38 (0.12 – 1.18) 
(ref) 
Fish spa treatment in 
Turkey 
   Yes  
















Abbreviation: OR: odds ratio; CI: confidence interval; FGM: first-generation migrants; SGM: second-
generation migrants. First-generation migrants: foreign-born individuals; second-generation migrants: 
individuals born in Belgium with foreign-born parents; unsafe circumcision: collective circumcision and/or 
circumcision not carried out by medical doctor. 
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Table S 5.6: Vaccination status (solely anti-HBs positive) by different risk factors among the 
total population with information on anti-HBs (n = 1,077) (weighted univariate GEE) 




Crude OR (95% 
CI) 
Overall  247 1,077 22.9% - - 
Gender 
   Male 













0.67 (0.50 – 0.89) 
(ref) 
Age group 
   18-39 years 
   40-59 years 















0.12 (0.08 – 0.17) 
0.04 (0.02 – 0.11) 
Ethnicity 
   FGM  











0.13 (0.09 – 0.18) 
(ref) 
Year of immigration (if 
FGM) 
   Before 1987    















0.38 (0.21 – 0.70) 
(ref) 
Mother’s educational level 
   None 
   Primary school 
   Secondary school 

















0.05 (0.02 – 0.18) 
0.13 (0.04 – 0.46) 
0.40 (0.11 – 1.43) 
(ref) 
Vaccination history 
   Not vaccinated/Unknown 











0.11 (0.08 – 0.15) 
(ref) 
Abbreviation: OR: odds ratio; CI: confidence interval; FGM: first-generation migrants; SGM: second-
generation migrants. First-generation migrants: foreign-born individuals; second-generation migrants: 
individuals born in Belgium with foreign-born parents; unsafe circumcision: collective circumcision and/or 

































































Safety and immunogenicity of HBAI20 vaccine 
in healthy naïve and nonresponding adults 
 
Koc ÖM, Savelkoul PHM, van Loo IHM, Peeters A, Oude Lashof AML  
 










134 | Chapter 6 
 
ABSTRACT  
Background: Approximately 5% of the healthy adult population respond inadequately to 
the commercial recombinant hepatitis B vaccines. As the recombinant vaccines all have an  
aluminium-based adjuvant, we tried to enhance the immune response by adding a 
cytokine-based adjuvant. This new adjuvant AI20, containing 20 μg recombinant human 
IL-2 attached to 20 μg aluminium hydroxide, was added to HBVaxPro©-10 μg (HBAI20). 
Methods: In a double-blind randomized controlled trial (RCT), 24 naïve subjects were 
randomized to receive either HBAI20 or commercial HBVaxPro©-10 μg vaccine. In an open-
label study, 10 nonresponders received HBAI20 vaccine. All participants received 3 
vaccinations (0, 1 and 6 months). 
Results: In the RCT, the occurrence of any adverse events or severe events was similar 
between the trial arms. At month 7, all naïve participants were seroprotected; moreover, 
92% in the HBAI20 group had protective antibodies 10 days after the second vaccination 
vs 58% in the HBVaxPro©-10 μg group, P = .16. In the open-label study, no serious 
adverse events were noted. The HBAI20 vaccine was able to elicit protective anti-HBs titres 
in 90% of nonresponders, 1 month after the third vaccination. 
Conclusions: According to these results, the new HBAI20 vaccine seems safe, well-
tolerated and may promote more rapid protection against hepatitis B infection.  
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INTRODUCTION 
Hepatitis B virus (HBV) infection is still a constant and serious threat to world health. 
According to the World Health Organization (WHO), one third of the world’s population has 
been infected with HBV, and more than 240 million suffer from chronic hepatitis B 
infection.57 It is estimated that 15-40% of patients with hepatitis B will develop cirrhosis, 
liver failure or hepatocellular carcinoma, thus creating a significant burden to healthcare 
systems due to high morbidity, mortality and costs of treatment.172, 205 
Hepatitis B vaccination remains the best tool to  prevent HBV infection and its complications. 
During the past two decades, universal implementation of HBV vaccine programs led to a 
dramatic decrease in the incidence of HBV infection and a subsequent decrease in 
hepatocellular carcinoma.206, 207 Currently available HBV vaccines in Europe and North 
America are formulated with recombinant hepatitis B surface antigen adsorbed to aluminum 
hydroxide or aluminum phosphate adjuvant. However, after a standard three-dose 
vaccination regimen, approximately 5% of vaccinated healthy adults have an inadequate 
antibody response (anti-HBs titre <10 mIU/mL).208-212 In the Netherlands, the vaccination 
schedule is stopped after a total of six hepatitis B vaccinations when development of 
protective antibodies is lacking. The persons with this deficient antibody response are so 
called true non-responders. Risk factors for non-response include age >40, smoking, 
obesity, male sex, and immunodeficiency.213, 214 In addition, genetic factors are most likely 
involved.102 Thus, there appears to be a medical need for a more immunogenic hepatitis B 
vaccine to develop an adequate antibody response. 
One way to improve the immunogenicity to the current HBV vaccines is to enhance the 
adjuvant. Adjuvants are thought to improve immune response by (1) causing depot 
formation at the injection site; (2) increasing interaction between immunogen and antigen 
presenting cell and (3) improving antigen presentation to T-cells, overall producing a more 
targeted immune response.215 
As the recombinant HBV vaccines all have an aluminum-based adjuvant, we tried to 
enhance the immune response by adding a cytokine-based adjuvant. This new adjuvant 
AI20, containing 20µg recombinant human IL-2 attached to 20µg aluminum hydroxide 
(CyTuVax B.V., Maastricht, the Netherlands), was added to HBVaxPro©-10µg (Sanofi 
Pasteur MSD, Haarlem, the Netherlands). This combined vaccine is called HBAI20. 
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In this study, we assessed the safety and immunogenicity of the HBAI20 vaccine in a 









This phase I study involved two trials: a double-blinded RCT in naïve participants and an 
open-label study in a cohort of true non-responders. At the first visit, a physical examination 
was performed and blood and urine sampling were taken, and informed written consent 
was required to participate in the study. For the RCT, a total of 27 participants were screened 
and three naïve participants were excluded for the following reasons: one with liver function 
test abnormalities, one with anti-HBs titre >10 mIU/mL and one had a suspicion of 
Cushing’s syndrome. As such, we included 24 healthy HBV vaccine naïve volunteers in the 
RCT. In the open-label study we screened and included 10 true non-responders. True non-
responders had to have received at least six HBV vaccinations with a documented non 
response (anti-HBs <10 mIU/mL) within six to eight weeks after the last vaccination. All 
participants were between 18 and 59 years of age.  
The study was approved by the local ethics committee and was conducted in accordance 
with the provisions of the Declaration of Helsinki and its amendments. Good clinical practice 
guidelines were followed throughout the study. The study is registered at clinicaltrials.gov 
(NCT02540538). 
Exclusion criteria for participation in both the RCT and open-label study were: seropositivity 
for HBV, hepatitis C virus and/or HIV infection, a known or suspected immune deficiency, 
known or suspected disease that influences the immune system (e.g. cancer, 
transplantation recipients), known or suspected allergy to any of the vaccine components, 
haemodialysis, peritoneal dialysis, a history of unusual or severe reactions to any previous 
vaccination, a history of any neurologic disorder (e.g. epilepsy, autism), use of systemic 
medication that influences the immune system (e.g. immune suppressive treatment), any 
vaccination within three months before screening, blood donation within one month before 
screening, administration of plasma (including immunoglobulins) or blood products within 
12 months before screening, participation in another clinical trial within three months before 
screening, abnormal pre-treatment laboratory parameters which are clinically relevant 
according to the investigator, bleeding disorders or use of medication for bleeding disorders, 
use of anti-coagulants, female subjects planning to become pregnant or breastfeeding 
babies before the last study visit, females with positive urine pregnancy test at screening 
date, excessive alcohol or controlled drug use. Additional exclusion criterion for participants 
in the RCT was a previous hepatitis B vaccination. 
 
138 | Chapter 6 
 
VACCINES  
The experimental vaccine consisted of AI20, containing 20µg recombinant human IL-2 
aggregates adsorbed to 20µg aluminum hydroxide (CyTuVax B.V., Maastricht, the 
Netherlands), combined with HBVaxPro©-10µg (HBAI20). The selection of “20µg” IL-2 was 
based on anti-HBs response study in BALB/c and SJL strain mice, determination of the 
optimal dose in Lewis rats and a toxicology study in New Zealand White rabbits.216 The 
control vaccine was the standard HBVaxPro©-10µg vaccine (Sanofi Pasteur MSD, Haarlem, 
the Netherlands). HBAI20 was prepared by an unblinded nurse immediately before 
administration. HBVaxPro©-10µg was added to the AI20 adjuvant, gently mixed by 
inversion and aspired with a needle in one syringe (1.3 ml). The label on all vaccines 
conceals the volume difference between the two study vaccines.  Both the HBAI20 vaccine 
and the HBVaxPro©-10µg vaccine were injected into the deltoid muscle of the non-
dominant arm by a blinded nurse. 
STUDY DESIGN  
In the RCT, 24 healthy HBV vaccine naïve subjects were randomized in a 1:1 ratio into 
Group 1 (n=12) and Group 2 (n=12). Subjects in Group 1 received the HBAI20 vaccine at 
0 and one  month. The third vaccination, six months after the initial vaccination, consisted 
of the HBVaxPro©-10µg since data concerning shelf life of AI20 adjuvant after three months 
were not yet present at the time of the study. Subjects in Group 2 received the standard 
HBVaxPro©-10µg vaccine at 0, one and six months. Randomisation was performed by the 
ALEA screening and Enrolment Application Software of Formvision BV (Abcoude, the 
Netherlands). Minimisation of stratification factors age and gender were performed.  
In the open-label study, 10 HBV vaccine true non-responders received the HBAI20 vaccine 
at 0 and one month and the HBVaxPro©-10µg vaccine six months after the initial 
vaccination.  
All vaccines were given as intramuscular injections into the deltoid muscle of the non-
dominant arm. Vaccination response (anti-HBs titre) was evaluated 10 and 30 days after 
the first vaccination, 10 and 30 days after the second vaccination, on the day of third 
vaccination and 30 days after the third vaccination. Next to this, at each visit after the first 
vaccination, haematological and biochemical parameters were evaluated for safety reasons. 
Figure 6.1 illustrates the flowchart of the study. 
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Figure 6.1.: Flowchart of the study. The phase I study involved two trials: A) a RCT in naïve 
participants and B) an open-label study in true non-responders. In both the RCT and open-label study, 
there were eight visits (V0-V7) with three vaccinations at day 0 (V1), 30 (V3) and 180 (V6). 
Abbreviations: PIF/IC: patient information file/informed consent; HBV: hepatitis B virus; V: visit; RCT: 
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Participants were closely observed for 30 minutes after the immunization for any immediate 
adverse events. In addition, the subjects were asked to measure their temperature and to 
fill in a symptom diary on the day of first and second vaccination and the subsequent four 
days.  They were asked to record any local (pain, impaired movement of injected arm, 
redness, swelling and induration) and general reactions (fever, headache, fatigue, myalgia, 
vomiting and diarrhoea). Pain at the injection site was scored as none, mild (painful to 
touch), moderate (painful when limb is moved) or severe (spontaneously painful). Impaired 
movement of injected arm was scored as none, mild (bit less than normal), moderate (much 
less than normal) or severe (hardly, or not at all). The size of redness, swelling and 
induration was obtained by measuring their largest diameter and was scored as none, mild 
(>5- 25 mm), moderate (>25 – 50 mm) or severe (>50 mm). General reactions were 
scored as none, mild  (easily tolerated), moderate (interfered with daily activities) and 
severe (prevented normal daily activities). Fever was defined as oral body temperature 
above 37.5°C and was scored as none, mild (37.6 – 37.9°C), moderate (38.0 – 38.9°C) or 
severe (>39.0°C). Diarrhoea was scored as none, mild (1-3 more watery stools compared 
to baseline), moderate (4-5 more watery stools compared to baseline) and severe (>5 
watery stools compared to baseline). Vomiting was scored as none, mild (once in 24 hours), 
moderate (twice in 24 hours) and severe (>3 times in 24 hours). Unsolicited symptoms and 
serious adverse events were recorded throughout the whole study period. All solicited local 
symptoms were considered as related to vaccination. 
LABORATORY ASSAYS  
Haematological parameters, biochemical parameters including thyroid function and 
urinalysis were determined using commercially available laboratory methods 
(Supplementary files, Table S6.1). Further measurements of anti-HBs antibodies assayed 
using routine chemiluminescence assay (Anti-HBs, Cobas 8000, Roche, Germany). Titres 









The demographics of the participants in the RCT and open-label study are listed in Table 
6.1. The healthy HBV vaccine naïve volunteers in the RCT were comparable for mean age 
and mean body mass index (BMI) in both trial arms. In the open-label study, the anti-HBs 
titre in eight out of 10 true non-responders was <2 mIU/mL, two persons had a non 
protective anti-HBs titre of 4 and 5 mIU/mL.  
Table 6.1: Demographic characteristics in the RCT and open-label study 








Number of subjects 12 12 10 
Gender, male (%) 3 (25%) 4 (33%) 5 (50%) 
Mean age, years (IQR) 29 (22 to 32) 29 (22 to 35) 48 (42 to 58) 
Mean BMI, kg/m2 (IQR) 23 (22 to 27) 25 (20 to 25) 29 (24 to 31) 
Anti-HBs titre <2 IU/mL (%) 12 (100%) 12 (100%) 8 (80%) 
Values shown as mean (IQR) or as n (%). Abbreviations: RCT: randomized controlled trial; BMI: body 
mass index; IQR: interquartile range. 
SAFETY AND TOLERABILITY OF THE VACCINE   
After HBAI20 administration there were no laboratory abnormalities that would indicate 
renal, hepatic, thyroid, muscular or bone marrow dysfunctions or detectable inflammatory 
processes potentially attributable to the vaccine.  
In the RCT, there was no significant difference between the HBAI20 group and HBVaxPro©-
10µg group in any adverse events (21.7% vs 21.3%, p = 0.91), mild events (18.3% vs 
19.2%, p = 0.82), moderate events (2.5% vs 1.3%, p = 0.31)  or severe events (0.8% vs 
0.8%, p = 1.00) during each of the four consecutive days after the first and second 
vaccination (Figure 6.2).  
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Figure 6.2.: Percentage of any adverse events and intensity of adverse events during each of 
the four consecutive days after the first and second vaccination in the RCT and in the open-
label study. In the RCT, naïve volunteers were randomized to receive the HBAI20 vaccine or the 
HBVaxPro©-10µg vaccine. In the open-label study, all true non-responders received the HBAI20 vaccine. 
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Table 6.2 lists the overall incidence of solicited local symptoms in the RCT and in the open-
label study. The most frequently reported local symptom in both the RCT and open-label 
study was pain at the injection site. In the RCT, there was no statistically significant 
difference between the HBAI20 group (75.0%) and the HBVaxPro©-10µg (66.7%) 
regarding pain at the injection site, p = 1.00. There were no severe local symptoms in the 
HBAI20 group, and in the HBVaxPro©-10µg group the incidence of these was low: severe 
redness was reported in only one subject. In the open-label study there was one subject 
with severe redness and severe induration. All local reactions in both the RCT and open-
label study resolved within four days after vaccination for 98.5% of subjects.  
Table 6.2: Incidence of solicited local symptoms in the RCT and open-label study 


















(n = 12) 
HBVaxPro©-
10µg  Naïve 
 






(n = 10) 
Pain at the injection 
site 
     
Any 9 (75%) 8 (67%) 1.00 7 (70%) 
Severe 0 (0%) 0 (0%) 1.00 0 (0%) 
Impaired movement 
of injected arm 
Any 8 (67%) 7 (58%) 1.00 4 (40%) 
Severe 0 (0%) 0 (0%) 1.00 0 (0%) 
Redness Any 4 (33%) 5 (42%) 1.00 3 (30%) 
Severe 0 (0%) 1 (8%) 1.00 1 (10%) 
Swelling 
 
Any 2 (17%) 3 (25%) 1.00 0 (0%) 
Severe 0 (0%) 0 (0%) 1.00 0 (0%) 
Induration 
     
Any 1 (8%) 1 (8%) 1.00 3 (30%) 
Severe 0 (0%) 0 (0%) 1.00 1 (10%) 
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The frequencies of any and severe solicited general symptoms are shown in Table 6.3. 
Myalgia was the most frequently reported general symptom in both studies (75% in each 
trial arm in the RCT and 70% in the open label study). In the RCT, the incidence of severe 
events was low and only reported in the HBAI20 group. One naïve participant on HBAI20 
vaccine, with known episodes of migraine, experienced severe headache from day five till 
day 10 after second vaccination. Another participant complained of severe diarrhoea for only 
one day (day three after the first vaccination). The underlying cause of the headache was 
most probably migraine, the cause of diarrhoea was unknown. No treatment was initiated 
concerning the severe headache while the participant with severe diarrhoea started antidota 
on his own initiative. Both occasions were possibly related to the HBAI20 vaccine, there was 
no requirement of hospitalization or referral to a specialist. 
There were no severe general symptoms in the open-label study. In 97.1% of the subjects 
in both the RCT and the open-label study, the solicited general symptoms resolved within 
four days after vaccination.  
Table 6.3: Incidence of solicited general symptoms in the RCT and open-label study 












(n = 12) 
HBVaxPro©-
10µg  Naïve 
 






(n = 10) 
Fever 
     
Any 0 (0%) 0 (0%) 1.00 1 (10%) 
Severe 0 (0%) 0 (0%) 1.00 0 (0%) 
Headache Any 2 (17%) 4 (33%) 0.64 1 (10%) 
Severe 1 (8%) 0 (0%) 1.00 0 (0%) 
Fatigue Any 3 (25%) 5 (42%) 0.67 3 (30%) 
Severe 0 (0%) 0 (0%) 1.00 0 (0%) 
Myalgia Any 9 (75%) 9 (75%) 1.00 7 (70%) 
Severe 0 (0%) 0 (0%) 1.00 0 (0%) 
Vomiting 
     
Any 1 (8%) 0 (0%) 1.00 0 (0%) 
Severe 0 (0%) 0 (0%) 1.00 0 (0%) 
Diarrhoea 
     
Any 2 (17%) 2 (17%) 1.00 0 (0%) 
Severe 1 (8%) 0 (0%) 1.00 0 (0%) 
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Unsolicited symptoms were reported in the RCT by four subjects receiving HBAI20 and two 
subjects receiving HBVaxPro©-10µg. In the open-label study, five subjects reported 
unsolicited symptoms. The reported symptoms were not identical between the subject. 
There were no symptoms, such as migraine and bronchitis, considered to be related to the 
vaccine No serious adverse event was reported for any subject in the RCT or open-label 
study. 
IMMUNOGENICITY OF THE VACCINE  
In the RCT, which included naïve seronegative subjects, all patients achieved seroprotection 
at visit 7, one month after the third vaccination (Figure 6.3). There was no statistically 
significant difference in seroprotection between the groups across the visits, OR = 0.455, 
95% CI 0.036- 5.813, p=0.534 at visit 3 (30 days after the first vaccination) and OR = 
0.600, 95% CI 0.081- 4.447, p=0.614 at visit 5 (30 days after the second vaccination). 
Corrected for age and gender in logistic regression analysis of the 10log anti-HBs data similar 
results were obtained.  At visit 4 (10 days after the second vaccination) 11 subjects (92%) 
in the HBAI20 group versus 7 subjects (58%) in the HBVaxPro©-10µg had protective level 
of antibodies (p=0.16).  
In the repeated measures ANOVA analysis the general trend over the visits 2 to 7 showed 
a significant increase in anti-HBs titre (p<0.001). Linear trend difference between treatment 
groups was not significant (p=0.237).  Age and gender showed no significant differences in 
the linear trend. The GMTs in the subjects receiving the HBAI20 vaccine versus HBVaxPro©-
10µg vaccine almost reached statistical significance 10 days after the first vaccination with 
584.7 mIU/mL (95% CI: 300.3-869.1) and 369.7 mIU/mL (95% CI: 74.9-664.6), p = 0.05 
(Figure 6.4). At visits 5 and 7 older patients had significantly more difficulty to build up 
immune response (p=0.014, resp. p < 0.001). Effect of gender was not significant.  
In the open-label study, HBAI20 vaccine was able to elicit protective anti-HBs titres in 90% 
of the true non-responders at one month after the third vaccination (Figure 6.3). The GMTs 
of anti-HBs antibodies of the non-responders can be found in Figure 6.4. 
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Figure 6.3.: Seroprotection rate in the RCT of healthy naïve volunteers and in the open-label 
study of true non-responders. In the RCT, naïve subjects received the HBAI20 vaccine (circles) or 
the HBVaxPro©-10µg vaccine (squares). In the open-label study, all true non-responders received the 
HBAI20 vaccine (triangles). The first and second vaccination consisted of the HBAI20 vaccine or 
HBVaxPro©-10µg. All participants received HBVaxPro©-10µg as the third vaccination. Abbreviation: 
RCT: randomized controlled trial; vac: vaccination. 
 
Figure 6.4.: Geometric mean titres (GMTs) of anti-HBs antibodies in the RCT of healthy naïve 
volunteers and in the open-label study of true non-responders. In the RCT, naïve subjects 
received the HBAI20 vaccine (circles) or the HBVaxPro©-10µg vaccine (squares). In the open-label study 
of true non-responders all received the HBAI20 vaccine (triangles). The first and second vaccination 
consisted of the HBAI20 vaccine or HBVaxPro©-10µg. All participants received HBVaxPro©-10µg as the 
third vaccination. Abbreviation: RCT: randomized controlled trial; vac: vaccination. 
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DISCUSSION 
According to this phase I study, the HBAI20 vaccine seems safe, well-tolerated and may 
promote more rapid protection against HBV infection. In the RCT, the HBAI20 vaccine 
achieved seroprotection in 11 (92%) of the naïve subjects 10 days after the second 
vaccination in comparison to 7 subjects (58%) in the HBVaxPro©-10µg vaccine. Moreover, 
in the open-label study the HBAI20 vaccine provided protective antibodies in 90% of the 
true non-responders. However, one true-non responder remained seronegative at month 
7. This might be due to chronic local corticosteroid use. 
Severe side effects like hypotension, pulmonary edema and renal dysfunction have been 
associated with high-dose intravenous bolus IL-2 in metastatic renal cell cancer.217 However, 
the AI20 adjuvant applied intramuscularly in this trial used only 20µg of IL-2 that represents 
1.8% of the recommended dose for the treatment of metastatic renal cell cancer. Moreover, 
95% of the IL-2 in the adjuvant is depot bound allowing a slow release of the drug and thus 
effectively decreasing the local and, as a consequence, also the systemic IL-2 concentration. 
As the undesirable effects of IL-2 are dependent on the dose and way of administration 
(intravenously, subcutaneously or intramuscularly)218-220, we did not see any of the 
described adverse drug reactions reported for IL-2 except the common side effects seen in 
injection-site reactions. In clinical studies with a similar set-up, IL-2 used as adjuvant in a 
liposome-based influenza vaccine showed that the use of a similar dose of IL-2 (33µg) in a 
liposome formulation indeed resulted in a similar rate of adverse reactions compared with 
the current commercial influenza vaccines.218, 221 
The possibility of inducing specific production of antibodies against hepatitis B surface 
antigen (anti-HBs) with IL-2 has been studied previously in healthy HBV vaccine naïve 
participants222 and in HBV vaccine non-responders223-225. In a pilot study of Meuer et al225, 
six of only 10 non-responder patients appeared to respond to concurrent IL-2 administration 
and HBV revaccination. The patients had renal failure and were on long-term hemodialysis. 
However, these encouraging results have not been confirmed by other groups.222-224 
Nonetheless, previous studies assessing IL-2 as an efficient mean of inducing HBsAg specific 
immune response have been hampered by the short half-life of IL-2.222-227 Our current study 
is the first report in humans using aggregated IL-2 molecules attached to aluminum 
hydroxide, facilitating the slow release of highly concentrated IL-2 nano aggregates. 
Although much is known about the immunological effects of IL-2226, 228-235, the mechanism 
of their adjuvancy with hepatitis B vaccine has not been characterized. IL-2 exerts its effect 
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by binding on the high-affinity trimeric IL-2 receptor or the low-affinity IL-2 receptor.236 The 
group of Velten237 and Mnasria238 have reported that dendritic cells upregulate their 
expression of CD25 after antigen stimulation, and CD25 expression can serve to present IL-
2 in trans to antigen-specific T cells. This CD25 upregulation correlated with improved 
dendritic cell-mediated stimulation of allogeneic CD4 T cell proliferation.226, 237, 238 IL-2 also 
promotes TH1 cell generation by increasing the levels of IL-12 receptor β2 subunit and via 
the induction of T-bet expression.226, 231, 239 Similarly to the generation of  TH1 cells, TH2 cell 
differentiation appears to require stimulation by IL-2. IL-2 signals induce the upregulation 
of IL-4 receptor α and enhance the production of typical TH2-type cytokines, notably IL-4, 
IL-5 and IL-13.226, 232, 240 
CONCLUSION 
The results of this phase I study support further studies with HBAI20 vaccine in healthy 
naïve adults and non-responders. The accelerated antibody response after two doses 
indicate that the HBAI20 vaccine may be useful in immunizing difficult to access populations 
such as injection-drug users and homeless people. Other potential uses for this novel 
HBAI20 vaccine with enhanced immunogenicity would be for the populations known to be 
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SUPPLEMENTARY FILES 
Table S 6.1: Laboratory parameters and normal ranges for haematology, biochemistry and 
urinalysis 
HAEMATOLOGY  Differential WBC count 
Hematocrit (%)  ♂42-52 % ♀36-48% 
 
Neutrophils (%) 40 - 70 % 
Hemoglobin (mmol/L) ♂8.2-10.4 ♀7.3-9.7 mmol/L Eosinophils (%) 0 - 10 % 
RBC count (1012/L) ♂4.2-6.0 ♀3.7-5.0 1012/L Basophils (%) 0 - 2 % 
WBC count (109/L) 3.5 - 11.0 109/L Lymphocytes (%) 15 - 48 % 
Platelet count (109/L) 130 - 350 109/L Monocytes (%) 4 - 11 % 
  
BIOCHEMISTRY VIROLOGY 
Creatinine (µmol/L) ♂64-104 ♀50-100 µmol/L HIV-test - Negative 
Albumin (g/L) 32.0 - 47.0 g/L HBV serology and quantitative anti-HBs 
titre 
Alkaline phosphatase (U/L) ♂53-128 ♀42 - 98 U/L HCV - Negative 
Total Bilirubin (µmol/L) < 20 µmol/L  
ALAT  (U/L) < 34 U/L Immunogenicity of adjuvant 
ASAT  (U/L) ♂<40 ♀< 31 U/L  IL-2 antibody titre 
Gamma-GT (U/L) < 38 U/L   
CRP test (mg/dL) < 10 mg/dL  
TSH (mU/L) 0.4 - 4.3 mU/L  
FT4sdmfksadjlfkjsalkpspdfjlkasdjffsadf 
 
  (p ol/L) 8.0 - 18.0 pmol/L  
  
URINALYSIS Only if urinalysis is abnormal, Urinary 
sediment microscopically 
Leukocytes [0-15] Leucocytes (0 - 5HPF) 
Nitrite [negative] Erythrocytes (fresh) (0 - 3HPF) 
pH 4.5 - 8.0 Erythrocytes (dysmorphic) 
Erythrocytes [0-10] Mucus track 
Protein (albumin) [<0.3 g/L] Crystals 
Glucose [negative] Yeast cells 
Pregnancy test Threads of mycelium 
 Bacteria 
 Squamous cells 
Abbreviations: RBC: red blood cell; WBC: white blood cell; HBV: hepatitis B virus; HCV: hepatitis C virus; 
ALAT: alanine-aminotransferase; ASAT: aspartate-aminotransferase; IL-2: interleukin-2; Gamma-GT: 
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gamma-glutamyltransferase; CRP: C-reactive protein; TSH: thyroid-stimulating hormone; FT4: free 
thyroxine. 
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ABSTRACT 
Background: Approximately 5 – 10% of the general population respond inadequately to 
licensed recombinant hepatitis B vaccines. We assessed the immunogenicity and safety of 
a new HBAI20 vaccine. 
Methods: In a double-blind, randomised, controlled phase 2 trial, 18 – 59 years old healthy 
non-responders were assigned (3:1 ratio) to receive either HBAI20 vaccine or HBVaxPro®-
10µg in a 0, 1 and 2 months schedule. The primary outcome was seroprotection (titre > 10 
mIU/mL) measured 1 – 3 months following the third vaccination. ClinicalTrials.gov number, 
NCT03415672. 
Findings: A total of 133 participants were randomised to receive either HBAI20 vaccine (n 
= 101) or HBVaxPro®-10µg (n = 32). In the modified intention-to-treat analysis (after 
excluding those according to the in- and exclusion criteria), the seroprotection rate after the 
third vaccination was higher in the HBAI20 group (80/87, 92·0%) than in the HBVaxPro®-
10µg group (23/29, 79·3%), p = 0·068. Using a generalized linear mixed model to adjust 
for stratification factors, a higher odds of seroprotection with HBAI20 vaccine was shown 
(adjusted odds ratio = 3·48, p = 0·028). Frequency of mild and moderate local adverse 
events was greater in the HBAI20 group than in the HBVaxPro®-10µg. Rates of severe local 
adverse events and systemic adverse events were low and similar in both groups. There 
were two serious adverse events, both unrelated to the intervention.  
Interpretation: In this group of hepatitis B vaccine non-responders, the HBAI20 vaccine 
demonstrated a higher seroprotection rate and a similar safety profile compared to the 
licensed recombinant HBVaxPro®-10µg.  
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Research in context 
Evidence before this study  
Currently, several hepatitis B vaccines are commercially available to protect people from 
hepatitis B virus infection. However, these vaccines do not induce protective immunity (anti-
HBs level > 10 mIU/mL) in 5 – 10% of the healthy adult population. Persons with this 
inadequate immune response after a complete hepatitis B vaccination schedule are called 
non-responders. The standard of care for healthy non-responders consists of revaccination 
with commercially available hepatitis B vaccines and is associated with a seroprotection rate 
of 50 – 69% after three doses. We searched PubMed, without language restrictions, from 
inception until Aug 21, 2019, using the following terms: (((("Hepatitis B Vaccines"[Mesh]) 
OR hepatitis b vaccine)) AND ((non-responder) OR nonresponder)) AND (("Adult"[Mesh]) 
OR healthy adult). Among a total of 57 articles retrieved and screened, we identified one 
double-blind, randomised, controlled trial assessing the immunogenicity of hepatitis B 
vaccines in healthy non-responding adults. This study conducted in China reported a higher 
immunogenic response to revaccination with high antigen content (60µg vs 10µg hepatitis 
B surface antigen in the commercially available hepatitis B vaccine). Further, two single-
blind randomised controlled trials in healthy non-responding adults showed a higher 
immunogenic response with adjuvanted vaccines compared to a commercially available 
hepatitis B vaccine. The first adjuvanted hepatitis B vaccine Fendrix® is currently licensed 
in Europe for patients with renal dysfunction, although not indicated for the healthy non-
responder population. One should also notice that the higher seroprotection rate with 
Fendrix®  is not only linked to the adjuvant 3-O-desacyl-4'-monophosphoryl lipid A (MPL) 
but also to the higher antigen content  (40µg in Fendrix®  vs 20µg in commercially available 
hepatitis B vaccine). The second vaccine Heplisav-B®, with a phosphorothioate 
oligodeoxyribonucleotide adjuvant, was never licensed in Europe.  
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Added value of this study 
This is the first double-blind, randomised, controlled trial in healthy adult non-responders 
assessing the immunogenic properties of a cytokine-based adjuvant (AI20 adjuvant: 20µg 
recombinant human IL-2 adsorbed to 20µg aluminium hydroxide). The new vaccine is called 
HBAI20 and consists of the new adjuvant AI20 in combination with HBVaxPro®-10µg 
vaccine. 
Implications of all the available evidence 
In this study, we demonstrated that the new HBAI20 vaccine was > 3 times more likely to 
induce seroprotection compared to the commercially available HBVaxPro®-10µg vaccine 
when given to healthy hepatitis B vaccine non-responders at 0, 1 and 2 months schedule. 
Safety was comparable between both groups. These results support further studies to 
assess the benefits of the HBAI20 vaccine in other populations known to have a suboptimal 
immune response to hepatitis B vaccination, i.e. older individuals, patients with advanced 
liver disease, haemodialysis patients and patients with other immunodeficient conditions. 
Taking into account the additional immunogenic properties of the AI20 adjuvant, it might 
be reasonable to consider the AI20 adjuvant for other vaccines conferring a suboptimal 
response, such as for influenza or tuberculosis vaccines.  
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INTRODUCTION 
Hepatitis B virus (HBV) infection is one of the most common and serious infectious diseases 
globally. It is estimated that one third of the world’s population has been exposed to HBV, 
which has resulted in 257 million chronic HBV carriers worldwide.57 The economic burden of 
HBV infection is substantial because of the high morbidity and mortality associated with 
cirrhosis, hepatocellular carcinoma and liver failure.13 
HBV is up to 100 times more infectious than HIV.57 As such, the development of a hepatitis 
B vaccine has been a major breakthrough in the global effort to eradicate HBV infection.241 
Current licensed HBV vaccines are produced in Saccharomyces cerevisiae and are 
composed of hepatitis B surface antigen (HBsAg) which is adsorbed to aluminium hydroxide 
or aluminium phosphate.242  Despite their proven immunogenicity and safety, currently 
available recombinant hepatitis B vaccines are unable to induce an adequate immune 
response in 5 – 10% of the general adult population.243 Persons lacking this antibody 
immune response (anti-HBs level < 10 mIU/mL measured at 1 to 3 months after completion 
of the hepatitis B vaccination schedule) are referred to as non-responders.243 The standard 
of care for non-responders consists of revaccination with currently licensed hepatitis B 
vaccines and is associated with a seroprotection rate of 50 – 69% after three doses.93, 96-99 
Thus, there is a need for a more immunogenic vaccine in defined groups such as healthy 
non-responders to recombinant hepatitis B vaccines. 
Among healthy adult non-responders to primary hepatitis B vaccination, a previous double-
blind, randomised, controlled trial in China demonstrated seroprotection in 92.1% 
(394/428), 87.1%  (371/426) and 83.0% (180/217) with hepatitis B vaccines respectively 
containing 60µg, 30µg and 10µg HBsAg.104 Moreover, two single-blind randomised 
controlled trials in healthy non-responders showed a higher immunogenic response with 
adjuvanted vaccines, one with Fendrix® and one with Heplisav-B®.97, 98 Among a total of 
82 participants, the seroprotection rate was 97.5% in the group that received three doses 
of Fendrix® compared to 68.0% with three doses of Engerix-B®.98 The observed higher 
seroprotection rate with Fendrix® was not only linked to the adjuvant 3-O-desacyl-4'-
monophosphoryl lipid A (MPL) but also to the higher antigen content, i.e. 40µg HBsAg in 
Fendrix® vs 20µg in Engerix-B®.98 The study of Halperin et al97 was conducted among 35 
non-responders and seroprotection was found in 88.9% and 66.7% after two doses with 
Heplisav-B® and Engerix-B®, respectively. At present, Fendrix® is only licensed for 
individuals with renal alteration, while Heplisav-B® is never licensed in Europe. 
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Since the available recombinant hepatitis B vaccines all have an aluminium-based adjuvant, 
we report for the first time the immunogenic properties of a cytokine-based adjuvant in a 
well-designed double-blind, randomised controlled trial in healthy adult non-responders. In 
a phase 1 trial, the new AI20 adjuvanted (HBAI20) vaccine was shown to be safe, well-
tolerated and immunogenic in healthy naive and non-responding adults.244 The current 
study describes a phase 2 trial to evaluate in healthy non-responders the immunogenicity 
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MATERIALS AND METHODS 
STUDY DESIGN 
The study was a phase 2, double-blind (participant and investigator), randomised, 
controlled, multicentre trial. The protocol (in accordance with the CONSORT statement 
which is available at thelancet.com) was approved by the local ethics committee and was 
conducted in accordance with the guidelines of the Declaration of Helsinki and its 
amendments and in accordance with good clinical practice and local laws. 
PARTICIPANTS 
The participants were hepatitis B vaccine non-responders, ranging in age from 18 to 59 
years. Non-responders were defined as subjects with documented three or more hepatitis 
B vaccinations and documentation of hepatitis B surface antibody (anti-HBs) level < 10 
mIU/mL measured within 1 – 3 months after the last vaccination.243 Non-responders were 
identified from Occupational Health Services located in the Netherlands and Belgium, and 
subsequently invited for enrolment in one of the trial sites: Maastricht UMC+ (Maastricht, 
the Netherlands), Antwerp University (Antwerp, Belgium) or Hospital East-Limburg (Genk, 
Belgium). The following exclusion criteria were used in the study: anti-HBs level  > 10 
mIU/mL, HBsAg positivity, positive for hepatitis B core antibodies (anti-HBc), positive for 
HCV antibodies, positive for HIV antibodies, any infectious disease at the time of screening 
or enrolment, known or suspected immune deficiency, known or suspected disease that 
influences the immune system (e.g. cancer and transplantation recipients), known or 
suspected allergy to any of the vaccine components, dialysis patients, history of unusual or 
severe reactions to any previous vaccination, history of any neurologic disorder (e.g. 
epilepsy and autism), use of medication that influences the immune system (e.g. 
corticosteroids), hepatitis B vaccination or any other vaccination within three months before 
screening (with the exception of influenza vaccinated individuals who were included), blood 
donation within one month before screening, administration of plasma or blood products 
within 12 months before screening, participation in another clinical trial within three months 
before screening, abnormal pre-treatment laboratory parameters which are clinically 
relevant according to the investigator, bleeding disorders, participants on coumarin 
anticoagulants and participants receiving two or more platelet aggregation inhibitors, female 
subjects planning to become pregnant or breastfeeding babies until the last study visit, 
females with positive urine pregnancy test at screening date, excessive alcohol or illicit drug 
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use. Excessive alcohol use was defined as > 14 units per week in males and > 7 units per 
week in females.245 
RANDOMISATION AND BLINDING 
Participants were randomly assigned to the HBAI20 vaccine or the HBVaxPro®-10µg 
vaccine at a 3:1 ratio. Randomisation was performed by the ALEA screening and Enrolment 
Application Software (Formvision B.V., Abcoude, the Netherlands) and with minimization of 
stratification factors: age (18 - 25, 26 - 35, 36 - 50 or 51 - 59 years), sex (male or female), 
hepatitis B vaccination history (one complete cycle or more than one cycle) and trial site 
(Maastricht UMC+, Antwerp University or Hospital East-Limburg). Blinding of participants 
and investigators was achieved by a label that concealed the volume difference between 
the two vaccines. The colour was similar in both vaccines. All investigators and participants 
were kept blinded for the respective anti-HBs results after the study vaccinations. 
PROCEDURES 
The investigational vaccine (HBAI20) consisted of a new adjuvant AI20, containing 20µg 
recombinant human IL-2 attached to 20µg aluminium hydroxide (CyTuVax B.V., Maastricht, 
the Netherlands), in combination with HBVaxPro®-10µg.244 The comparator vaccine was 
the licensed HBVaxPro®-10µg vaccine 1.0 mL (MSD VACCINS, Lyon, France). Within one 
hour before administration, the HBAI20 vaccine was prepared by an unblinded study 
personnel. HBVaxPro®-10µg was added to the AI20 adjuvant, gently mixed by inversion 
and aspired with a needle in one syringe (1.3 mL). Vaccines were injected into the deltoid 
muscle of the non-dominant arm by an unblinded nurse following the recommended 0, 1 
and 2 months revaccination schedule for non-responders in the Netherlands.243 The 
unblinded nurse did not perform any other study tasks. 
Blood samples were drawn at screening visit 0 (day -30 – 0), visit 1 (day 0), visit 2 (day 28 
– 40), visit 3 (day 56 – 80) and visit 4 (day 96 – 132). At the first visit (visit 0), study 
participants gave written informed consent, were checked for in- and exclusion criteria, 
underwent physical examination, serological screening (complete and differential blood 
count, renal function, liver function, thyroid function, inflammatory parameters, HIV, 
hepatitis C virus (HCV) and HBV serology) and urine sampling. Urinalysis consisted of 
leukocytes, nitrite, pH, erythrocytes, protein and glucose measurement in all participants. A 
pregnancy test was taken from female participants. At visit 2, 3 and 4 anti-HBs antibody 
levels were determined, and at visit 4 additional blood samples were drawn for 
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haematological and biochemical evaluation. For organizational reasons, screening visit 0 and 
visit 1 were combined in one out of three trial sites. 
Participants were closely observed for 30 minutes after each vaccination for any immediate 
adverse events.  On the day of vaccination and the subsequent four days, subjects were 
asked to record local adverse events (pain, impaired movement of injected arm, redness, 
swelling and induration) and systemic adverse events (fever, headache, fatigue, vomiting 
and diarrhoea) in individual diary cards. 
OUTCOMES 
The primary endpoint of this study was the immunogenicity of the HBAI20 vaccine, tested 
in terms of proportion with seroprotection at 1 – 3 months after the third vaccination. 
Seroprotection rates measured at earlier time points and geometric mean concentrations 
(GMC) were secondary endpoints. 
Local and systemic adverse events were scored as absent, mild (no interference with daily 
activity), moderate (some interference with daily activity), or severe (prevented normal 
daily activities). The size of redness, swelling and induration was scored as absent, mild (> 
5 – 25 mm), moderate (> 25 – 50 mm), or severe (> 50 mm). Fever was defined as oral 
body temperature above 37·5°C and was scored as absent, mild (37·6 – 37·9°C), moderate 
(38·0 – 38·9°C), or severe (> 39·0°C). Vomiting was scored as absent, mild (once in 24 
hours), moderate (twice in 24 hours), or severe (three or more times in 24 hours). 
Diarrhoea was scored as absent, mild (1 – 3 stools above normal), moderate (4 – 5 stools 
above normal), or severe (> 5 stools above normal).  Unsolicited symptoms and serious 
adverse events were recorded throughout the study period. All solicited local adverse events 
were considered as related to study vaccine. The investigators assessed the relationship of 
all other reported adverse events to vaccination. 
LABORATORY ASSAYS 
Haematological, biochemical, virological parameters and urinalysis were determined using 
commercially available laboratory methods. Serum anti-HBs antibody levels were analysed 
with the Cobas 8000 chemiluminescence assay (Roche, Germany). Subjects with anti-HBs 
antibody levels > 10 mIU/mL were considered to be seroprotected and deemed vaccine 
responders.243 
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STATISTICAL ANALYSIS 
Sample size calculation could not directly be based on phase 1 HBAI20 study data because 
the study population characteristics were different with respect to hepatitis B vaccination 
history (naive subjects vs non-responders). Our aim was to include between 132 – 140 
subjects in agreement with other  phase 2 immunogenicity and safety studies for hepatitis 
B vaccines.97, 98, 246, 247 Sample size for this trial was based on superiority analysis. A non-
inferiority (NI) analysis was not initially performed. However, an NI margin is specified in 
case superiority cannot be shown, then a switch can be made to NI analysis. The NI margin 
was set to 10% in line with previous studies.248, 249 
All data of the outcome variable anti-HBs level were log10-transformed. To overcome 
problems with zero values, a value of + 0·5 was added to all anti-HBs levels. Continuous 
variables were expressed as mean ± standard deviation, SD. For the comparison of 
categorical variables, either Chi squared test or Fisher’s exact test was used. Student’s t test 
or Kruskall-Wallis test was used to compare groups in terms of continuous outcomes.  
Safety analysis was performed including all participants that received at least one 
vaccination (Figure 7.1). The percentage of adverse events for the two vaccines was 
compared using a Chi squared test for the equality of proportions, or a Fisher’s exact test in 
case of small samples. A modified intention-to-treat (mITT) approach was used for 
superiority analysis. In order to establish statistically significant superiority of the new 
vaccine, the one-sided 95% confidence interval (CI) for the odds ratio (OR) of seroprotection 
has to lie entirely above one.  
Since there was one missing seroprotection outcome at visit 3 and 4, and two at visit 2, 
multiple imputation was used to impute these values. The GMC values were imputed. 
Multiple imputation was done using the Statistical Analysis Software (SAS Institute Inc., NC, 
USA) procedure PROC MI. Considering the non-monotone pattern of missingness, the fully 
conditional specification (FCS) regression method was used to fill in the missing values.250 
Imputation was done separately for the two vaccine allocations, to avoid imposing any 
relationship between the outcome variables and this covariate. The data were imputed five 
times. For each imputed dataset, a generalized linear mixed model was used to estimate 
the vaccine effect at visit 4, i.e. 1 – 3 months following the last vaccination. The stratification 
factors vaccination history, age, and sex were included as fixed effects in the model, in 
addition to vaccine allocation (i.e. treatment effect). Interactions between these stratification 
factors and vaccine allocation were also included in the model. If not significant, the 
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interaction effect was removed from the model, indicating no difference between vaccine 
allocations within the stratification group. Trial site was included as a random effect. To 
assess the sensitivity of the results to the method of handling missing data, extreme case 
analyses were done, i.e. worst case and best case analysis. All reported p-values for vaccine 
allocation were based on one-sided tests. 
Independent data monitoring committee Clinical Trial Center Maastricht oversaw the study. 
The study was registered at clinicaltrials.gov (NCT03415672). 
ROLE OF THE FUNDING SOURCE  
The study was partially sponsored by CyTuVax B.V., and the sponsor was involved in the 
study design, interpretation of the data, review and approval of the manuscript in 
accordance with good clinical practice. The funding source had no input in data collection 
and statistical analysis of the data. ÖK, CK, NH and AOL had full access to all the data in the 
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RESULTS 
Participants were recruited from January 5, 2017 to September 21, 2018. The last visit 
occurred on January 18, 2019. Out of 1,074 persons invited, 335 HBV vaccine non-
responders replied initially for participation. A total of 41/335 (12·2%) individuals were 
deemed ineligible by the investigator and 149/335 (44·5%) subjects could not be contacted 
after at least two attempts. In the end, 145/335 (43·3%)  participants were screened and 
a total of 133 subjects were enrolled and randomly assigned to receive either HBAI20 
vaccine (n = 101) or HBVaxPro®-10µg vaccine (n = 32) (Figure 7.1).  
The baseline characteristics of the 133 included subjects are shown in Table 7.1. The HBAI20 
and HBVaxPro®-10µg groups were balanced in terms of Body-Mass Index (26 ±  4·9 vs 26 
±  6·5, p = 0·543) and the number of individuals with undetectable anti-HBs levels (< 2 
mIU/mL) prior to study vaccination (69/101 (68·3%) vs 27/32 (84·4%), p = 0·124). 









Mean age – years  40 + 14·3 40 + 14·8 
Sex – no. (%) 
   Male 







Hepatitis B vaccination – no. (%) 
   1 complete cycle 
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Of the 133 randomised participants, 132 received at least one dose of HBAI20 vaccine or 
HBVaxPro®-10µg vaccine. There were 117 participants included in the mITT 
immunogenicity analysis; 15 subjects were excluded, mainly due to seroprotection attained 
prior to study vaccination (Figure 7.1). A total of 116 participants received all three doses 
(one drop out in the HBAI20 group due to an adverse event after one vaccination). 
A total of 80 (92·0%) participants in the HBAI20 group and 23 (79·3%) participants in the 
HBVaxPro®-10µg group achieved seroprotection, as measured at 1 – 3 months after the 
third vaccination, p = 0·068.  At one month after the first vaccination, seroprotection rates  
were respectively 64·0% vs 69·0% (p = 0·761) and these numbers were 82·8% vs 72·4% 
(p = 0·172) at one month after the second vaccination. One to 3 months following the last 
vaccination, 55 participants (63·2%) in the HBAI20 group and 15 (51·7%) in the 
HBVaxPro®-10µg group had anti-HBs levels > 100 mIU/mL (p = 0·190). 
The GMCs were higher in the HBAI20 group than in the HBVaxPro®-10µg group after 
vaccination with one (21·9 ± 15·1 vs 17·8 ± 10·7, p = 0·390), two (72·4 ± 12·3 vs 41·7 ± 
11·5, p = 0·157) and three study vaccines (162·2 ± 7·9 vs 64·6 ± 10·2, p = 0·037).  
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Figure 7.1: Flow chart of the study. Abbreviations: ITT: intention-to-treat analysis; mITT: modified ITT analysis; HCV: hepatitis C virus; HBsAg: hepatitis B 
surface antigen. 
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Using a generalized linear mixed model, adjusting for stratification factors, the primary 
endpoint was met and a higher odds of seroprotection with the HBAI20 vaccine was shown 
(adjusted OR = 3·48, lower bound of 95% CI = 1·19, p = 0·028) (Table 7.2). Since 
imputation of one missing value at visit 4, i.e. 1 – 3 months after the third vaccination, 
resulted in a seroprotected score, results from table 2 correspond to the best case scenario. 
For the worst case scenario, i.e. person with missing value did not achieve seroprotection, 
HBAI20 vaccine was still shown to give a higher odds of seroprotection (adjusted OR = 2·95, 
lower bound of 95% CI = 1·05, p = 0·042). 
Table 7.2: Results of the generalised linear mixed model. Age, sex and hepatitis B vaccination 
history were included as fixed effects in the model, in addition to vaccine allocation, i.e. treatment effect. 
Trial site was included as a random effect 
Characteristic Estimate 
(SE) 
OR (95% CI) P Value 
HBAI20 vaccine† 1·25 (0·65) 3·48 (1·19 – ∞) 0·028 
Age (> 40 years) - 0·88 (0·73) 0·42 (0·10 – 1·76) 0·231 
Male sex - 0·47 (0·64) 0·62 (0·18 – 2·19) 0·459 
More than 1 hepatitis B vaccination cycle - 1·60 (0·82) 0·20 (0·04 – 1·03) 0·054 
Abbreviations: SE: standard error; OR: odds ratio; CI: confidence interval.  
Within the group of individuals who received the HBAI20 vaccine, seroprotection after three 
vaccinations was seen in 11 (73·3%) out of 15 participants without pain at the injection site, 
compared to 76 (96·2%) out of 79 participants with pain at the injection site, p = 0·012. In 
the HBVaxPro®-10µg group, no association was found between pain at the injection site 
and seroprotection after three vaccinations (6/10 (60·0%) without pain at the injection site 
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There was a higher incidence of solicited local adverse events in the HBAI20 group than 
HBVaxPro®-10µg group (13·7% vs 8·7%, p < 0·001), while the overall incidence of 
systemic adverse events was similar for both vaccines (4·0% vs 3·4%, p = 0·198). The 
percentage of participants with mild, moderate and severe adverse events (local and 
systemic) in each group is illustrated in figure 7.2. 








































Figure 7.2: Percentage of mild, moderate and severe adverse events (local and systemic) at 
the day of vaccination and the four consecutive days after three vaccinations with the 
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The most frequently reported local adverse event in both the HBAI20 group (32·7%) and 
HBVaxPro®-10µg group (18·6%) was pain at the injection site, p < 0·001. Pain at the 
injection site resolved within four days after vaccination for 94% and 97%, respectively. 
There were no severe local adverse events in the HBVaxPro®-10µg group and these were 
low in the HBAI20 group. None of the participants experienced severe local adverse events 
for longer than four days. The frequencies of any and severe local adverse events are shown 
in Table 7.3. 
Table 7.3: Incidence of local solicited adverse events during the day of vaccination and each 









Local adverse events  HBAI20 
(n = 1,345 days) 
HBVaxPro®-10µg 
(n = 435 days) 
P Value 
Pain at the injection site 
     
Any 440 (32·7%) 81 (18·6%) < 0·001 
Severe 0 (0·0%) 0 (0·0%) ·· 
Impaired movement of 
injected arm 
Any 198 (14·7%) 43 (9·9%) 0·013 
Severe 0 (0·0%) 0 (0·0%) ·· 
Redness Any 95 (7·06%) 16 (3·7%) 0·015 
Severe 2 (0·1%) 0 (0·0%) 1·000 
Swelling 
 
Any 79 (5·9%) 25 (5·8%) 1·000 
Severe 1 (0·1%) 0 (0·0%) 1·000 
Induration 
     
Any 106 (7·9%) 24 (5·5%) 0·123 
Severe 1 (0·1%) 0 (0·0%) 1·000 
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The most frequently reported systemic adverse event was fatigue (10·6% vs 9·7%, p = 
0·655), which resolved within four days post-vaccination in 96% and 91% of the participants 
in the HBAI20 group and HBVaxPro®-10µg group, respectively. The incidence of severe 
systemic adverse events was low and comparable in both groups. In all cases, severe 
systemic adverse events resolved within four days. Table 7.4 lists the overall incidence of 
systemic adverse events. 
Table 7.4: Incidence of systemic solicited adverse events during the day of vaccination and 
each of the consecutive four days after the first, second and third vaccination 
 
Unsolicited symptoms were reported by 58 (57·4%) subjects receiving HBAI20 vaccine and 
by 18 (56·3%) subjects receiving HBVaxPro®-10µg, p = 0·210. Six (5·9%) individuals in 
the HBAI20 group and four (12·5%) individuals in the HBVaxPro®-10µg had increased 
alanine aminotransferase values (> ULN) after intervention, p = 0·220. There were 10 cases 
with signs of asymptomatic urinary tract infection, all in healthy non-pregnant women 
receiving HBAI20 vaccine; this number was zero in those receiving HBVaxPro®-10µg 
vaccine, p = 0·250. No medically significant abnormalities were observed in haematological, 
renal and thyroid parameters. Two serious adverse events were reported during the study 
period, one in the HBAI20 group (i.e. hernia nuclei pulposi) and one in the HBVaxPro®-






(n = 1,345 days) 
HBVaxPro©-10µg 
(n = 435 days) 
P  Value 
Fever Any 10 (0·7%) 2 (0·5%) 0·771 
Severe 1 (0·1%) 1 (0·2%) 0·985 
Headache Any 89 (6·6%) 25 (5·7%) 0·595 
Severe 0 (0·0%) 1 (0·2%) 0·552 
Fatigue Any 142 (10·6%) 42 (9·7%) 0·655 
Severe 2 (0·1%) 0 (0·0%) 1·000 
Vomiting Any 1 (0·1%) 1 (0·2%) 0·985 
Severe 0 (0·0%) 0 (0·0%) ·· 
Diarrhoea Any 28 (2·1%) 4 (0·9%) 0·168 
Severe 0 (0·0%) 0 (0·0%) ·· 
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DISCUSSION 
Hepatitis B vaccine non-responders, i.e. individuals with a deficient antibody response after 
three or more vaccinations, represent an unresolved problem in hepatitis B vaccination.103 
In order to reach hepatitis B elimination by 2030 as advocated by the World Health 
Organization, it is important to establish protective anti-HBs levels also in hepatitis B vaccine 
non-responders, who represent 5 – 10% of the vaccinated adult population.14, 94, 103 
This phase 2 trial demonstrated that immunogenicity of the investigational HBAI20 vaccine 
was superior to that of the licensed HBVaxPro®-10µg vaccine, when given to hepatitis B 
vaccine non-responders at 0, 1- and 2-months schedule. Safety was comparable between 
both vaccines.  
Seroprotection rates in our comparator arm HBVaxPro®-10µg were higher compared to 
previous studies.93, 96-99 Previous studies enrolling hepatitis B vaccine non-responders have 
found that the first revaccination dose with a licensed hepatitis B vaccine induced 
seroprotection in 25 – 58% of the individuals, with seroprotection reaching 50 – 69% after 
three revaccination doses.93, 96-99 In our study, three revaccinations with HBVaxPro®-10µg 
induced protective anti-HBs levels in 79% of the non-responders. These variations can be 
explained by the use of different licensed vaccines (e.g. Engerix-B®, Recombivax HB®) 
and distinct study populations with different definitions of non-responder.102, 213, 214   
The primary endpoint of this study was met: compared to HBVaxPro®-10µg, subjects 
receiving HBAI20 vaccine were about 3·5 times more likely to be seroprotected around 1 – 
3 months following the last vaccination. The observed seroprotection rates after three 
vacccinations with HBAI20 vaccine was 92%, which is higher than expected in this 
population of hepatitis B vaccine non-responders. Moreover, seroprotection rates after two 
doses of HBAI20 vaccine were comparable to those attained after three doses of the licensed 
HBVaxPro®-10µg vaccine in this healthy non-responder population. It would be worth to 
investigate HBAI20 vaccine in HBV naive travellers to intermediate or high HBV endemic 
areas and those with high-risk behaviour (e.g. injecting drug users,  persons with multiple 
sex partners, men who have sex with men, and sex workers), whether  an accelerated 




172 | Chapter 7 
 
One should acknowledge that the difference in seroprotection between both vaccines in this 
study is only linked with the adjuvant AI20.244 AI20 is a cytokine-based adjuvant consisting 
of 20µg recombinant human IL-2 attached to 20µg aluminium hydroxide.216, 244 IL-2 is 
critical in promoting generation of T helper 1 (Th1) and Th2 cells, while IL-2 also improves 
dendritic cell-mediated stimulation of allogeneic CD4 T cell proliferation.226, 231, 232, 244, 251 
Taking into account the additional immunogenic properties of the AI20 adjuvant, it might 
be reasonable to consider the AI20 adjuvant for other vaccines conferring a suboptimal 
response, such as for influenza or tuberculosis vaccines. Moreover, the use of cytokines as 
adjuvants can support the rational design of vaccines by targeting specific immune 
pathways. 
Safety data from this phase 2 study indicate comparable rates of systemic solicited adverse 
events, unsolicited symptoms and serious adverse events, except for significantly higher 
rates of local adverse events within the HBAI20 group.  The majority of the adverse events 
resolved within five days and only a few adverse events were reported as severe. The higher 
incidence of local adverse events could mainly be attributed to pain at the injection site 
which was reported by 33% in HBAI20 group and 19% in HBVaxPro®-10µg group, 
respectively, and was similar to those reported in previous studies with adjuvanted hepatitis 
B vaccines.97, 98 With respect to local adverse events, we could also show greater immunity, 
i.e. seroprotection, in those participants with pain at the injection site in the HBAI20 group. 
Further research is warranted whether the presence of pain at the injection site is associated 
with more attraction of innate cells to the inoculum and subsequent higher seroprotection 
rate. 
CONCLUSIONS 
In conclusion, these results are suggestive of increased immunogenicity of the HBAI20 
vaccine among healthy non-responders to three or more hepatitis B vaccinations, in addition 
to confirming that the HBAI20 vaccine could be safely administered. These results support 
further studies to assess the benefits of the HBAI20 vaccine in other risk groups for a 
suboptimal immune response, i.e. patients with advanced liver disease, haemodialysis 
patients, and patients with other immunodeficient conditions. 
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GENERAL DISCUSSION 
Europe is one of the regions committed to the global goal of eliminating viral hepatitis B as 
a  major public health threat by 2030, i.e. 90% reduction in annual incidence and a 65% 
decrease in annual viral hepatitis B-related deaths.14 With a focus on the past, the present 
and future directions in HBV infection and control, this thesis partakes in this path to 
eliminate hepatitis B in Europe. 
HEPATITIS B DISEASE PROGRESSION 
In chapter 1 we aspired to understand the disease progression of Caucasian patients in the 
HBeAg-negative chronic infection phase (previously termed ‘inactive carrier’) with the aim 
to precise the management for chronic HBV infection. In fact, much of the data upon which 
the management of this infection phase is based has been derived from past studies in Asia. 
7, 59, 109-119 Considering the fact that sensitive PCR-based HBV DNA assays only became 
available the last decade, the long-term (10 years or more) disease outcome of Caucasian 
patients in Europe with HBeAg-negative chronic infection, particularly those with baseline 
HBV DNA level > 2,000 IU/mL, is unclear. Our study showed that the estimated 10-year 
risk of progression to chronic active hepatitis in patients with baseline HBV DNA level < 
2,000 IU/mL was significantly lower (1.2%) than those patients with baseline HBV DNA 
level > 2,000 IU/mL (11.7%). Advanced liver disease developed in 2.2% with higher 
probability in patients with HBV DNA level > 2,000 IU/mL (5.2%) in those with HBV DNA > 
2,000 IU/mL vs 1.5% in those with HBV DNA < 2,000 IU/mL). In conclusion, Caucasian 
patients living in Europe with a HBV DNA level < 2,000 IU/mL have an excellent long-term 
prognosis and can therefore be considered as true inactive carriers, challenging the need of 
a strict long-term follow-up by a hepatologist in these patients. On the other hand, patients 
with HBV DNA level > 2,000 IU/mL are at risk for advanced liver disease and need regular 
specialized follow-up. According to international practice guidelines on hepatitis B, this 
subgroup with HBV DNA levels > 2,000 IU/mL should be assessed with ALT determination 
every 3 months for 1 year and subsequently every 6 months in the absence of treatment 
indication.7, 59, 65 Patients with HBeAg-negative chronic infection should also be monitored 
with periodical determinations of HBV DNA levels as well as for liver fibrosis severity by non-
invasive methods.7, 59, 65 
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HEPATITIS B EPIDEMIOLOGY 
Along with a better understanding of disease progression in patients with chronic HBV 
infection, progress towards hepatitis B elimination in Europe will depend on the extent to 
which countries are able to elucidate the true extent of the hepatitis B disease burden. 
Accordingly, in chapter 2 we determined the present acute hepatitis B notification rates 
and in chapter 3 we assessed the current prevalence of chronic HBV infection in Belgium. 
Recent data on acute hepatitis B notification rates and prevalence of chronic HBV infection 
were available for the neighbouring countries (i.e. the Netherlands, France and Germany), 
but prior data on hepatitis B notification rates in Belgium could not distinguish between acute 
or chronic, and the last prevalence study in the general Belgian population dated from 
2003.44, 76-78, 131 
In our study on acute hepatitis B notification rates (chapter 2), we collaborated with the 
Agency for Care and Health, Flanders, Belgium. Before 2009, a differentiation between acute 
or chronic HBV infection was not possible. Accordingly, we collected information between 
2009 and 2017 since from that time only acute hepatitis B was reported to the Agency for 
Care and Health. In line with findings in other European countries, we showed a decreasing 
trend of acute hepatitis B notification rates in Flanders from 1.6 per 100,000 population in 
2009 to 0.7 in 2017.44 The downward trend in 5 – 14 year-olds, 15 – 24 year-olds and 25 
– 34 year-olds in our study might be explained by the universal infant vaccination with a 
temporarily catch-up vaccination for the age cohort 10 – 13 years, which has been 
implemented since 1999 in Flanders. A decrease in the acute hepatitis B notification rates 
for the age group > 35 years could not be explained by universal infant hepatitis B 
vaccination but might be clarified by targeted vaccination and health attitudes of specific 
adult patient groups (e.g. haemophilia patients), employees who have an occupational risk 
for HBV infection, travellers to HBV endemic countries and certain HBV risk groups (e.g. 
men who have sex with men). Besides reported vaccination uptake in sex workers, health 
care workers, travellers to HBV endemic countries and pregnant women, there are no recent 
studies assessing the uptake of vaccination in other adult groups in Belgium (e.g. men who 
have sex with men) which is howbeit warranted to further evaluate hepatitis B infection and 
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Belgium has a national hepatitis C plan, but a national strategy addressing hepatitis B is at 
present nonexistent. Neighbouring countries, i.e. the Netherlands, France and Germany, 
are – among others – one of the few European countries to implement a comprehensive 
viral hepatitis policy for prevention and control including hepatitis B.252-254  
Despite the recommendation of hepatitis B screening in pregnant women in Belgium and 
the reported high effectiveness of hepatitis B vaccination and immunoglobulins in preventing 
mother-to-child transmission, five mother-to-child infections were documented during study 
follow-up.137, 158  Infants who become infected perinatally have a 80 – 90% likelihood of 
developing chronic HBV infection if the mother is positive for hepatitis B e antigen, 
highlighting the need to strengthen the hepatitis B registration for pregnant women.30, 129  
As part of the European Vaccine Action Plan 2015 – 2020, the WHO European Region 
pledged to prioritize the control of hepatitis B through vaccination. The target for hepatitis B 
are as follows: (1) > 95% coverage with the three or four doses of hepatitis B vaccine within 
the universal infant vaccination program, (2) > 90% coverage with screening in pregnant 
women, (3) > 90% birth-dose vaccination coverage within 24 hours of birth and (4) HBsAg 
prevalence < 0.5% among vaccinated children.256 For the first target, the coverage with 
four doses hepatitis B vaccine was 92.9% in 2016, Flanders, Belgium.142 The HBsAg 
prevalence among the vaccinated cohort in Belgium was 0.2%, thereby attaining the fourth 
target of the European Vaccine Action Plan 2015 - 2020.134 For the second and third target, 
it is currently unknown how many pregnant women are actually screened for HBV infection 
and how many infants from infected mothers receive the timely birth dose vaccination in 
Belgium. A national electronic database for the recording of HBV markers in pregnant 
women, such as Praeventis in the Netherlands, is therefore desired in Belgium.257 Process 
evaluation on the data from Praeventis in the Netherlands indicated that >99% of the 
pregnant women were screened for HBV infection between the year 2009 – 2015.258 The 
implementation of an electronic registry database for pregnant women in Belgium with 
subsequent process evaluation could identify gaps in current HBV prevention and control. 
Aside from acute hepatitis B notification rates in chapter 2, chapter 3 described the 
present hepatitis B prevalence of chronic HBV infection in a multi-ethnic region situated in 
Middle-Limburg, Belgium, year 2017. In this study, we found an overall HBsAg prevalence 
of 1.0% in the emergency department population. Previous population-based studies in 
Belgium, one in 1993 – 1994 and one in 2003, indicated a lower HBsAg prevalence of 0.7% 
in the general population.130, 131 A concern is that the emergency department population in 
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our study might impose a bias towards subjects in certain risk groups. However, high risk 
groups for HBV infection might have been underrepresented in the previous population-
based studies.130, 131  Moreover, the inclusion of specific HBV risk groups in our study allowed 
us to demonstrate the most important risk factors for HBV infection in Belgium for the first 
time: age-gender-ethnicity interaction, presence of HBV infected household member, 
hepatitis C virus infection, men who have sex with men, and haemodialysis. Although we 
established the association between abovementioned characteristics and HBV infection, we 
could not accurately estimate the HBsAg prevalence in the different risk groups due to low 
numbers in each risk group. This was outside the scope of the current study. It is therefore 
warranted to conduct new epidemiological studies also in HBV risk groups, such as men who 
have sex with men and prisoners, in order to obtain complete figures for Belgium.  
Discrepancy in HBsAg prevalence in our study population in relation to previous population-
based studies could also be explained by the large immigrant population in Middle-Limburg, 
i.e. 21.0% in contrast to 8.0% in Flanders (Limburg in cijfers, personal communication). In 
this respect, we found a high HBsAg prevalence (4.7%) in first-generation migrants (FGMs) 
born in intermediate- or high-prevalence areas, highlighting the fact that migrants are an 
important group at risk for HBV infection and therefore national HBV screening in this group 
is warranted.167, 168 In line with our findings, compared to the native population a higher 
HBsAg prevalence was found in FGMs living in neighbouring countries such as the 
Netherlands, France and Germany.76, 77, 154  
HEPATITIS B SCREENING 
Surveillance data show that more than 50% of chronic HBV patients in Belgium were born 
in intermediate- or high-prevalence countries.79 In the Netherlands, Ireland, Sweden and 
Cyprus, migrants from intermediate or high endemic countries even contribute up to > 90% 
of the total chronic HBV cases.79 The difference between Belgium and the Netherlands in 
relative contribution of foreign-born migrants to the total chronic HBV population could be 
explained by the higher HBsAg prevalence among native Belgians (0.4-1.2%) compared to 
native Dutch (0.1 – 0.2%) individuals, which subsequently might be a reflection of variations 
in prevention and control strategies between both countries.79  Modelling studies further 
established that screening migrants for HBV infection is likely to be clinically effective and 
cost-effective.74, 75, 259, 260 However, most hepatitis B screening studies in FGMs involved 
southeast Asians in the USA, Canada and Australia.81-90 Less is known about Turkish 
migrants in Belgium, especially those born in Belgium with a foreign-born parent, i.e. 
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second-generation migrants (SGMs). Henceforth, in chapter 4, we described a study 
protocol for an outreach hepatitis B screening program in the Turkish migrant population 
(FGMs and SGMs), Middle-Limburg. The results from this outreach hepatitis B testing 
campaign were consecutively depicted in chapter 5.  
Focus group discussions with Turkish delegates in Middle Limburg suggested several socio-
cultural, religious and other factors to be important for hepatitis B screening. These were – 
among others – the belief of being responsible for one’s own health, association of HBV 
infection with high-risk sexual behaviour and little knowledge about hepatitis B. Our findings 
with respect to determinants of screening are supported by other researchers in the field of 
cancer screening as well as hepatitis B screening.181, 261-264 We therefore developed a flyer 
and poster to increase the awareness regarding hepatitis B and to emphasize the benefits 
of screening in order to motivate the Turkish population to opt for HBV screening. The 
information was made available in the Dutch and Turkish language. Key figures of Turkish 
organizations were also engaged in the outreach hepatitis B testing as they were to invite 
the Turkish population for educational sessions using flyers and posters. Educational 
sessions in Turkish organizations were to be coordinated after traditional meetings and the 
Turkish participants would subsequently have the opportunity to be screened for HBV 
infection.  
In our outreach hepatitis B program, increasing awareness of the Turkish migrant population 
might explain the high participation rate (97%) and the high referral to the hepatologist 
(90%) in case of newly diagnosed HBsAg positive patients.81 While we did not evaluate 
changes in knowledge, earlier studies suggest that using the target population’s language 
and engaging community leaders – as was the case in our study – are important in 
improving awareness of viral hepatitis.81, 84   Collaborations with general practitioners and 
other health care professionals are also crucial as it increases referral numbers and 
adherence to follow-up.81, 265 In that respect, our study was communicated with the general 
practitioners in the pre-screening phase as well as during and after the conduct of the 
community-based hepatitis B testing. The study was also embedded within Limburg Clinical 
Research Center (LCRC) with a close collaboration between the two hospitals in Middle 
Limburg, i.e. Hospital East-Limburg (ZOL) and Jessa Hospital, and the University Hasselt.  
With a HBsAg prevalence of 3.0% in Turkish FGMs in our study, we confirmed previous 
findings of 3.0 – 5.0% HBsAg positivity in studies conducted in the Netherlands and 
Germany.184, 185 Although the high HBsAg prevalence in Turkish FGMs reflects the hepatitis 
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B endemicity in the country of origin, our finding of 1.5% HBsAg positivity in Turkish SGM 
is higher than that found in the native Belgian population (0.7%) and might be explained 
by the combination of intermediate hepatitis B prevalence in Turkey and suboptimal primary 
prevention strategies in the country of birth, i.e. Belgium.80, 130-132, 193 First, all Turkish SGM 
with chronic HBV infection were born before the recommendation of hepatitis B screening 
in pregnant women in Belgium in 1998.191 Second, all of the seven HBsAg positive SGMs 
were born before 1999, the year universal infant vaccination with catch-up of one age cohort 
10 – 13 year-olds was implemented in Belgium. However, although catch-up vaccination of 
adolescents in Belgium should also cover birth cohorts between 1987 and 1999, one out of 
seven SGMs with chronic HBV infection in our study belonged to one of these birth cohorts. 
An explanation for this could be sought in the reported high coverage rates in the birth 
cohorts targeted by the Belgian vaccination program (after 1999 and 1987–1989) with a 
clear dip in between (1990 – 1998).134 Moreover, in birth cohorts targeted by catch-up 
vaccination in adolescents (1987 – 1998), prior Belgian studies indicated lower 
immunisation coverage rates when the mother was born outside of Western Europe.144, 194 
Thus, our study adds interesting data to support national HBV screening in Turkish FGMs 
and emphasizes the importance of further research on HBV prevalence in SGMs not covered 
by primary prevention strategies. 
All Turkish participants who ought to be susceptible for HBV infection were asked by letter 
to contact their general practitioner for initiation of hepatitis B vaccination. In our study, 
general practitioners were also informed of the hepatitis B screening result by letter. 
However, only 20% of the susceptible individuals initiated hepatitis B vaccination in our 
study, which is lower than the expected 52 – 89% among migrant populations in the USA 
but in line with an outreach screening project among Chinese migrants in the Netherlands 
reporting a vaccination uptake of 22%.81, 83, 200-204 These differences could be attributed to 
different migrant populations, costs for vaccination and different contact approaches to 
invite for vaccination.  
When assuming an HBsAg prevalence of 2.6 – 5.3% in the Turkish FGMs, a participation 
rate of 30%, a linkage to care of 80% and a HBeAg-negative chronic infection state in 90% 
of HBsAg positive patients, a community-based HBsAg testing and subsequent treatment 
in Turkish FGMs within a European health system would be cost-effective.49 Even in the 
situation of low participation rate (10%) and low linkage to care (60%), HBsAg screening 
and early antiviral treatment would still be cost-effective according to Suijkerbuijk and 
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colleagues.49 HBsAg screening and treatment in FGMs dominated the strategy of adding 
vaccination to all susceptible migrants in two studies conducted in Canada and one study 
from USA with the majority of migrants being Asian and African.266-268 The approach of 
screening all migrants for anti-HBs and vaccination was furthermore not cost-effective in 
the three studies.266-268 Nonetheless, when screening for HBsAg and anti-HBs was offered 
to close contacts of HBsAg positive patients and vaccinated if needed, it was associated with 
more gained quality-adjusted life years (QALY) and only a little increase in costs compared 
to screen and treat strategy (39,903 dollars/QALY vs 36,088 dollars/QALY).266 In the 
absence of cost-effectiveness studies of vaccination in migrants within the European health 
system, we call for a European cost-effective analysis of three strategies compared to no 
HBV screening in FGMs: 1) screen and treat strategy, 2) screen, treat and vaccinate close 
contacts if needed and 3) screen, treat and vaccinate all. 
Along with our outreach hepatitis B testing in the Turkish migrant population, large-scale 
trials in USA, Asia and Europe demonstrated the feasibility of community-based hepatitis B 
screening.83, 169, 185, 200, 202-204, 269-273 Although testing in community setting is more resource 
intensive than testing in health care setting, scaling up community based interventions could 
screen patients who may not otherwise reach the health care system and these 
interventions could decrease the hepatitis B disease burden in Europe.274  
UNRESOLVED PROBLEM IN HEPATITIS B VACCINATION  
Since the introduction of recombinant hepatitis B vaccines in 1986, over 1,000 million doses 
have been given and these vaccines have been proven to be safe. However, non-response 
(anti-HBs titre < 10 mIU/mL) to primary hepatitis B vaccination schedule occurs in 5 – 12% 
of the healthy people.93-95  Persons with this deficient antibody response are called non-
responders and remain an unresolved problem in hepatitis B vaccination in order to reach 
hepatitis B elimination. As the currently recombinant hepatitis B vaccines all have an 
aluminium-based adjuvant, we attempted to increase the immune response by combining 
the current recombinant HBVaxPro©-10 μg vaccine with a new cytokine-based adjuvant 
AI20. The new AI20 adjuvant consists of IL-2 (20 μg) adsorbed to aluminium-hydroxide 
(20 μg). This new combined vaccine is called HBAI20 hepatitis B vaccine and seemed safe 
according to the phase 1 study in healthy naïve adults and non-responders as described in 
chapter 6. Moreover, seroprotection was achieved in 90% of the healthy non-responders. 
The number of healthy naïve adults (n = 24) and healthy non-responders (n = 10) was 
small in this phase 1 study. Subsequently, in a well-designed double-blinded, randomised, 
 
184 | General discussion 
 
controlled phase 2 trial in healthy non-responders (n = 133) we further assessed the 
immunogenicity and safety of the new HBAI20 hepatitis B vaccine compared to the 
recombinant HBVaxPro©-10 μg vaccine. As shown in chapter 7, next to confirming safety 
of the HBAI20 vaccine, the results of the phase 2 study demonstrated increased 
immunogenicity of the HBAI20 vaccine compared to the recombinant HBVaxPro©-10 μg 
vaccine when given at a 0, 1 and 2 months schedule in healthy non-responders. These 
results support future studies on the immunogenicity and safety of HBAI20 vaccine in other 
persons who are at an increased risk of a deficient immune response to hepatitis B 
vaccination, e.g. transplant recipients and haemodialysis patients. Moreover, our finding of 
comparable seroprotection rates after two doses of HBAI20 vaccine with three doses of 
HBVaxPro©-10 μg vaccine highlights the need to investigate whether HBAI20 vaccines 
could provide an accelerated antibody response in individuals with high-risk at HBV infection, 
e.g. injecting drug users and men who have sex with men. Since the increased 
immunogenicity of HBAI20 vaccine compared to HBVaxPro©-10 μg vaccine is only linked 
to the new adjuvant AI20, it is also worth to investigate the benefits of adding this new AI20 
adjuvant to other vaccines conferring a suboptimal immune response, such as for influenza 
or tuberculosis vaccine.  
Although vaccine hesitancy, i.e. delay in acceptance or refusal of vaccination, is a global 
problem impairing the success of vaccination programs, vaccine hesitancy in hepatitis B 
naïve and non-responder population was not systematically assessed in the current 
thesis.279 Determinants of vaccine hesitancy could be arranged in three categories according 
to the Strategic Advisory Group of Experts (SAGE) on immunization: contextual influences 
(e.g. media environment), individual and group influences (e.g. knowledge/awareness), 
and vaccine-specific issues (e.g. risk/benefit, costs).280 In view of risk-benefit relations, 
knowledge/awareness and religion/culture/gender/socio-economic factors being the three 
main reasons for vaccine hesitancy across the globe, we presume that vaccine hesitancy is 
less prevalent among our study population of healthcare workers compared to the general 
adult population.280 An important first step to address vaccine hesitancy is active listening 
and understanding the reasons why an individual is hesitant. Once there is more information 
available about what is motivating vaccine hesitancy, one should engage accordingly. On a 
community level, online platforms or the engagement of local figures were found to increase 
positive impressions on vaccination programs and reduce misperceptions.281 
 
   General discussion | 185  
 
CONCLUSION 
In this thesis, we focused on the past, present and future directions of HBV infection and 
control in Europe. First, we illustrated that using the cut-off HBV DNA value of < 2,000 
IU/mL in Caucasian patients from Western Europe with HBeAg-negative chronic infection 
truly identified patients with a favourable long-term prognosis.  Second, we determined 
present estimates on acute hepatitis B notification rates and prevalence of chronic HBV 
infection in Belgium. Although recent data were available for the neighbouring countries, 
this information was nonexistent for Belgium. Third, focusing on the Turkish migrant 
population in Belgium, we provided data on the necessity of a national screening program 
in Europe for migrants from intermediate or high endemic countries, in addition to showing 
the feasibility of a community-based screening. Lastly, we demonstrated future directions 
for a new potent adjuvanted HBAI20 hepatitis B vaccine.  
FUTURE WORK 
Along with the contribution of new data on HBV infection and control in Europe, this thesis 
identified gaps in the systematic collection and monitoring of data related to prevention, e.g. 
number of pregnant women screened for HBV infection and timely birth dose vaccination in 
children from HBsAg positive mothers. Systematic data collection for the different steps 
along the cascade of care are also required at the level of the Agencies and Federal 
Government in Belgium. We further await the results from the recent population-based 
hepatitis B and C prevalence study conducted in Belgium by Sciensano. Moreover, while the 
number of new HBV infections have declined as a result of the implementation of a universal 
hepatitis B vaccination program in most European countries, large-scale interventions aimed 
to identify and treat those already infected (e.g. migrants from intermediate or high endemic 
country) are still necessary to achieve a 65% reduction in viral hepatitis B-related mortality 
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SUMMARY 
An estimated 257 million people are chronically infected with the hepatitis B virus (HBV), a 
disease that could manifest as none/minimal to severe inflammation of the liver. Patients 
with chronic HBV infection are mostly asymptomatic until severe complications develop, 
such as cirrhosis and hepatocellular carcinoma.  Due to the asymptomatic nature of the 
disease, there is a considerable underdiagnosis of chronic HBV infection. This is a missed 
opportunity since diagnosis and subsequent early antiviral treatment could reduce the risk 
of cirrhosis and hepatocellular carcinoma. The numbers of hepatitis B-related deaths 
worldwide further show an increase from 520 thousand deaths in 1990 to 690 thousand in 
2013. This number is 36 thousand for the European region. The World Health Organization, 
an organisation aiming at promoting public health, has called action towards the elimination 
of hepatitis B by 2030. The current thesis is embedded within these goals and strives 
towards elimination of HBV infection in Europe.  
Inactive carriership, i.e. a chronic HBV infection phase with none/minimal liver inflammation, 
was previously defined on a maximum viral load of 20,000 units in the blood, i.e. HBV DNA 
< 20,000 IU/mL. However, in chapter 1 we illustrated that those patients with a viral load 
below 2,000 IU/mL are the true inactive carriers with an excellent long-term prognosis and 
could be followed by the general practitioner. In contrast, patients with a viral load between 
2,000 and 20,000 have a higher risk of advanced liver disease and are therefore in need of 
regular specialized follow-up.  
Besides reviewing the natural history of chronic HBV infection, we determined the current 
hepatitis B burden in Belgium (chapter 2 and chapter 3). Recent data on hepatitis B were 
available for the neighbouring countries the Netherlands, France and Germany. In line with 
other European countries, a declining trend of new hepatitis B cases were found in Belgium. 
While hepatitis B vaccination induces a decrease in the number of new cases, it has no 
impact on the number of individuals already infected with HBV infection. Accordingly it is of 
importance to diagnose and treat the undiagnosed patients with chronic HBV infection. In 
chapter 3, we tested the emergency department population of Ziekenhuis Oost-Limburg for 
HBV infection and showed that 1 out of 100 individuals was already infected with chronic 
HBV infection. Individuals born in countries endemic for hepatitis B (e.g. Middle-East, Africa) 
had a higher risk of chronic HBV infection, namely 4.5 out of 100, compared to only 0.7 out 
of 100 individuals born in Belgium. 
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In chapter 4 we described a protocol for hepatitis B testing in the Turkish community living 
in Belgium. Turkey is a country with a high prevalence for HBV infection and it is estimated 
that approximately 92 thousand Turkish individuals with chronic HBV infection live in 
Europe. The results from this study are found in chapter 5. In conclusion, we showed that 
3 out of 100 individuals born in Turkey had chronic HBV infection. This number was 
comparable to the country of origin, i.e. Turkey. Interestingly, we found that individuals born 
in Belgium with Turkish parents also had an increased risk of chronic HBV infection, namely 
2 out of 100. This could be attributed to a combination of 1) hepatitis B endemicity in country 
of origin, i.e. Turkey, and 2) inadequate prevention strategies in country of birth, i.e. 
Belgium. 
Lastly, in chapter 6 and 7 we analysed a promising new HBAI20 hepatitis B vaccine. The 
new HBAI20 vaccine contributed to a higher seroprotection rate when compared to the 
standard hepatitis B vaccine, although safety was comparable. These studies were 
conducted in healthy hepatitis B vaccine non-responders, i.e. individuals with inadequate 
immune response after primary hepatitis B vaccination schedule. The future directions of 
the new HBAI20 hepatitis B vaccine should subsequently be assessed in other groups at risk 
of suboptimal immune response after hepatitis B vaccination (e.g. patients with renal 
insufficiency, transplant recipients). 
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SAMENVATTING 
Naar schatting zijn er wereldwijd 257 miljoen mensen met een chronische hepatitis B virus 
infectie. Deze ziekte veroorzaakt door het hepatitis B virus kan zich manifesteren als 
geen/minimale tot agressieve ontsteking van de lever. Een patiënt met chronische hepatitis 
B virus infectie heeft meestal geen klachten totdat er sprake is van ernstige 
leverbeschadiging of leverkanker. De diagnose van hepatitis B virus infectie wordt dan ook 
regelmatig over het hoofd gezien. Dit is echter een gemiste kans omdat vroegtijdige 
behandeling van hepatitis B het risico op ernstige leverbeschadiging en leverkanker 
aanzienlijk kan doen dalen. We merken dit ook aan het aantal doden door chronische 
hepatitis B virus infectie. Cijfers wereldwijd tonen namelijk aan dat het aantal doden door 
chronische hepatitis B virus infectie is gestegen van 520 duizend doden in 1990 naar 690 
duizend in 2013. Dit aantal is 36 duizend voor de regio Europa. De 
Wereldgezondheidsorganisatie, een organisatie met als doel de gezondheid van de 
wereldbevolking te bevorderen, heeft dan ook opgeroepen om hepatitis B te elimineren in 
2030. De huidige thesis ondersteunt deze doelstellingen met wetenschappelijke 
onderbouwing en streeft naar eliminatie van hepatitis B virus infectie in Europa.  
Inactieve dragerschap (een vorm van chronische hepatitis B virus infectie met 
geen/minimale leverontsteking) werd vroeger gedefinieerd op basis van een maximum 
hoeveelheid virus in het bloed van 20,000 eenheden. In hoofdstuk 1 tonen wij echter aan 
dat patiënten met een hoeveelheid van < 2,000 viruseenheden in het bloed echte inactieve 
dragers zijn met een zeer lage kans op ernstige gevolgen door chronische hepatitis B virus 
infectie. Deze patiënten zouden dan ook opgevolgd kunnen worden door de huisarts. 
Anderzijds lopen patiënten met een hoeveelheid van 2,000 – 20,000 viruseenheden in het 
bloed een degelijk risico op ernstige beschadiging van de lever en hebben regelmatig 
gespecialiseerde opvolging nodig.  
Naast de herbeoordeling van het natuurlijk beloop van chronische hepatitis B virus infectie, 
hebben we in hoofdstuk 2 en 3 de huidige situatie in België beoordeeld. Recente informatie 
rond hepatitis B was wel beschikbaar voor de naburige landen Nederland, Frankrijk en 
Duitsland. In lijn met de rest van Europa, zagen we een daling van het aantal nieuwe 
gevallen van hepatitis B in België. Ondanks dat hepatitis B vaccinatie het aantal nieuwe 
gevallen van hepatitis B virus infectie kan doen dalen, heeft vaccinatie geen effect op het 
aantal personen die reeds geïnfecteerd zijn met het hepatitis B virus. Het is dan ook 
belangrijk om te achterhalen hoeveel mensen reeds geïnfecteerd zijn met het hepatitis B 
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virus, opdat vroegtijdige behandeling gestart kan worden. In de afwezigheid van recente 
gegevens in België, hebben we in 2017 alle patiënten in de spoedgevallen Ziekenhuis Oost-
Limburg getest op hepatitis B (hoofdstuk 3). Hieruit bleek dat 1 op de 100 individuen 
geïnfecteerd was met het hepatitis B virus. Mensen die geboren waren in een land waar 
hepatitis B vaker voorkomt (vb. Midden-Oosten, Afrika) hadden een hogere risico op 
chronische hepatitis B virus infectie, namelijk 4.5 op de 100, in vergelijking met 0.7 op de 
100 individuen geboren in België. 
In hoofdstuk 4 beschreven we de opzet van een studie om de Turkse bevolking in België 
buiten het ziekenhuis te testen op hepatitis B virus infectie. Turkije is namelijk een land waar 
chronische hepatitis B virus infectie vaak voorkomt. De resultaten van deze studie hebben 
we vermeld onder hoofdstuk 5. Samenvattend toonden wij aan dat 3 op de 100 individuen 
geboren in Turkije een chronische hepatitis B virus infectie hadden. Dit getal was 
vergelijkbaar met dat van de algemene bevolking in Turkije. Verrassend vonden we dat 
individuen geboren in België met Turkse ouders ook een verhoogd risico hadden op 
chronische hepatitis B virus infectie, namelijk 2 op de 100. Dit zou te wijten kunnen zijn aan 
de combinatie 1) verhoogd risico van hepatitis B virus infectie in Turkije en 2) inadequate 
preventiestrategieën in België. 
Als laatste toonden wij in hoofdstuk 6 en 7 een beloftevolle nieuw HBAI20 hepatitis B vaccin. 
Het nieuw HBAI20 vaccin zorgde voor een grotere beschermingsgraad dan het standaard 
hepatitis B vaccin, terwijl de veiligheid vergelijkbaar was. Dit werd aangetoond bij gezonde 
hepatitis B vaccin non-responders. Non-responders zijn personen die geen beschermende 
antilichamen hebben gevormd na een primair hepatitis B vaccinatieschema. Aangezien wij 
enkel gekeken hebben naar de rol van het nieuw HBAI20 vaccin bij gezonde non-
responders, dient de toekomstmogelijkheden van dit nieuw vaccin ook verder bekeken te 
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ÖZET  
Hepatit B virüs enfeksiyonu karaciğerde hepatit B virüsünden dolayı oluşan bir 
iltihaplanmadır. Bu hepatit B virüs enfeksiyonu dünyada olagelen ve sıkça görülen 
enfeksiyon hastalıkları arasında ilk başta gelen ve ölümcüldür. Dünya Sağlık Organizasyonu 
tahminlerine göre,  dünyada aşağı yukarı 257 milyon insan uzun süreli (diğer adıyla kronik) 
hepatit B virüs enfeksiyonu ile yaşamaktadır. Hepatit B hastalıkların genelde hiçbir uyarı 
işareti ya da semptom göstermeden, siroz (karaciğerde ciddi yaralanma)  ve  karaciğer 
kanserine ilerliyebilir. Bu nedenle hepatit B virüs enfeksiyonu çoğunlukla geç teşhis edilir. Bu 
kaçırılmış bir fırsattır çünkü hepatit B virüs enfeksiyonun başlangıç evresinde ve zamanında 
tedavi müdahalesi sunumuyla siroz ve karaciğer kanseri oluşması engellenebilmektedir. 
Bunu, kronik hepatit B virüs enfeksiyonundan kaynaklanan ölüm sayısı ile de fark ediyoruz. 
Dünya çapındaki rakamlar, kronik hepatit B virüs enfeksiyonundan ölümlerin sayısının 
1990'da 520.000'den 2013'te 690.000'e yükseldiğini göstermektedir. Avrupa bölgesi için bu 
sayı 36 bindir. Bu nedenle, Dünya Sağlık Organizasyonu 2030 yılına kadar hepatit B'nin 
ortadan kaldırılması çağrısında bulundu. Mevcut tez, bu hedefleri bilimsel kanıtlarla 
desteklemekte ve Avrupa'da hepatit B virüs enfeksiyonunu ortadan kaldırmayı 
amaçlamaktadır. 
Kronik infeksiyon klinik seyri açısından ikiye ayrılır. Çoğu kişide virüs vücutta olmasına 
rağmen, çoğalma yeteneği çok sınırlıdır ve karaciğer hasarı yapamayacak düzeydedir. Bu 
kişilerdeki durum "İnaktif Taşıyıcılık" olarak adlandırılır. Taşıyıcılık önceden virüs miktarı 
maksimum 20.000 ünitenin dayanarak tanımlanmıştı. Bölüm 1'de, kanda <2.000 virüs 
birimi olan hastaların gerçek inaktif taşıyıcılar olduğunu gösteriyoruz. Bu hastalar ev doktor 
tarafından izlenebilinir. Öte yandan, kanda 2.000 - 20.000 virüs ünitesi olan hastalar, 
karaciğerde ciddi hasar riski taşır ve düzenli olarak özel hekim tarafından takip gerektirir. 
Kronik hepatit B virüs enfeksiyonunun doğal seyrini değerlendirmenin yanında, Bölüm 2 ve 
3'te Belçika'daki mevcut hepatit B durumu değerlendirdik. Hepatit B ile ilgili son bilgiler 
Hollanda, Fransa ve Almanya komşu ülkeleri için mevcuttu. Avrupa'nın geri kalanına paralel 
olarak, Belçika'daki yeni hepatit B vakalarının sayısında bir azalma gördük. Hepatit B aşısı, 
yeni hepatit B virüs enfeksiyonu vakalarının sayısını azaltabilmesine rağmen, hepatit B virüs 
ile enfekte olan insan sayısı üzerinde aşılamanın hiçbir etkisi yoktur. Bu nedenle, kaç kişinin 
hepatit B virüs ile enfekte olduğunu bulmak önemlidir, böylece erken tedaviye başlanabilir. 
Belçika'da son verilerin yokluğunda, 2017 yılında Ziekenhuis Oost-Limburg hastanesindeki 
tüm acil hastaları hepatit B açısından test ettik (bölüm 3). Her 100 kişiden birine hepatit B 
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virüsü bulaştığını gösterdik. Hepatit B'nin daha yaygın olduğu bir ülkede doğan insanlar 
(örneğin, Orta Doğu, Afrika), Belçika'da doğan 100 kişiden 0.7'sine kıyasla, kronik hepatit B 
virüsü enfeksiyonu riski 100'den 4.5'e, daha yüksek bir riske sahipti. 
4. bölümde, Türk popülasyonunu hastane dışında hepatit B virüs enfeksiyonu açısından test 
etmek için bir çalışma tasarladık. Türkiye, kronik hepatit B virüs enfeksiyonunun sıklıkla 
meydana geldiği bir ülkedir. Bu çalışmanın sonuçlarını bölüm 5'te bildirdik. Özetle, Türkiye'de 
doğan her 100 kişiden 3'ünde kronik hepatit B virüs enfeksiyonu olduğunu gösterdik. Bu 
rakam Türkiye'deki genel nüfus ile karşılaştırılabilir düzeydeydi. Şaşırtıcı olan, ikinci nesil 
Türklerdede kronik hepatit B virüs enfeksiyonun riski yüksek olmasıdır (100'de 2). Bunun 
nedeni,  Belçika'daki önleme ve kontrol programı yetersiz olmasıdır. 
Son olarak, 6'ıncı ve 7'ıncı bölümde yeni bir HBAI20 hepatit B aşı hakkında bilgi veriyoruz. 
Standart hepatit B aşısıyla karşılaştırıldığında, HBAI20 hepatit B aşısı daha yüksek bir 
koruma seviyesi sağladığını görüyoruz. Bu sonuç standart hepatit B aşıya yanıt 
vermeyenlerde görülmüstür. Yeni aşının etkisi sadece sağlıklı kişilerde araştırılmıştır. 
Böylece, gelecekte yeni aşının faydaları hasta olan kişilerdede araştırılmasi önerilir (örneğin 
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IMPACT PARAGRAPH  
Europe has a considerable burden of viral hepatitis B with 13.3 million people with chronic 
(i.e. long-term) HBV infection.12 Since HBV infection predominantly affects men and women 
of working age, eliminating hepatitis B as a public health problem will not only benefit the 
individual and health system, but also the economy and business sectors.4 With a focus on 
the past, the present and future directions in HBV infection and control, this thesis supports 
the elimination of hepatitis B in Europe by substantiating scientific evidence. 
HEPATITIS B DISEASE PROGRESSION 
Patients with chronic HBV infection can be divided in four phases based on hepatitis B viral 
markers in blood.7, 59, 65 One of these phases is the inactive carrier phase, i.e. HBeAg-negative 
chronic infection phase. This phase is characterized by none/minimal liver inflammation and 
low viral load in the blood (i.e. < 20,000 units).   
With the introduction of sensitive laboratory detection methods in the last decade, it is now 
possible to differentiate patients with HBeAg-negative chronic infection into those with a 
viral load below 2,000 units versus those patients with a viral load between 2,000 and 
20,000 units. The long-term outcome of the subgroup of patients with a viral load between 
2,000 and 20,000 units/mL is less clear and mainly assessed in the Asian population.36, 39 
Subsequently, this thesis determined the risk of advanced liver disease progression in 
Caucasian patients with HBeAg-negative chronic infection and a viral load below 2,000 units 
versus those patients with a viral load between 2,000 and 20,000 units.  
In chapter 1, we illustrated that patients with a viral load below 2,000 units have an 
excellent long-term prognosis and accordingly they are no candidates for antiviral 
treatment.7, 59, 65 In contrast, patients with a viral load between 2,000 and 20,000 have a 
higher risk of advanced liver disease.  
These results could be of particular interest for general practitioners and specialist 
physicians. Based on regional cooperation agreements, one could suggest the follow-up of 
patients with a viral load below < 2,000 units by general practitioners while those patients 
with a viral load between 2,000 and 20,000 units are still in need of continued follow-up by 
specialist physicians. Follow-up in primary care should be conducted by a general 
practitioner with sufficient knowledge on hepatitis B management and close collaboration 
with specialist physician is invariably warranted, through the identification of their respective 
tasks.282  
 
196 | Impact paragraph 
 
HEPATITIS B EPIDEMIOLOGY 
Europe is one of the regions struggling to combat the viral hepatitis B pandemic, but the 
exact size of the problem remains unclear to adequately inform prevention strategies. 
Recent estimates on acute (i.e. new) and chronic (i.e. long-term) HBV infections among the 
general population are therefore necessary. These data were not available for Belgium, while 
recent information on HBV infection was available for neighbouring countries, i.e. the 
Netherlands, France and Germany.44, 76-78, 131 In chapter 2 and 3, we provided respectively 
the recent estimates for acute and chronic HBV infections in Belgium. In line with findings 
in other European countries, acute HBV infections per 100,000 population decreased from 
1.6 in 2009 to 0.7 in 2017, Flanders, Belgium.44 In our study conducted in 2017, the 
proportion of chronic HBV infection among the general population in Middle-Limburg 
Belgium was low (<2%), namely 1.0%.  
The decrease in acute HBV infection rates over the period 2009 to 2017 could in part be 
explained by the universal hepatitis B vaccination in Belgium vaccinating all infants since 
1999. In chapter 2, we also identified opportunities for improvement. We observed higher 
acute HBV infection rates among adults, there was a rise in the number of MSM over the 
period 2009 to 2017 and five mother-to-child infections were reported despite the 
recommendation of hepatitis B screening in pregnant women in Belgium.137, 158   
In contrast to neighbouring countries such as the Netherlands, France and Germany, to date 
no national hepatitis B strategy has been issued in Belgium to adequately eliminate hepatitis 
B by 2030 as advocated by the WHO. Accordingly, we call for the organization of a national 
hepatitis B plan in Belgium with the inclusion of action points concerning vaccination and 
identification of infected individuals. A national plan should be prepared conjointly by groups 
involved in the prevention and management of HBV infection in Belgium (e.g. Sciensano, 
general practitioners, gastroenterologists). An indispensable action point is the 
establishment of a uniform multidisciplinary registration system for HBV infection with 
subsequent yearly monitoring by involved parties (e.g. Sciensano, Belgian Association for 
the Study of the Liver (BASL), Vlaamse Vereniging voor Gastroenterologie (VVGE), Société 
Royale Belge de Gastroentérologie (SRBGE)). The collection of data should make a 
difference between acute, chronic and unknown HBV status in line with the 
recommendations of the European Centre for Disease Prevention and Control (ECDC).255 
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HEPATITIS B SCREENING  
In chapter 3, we noted a higher proportion of chronic HBV infection among FGMs compared 
to native Belgians. However, there is currently no national hepatitis B screening program 
targeted at FGMs. 
Considering the silent nature of chronic HBV infection until development of serious 
complications, there is an important role for HBV vaccination (primary prevention) and 
screening with subsequent early antiviral treatment (secondary prevention).41 HBV infection 
can cause acute and chronic hepatitis and subsequently life threatening liver complications, 
including cirrhosis (i.e. a late stage of liver scarring, annual risk of 1.6 – 9.7%) and HCC 
(0.1 – 0.6%).7, 59, 65 Liver transplantation is indicated in patients with cirrhosis and HCC in 
whom liver transplantation would extend the normal life expectancy.283 According to a 
European healthcare system, the annual medical management costs for compensated 
cirrhosis, decompensated cirrhosis, HCC and liver transplantation were estimated at €2,035, 
€7,068, €15,600 and €125,000, respectively.75  
To illustrate the priority, feasibility and acceptability of hepatitis B screening and vaccination 
in migrant populations, we conducted a screening program in the Turkish migrant 
population living in Middle-Limburg. The results of this campaign were depicted in chapter 
5. In our study, the proportion of chronic HBV infection among first-generation Turkish 
migrants was 3.0%, underlying the priority of screening in this population as screening for 
HBV is likely to be cost-effective in populations with a prevalence > 2.0%.49, 284 Two studies 
in USA found that HBV screening might even be effective in groups with a lower prevalence, 
namely > 0.3%.268, 284 Moreover, with a participation rate of >95% and linkage to care of 
>90%, our community-based approach was feasible and acceptable in this migrant group. 
As depicted in chapter 4, the high participation rate and high linkage to care of hepatitis B 
screening program might be explained through the preceding identification of motivating 
factors for hepatitis B virus screening during focus group discussions. 
Within a national hepatitis B strategy, combining hepatitis B testing in primary care, hospital 
and community-based setting may lead to a higher coverage of HBV diagnosis as well as a 
higher coverage of HBV treatment.  Utilization of electronic medical record reminders in 
primary care and health care setting may further increase HBV screening rates.275 In 
primary care, checking liver blood tests is another opportunity to diagnose liver problems 
(including HBV infection) and treat liver disease at an early stage.276  However, it was 
previously demonstrated that only 50% of abnormal liver blood tests were ever followed up 
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in patients seen in primary care.11, 277 In a study conducted in the United Kingdom,  an 
automated system was developed that investigated abnormal liver blood tests to generate 
a probable diagnosis. This system was further integrated into the laboratory management 
system and was able to substantially increase the diagnostic yield of abnormal liver blood 
tests.276 Efforts are currently being made to assess the feasibility of an electronic medical 
record reminder and automated liver blood test system in primary care, Belgium.  
Although our community-based hepatitis B screening program among the Turkish 
population in Middle Limburg used venipuncture for HBsAg testing, it has been shown that 
finger stick blood point-of-care testing could increase HBsAg testing rates.278 Finger stick 
blood tests should therefore be used in the community-based setting. Considering the 
attained experiences on regional outreach screening programs in Limburg, the next step is 
to set up a nationwide hepatitis B community-based screening program among migrants 
identifying legal and ethical challenges during development 
UNRESOLVED PROBLEM IN HEPATITIS B VACCINATION 
Globally, the introduction of hepatitis B vaccination has dramatically reduced the number of 
chronic HBV infection in children under 5 years from 4.7% in the 1990s to 1.3% in 2015, 
thereby preventing 4.5 million infections each year.256, 285 The implementation of a universal 
infant hepatitis B immunization program in 48 of the 53 WHO European countries has 
contributed to this worldwide decline in HBV infections by reaching a prevalence of chronic 
HBV infection of 0.4% in children under 5 years, thus achieving one of the targets of the 
European Vaccine Action Plan 2015 – 2020.254 
In spite of the abovementioned progress with hepatitis B vaccination, more is needed to 
eliminate hepatitis B. Five to 12% of the general adult population do not achieve adequate 
immune response (anti-HBs <10 mIU/mL) after completion of the primary hepatitis B 
vaccination schedule and are referred to as non-responders.96-100 Hepatitis B vaccine non-
responders remain susceptible for HBV infection and its complications, and are an 
unresolved problem in hepatitis B vaccination.243 The standard of care for non-responders 
consists of revaccination with currently licensed hepatitis B vaccines in a 0, 1, 6 months 
schedule or a schedule of two doses followed by another two doses after 2 months, which 
is associated with a seroprotection rate of approximately 50 – 69%.96-100 Thus, there 
appears to be a need for a more immunogenic hepatitis B vaccine. 
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We tried to enhance the immune response to currently licensed hepatitis B vaccines by 
adding a cytokine-based adjuvant. The new HBAI20 is a combination of the licensed 
HBVaxPro®-10µg vaccine and the AI20 adjuvant, containing 20 μg recombinant human IL-
2 adsorbed to 20 μg aluminium hydroxide. In the phase 1 study (chapter 6), the new 
HBAI20 vaccine seemed safe and well-tolerated among healthy naïve individuals and 
healthy non-responders. The phase 2 trial (chapter 7) further demonstrated superior 
immunogenicity of the HBAI20 vaccine compared to that of the licensed HBVaxPro®-10µg 
vaccine in healthy non-responders, in addition to confirming that the HBAI20 vaccine could 
be safely administered. 
The benefits of higher protection with HBAI20 vaccine among healthy non-responders as 
compared to the licensed HBVaxPro®-10µg vaccine are only linked to the AI20 adjuvant 
and make this an important option for HBV prevention. In the interest of licensing the AI20 
adjuvant, more randomized clinical trials would be necessary to further determine the 
effectiveness on HBV prevention, assess adverse events and increase the evidence. Aside 
from the healthy non-responding population, the results from chapter 6 & 7 support 
further studies to assess the benefits and harms of the HBAI20 vaccine in 
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voor mij. Dr. Annemie Forier, dank om de data van Agentschap Zorg en Gezondheid ter 
beschikking te stellen. 
Ik wil alle vrijwilligers bedanken voor hun hulp bij de hepatitis B studie bij de Turkse 
bevolking: dank aan mijn tweelingbroer Baris (arts), mijn goede vriend Ugur (arts), 
aangetrouwd familielid Özcan (verpleegkundige), Songül (verpleegkundige), Zeliha 
(verpleegkundige), Ceyda (verpleegkundige), Zeynep Akdag (verpleegkundige), mijn 
vrouw Kübra, mijn moeder Fatma, mijn zus Eylem, mijn goede vrienden Senol, Nazim, 
Koray, Muhammet, Ayber en mijn goede vriendinnen Zeynep Topçu, Sevgi en Sinem . Met 
sommigen van jullie heb ik zelfs tot laat in de avond (22u00) gewerkt aan dit project. Klinkt 
krankzinnig maar we waren een hechte en leuke groep! Natuurlijk was dit project niet 
mogelijk zonder de focusgroep discussies met de Turkse vertegenwoordigers van de vier 
moskeeën in Midden Limburg (Waterschei, Winterslag, Kolderbos en Sledderlo) en twee 
Turkse verantwoordelijken van het gemeentehuis. Arkan abi bedankt om de Turkse tekst 
in te spreken bij onze korte film rond hepatitis B. Vanuit ZOL en Universiteit Hasselt hadden 
we jullie nog graag willen bedanken met de beste keuken ter wereld, natuurlijk de Turkse! 
Er is wat vertraging maar als alles normaliseert, zullen we zeker samenkomen om bij te 
praten en te genieten van de Turkse gerechten!!!! 
Ik wil ook de tijd nemen om Lisa Castelli en Jurgen Ritzen (communicatie ZOL) te bedanken 
voor het opstellen van de flyers, posters en korte films die onmisbaar waren bij het 
communiceren van dit hepatitis B project met de Turkse bevolking. Ook ZOL labo verdient 
waardering voor hun bereidheid om naast hun dagelijks klinisch werk duizenden bloedstalen 
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te analyseren voor onderzoek. Ik verstoorde hun dagelijkse werkzaamheden namelijk niet 
enkel met de studie hepatitis B bij de Turkse bevolking maar ook met de projecten hepatitis 
B bij spoedgevallen en fase 2 HBAI20 vaccin studie. 
De fase 2 HBAI20 vaccin studie was van een zeer hoge kwaliteit om de werkzaamheid en 
veiligheid van het nieuw HBAI20 vaccin te beoordelen. Met kwaliteit komt echter ook 
complexiteit. Hiervoor kon ik gelukkig rekenen op de hulp van verschillende mensen. Jorge, 
we were very lucky to have you as a study coordinator arranging the many documents 
needed to initiate, conduct and close the study. You made it seem so easy! I learned a lot 
from you as an investigator. Thank you so much! Mohannad, you arrived in the last year of 
the study and I admire your commitment to be able to practice your profession again as a 
medical doctor in the Netherlands after leaving Syria. Your commitment is contagious. Keep 
up the good work! Deze studie was niet mogelijk zonder de zorgvuldige uitvoering van het 
onderzoek door het personeel van Ease Travel Clinic & Health Support (Maastricht, 
Nederland), de afdeling Gastroenterologie en Hepatologie (Genk, België) en het Centrum 
voor de Evaluatie van Vaccinaties (Antwerp, België). Ook dank aan Monique Rutten, Antoon 
de Schryver, Marienoelle Schmickler, Annemie Cattrysse, Vincent Moermans, Christel 
Schabon, Hans van der Krans, Jana Kalenda voor het uitnodigen van de hepatitis B vaccin 
nonresponders. 
Dank aan Helene Piccard, Leen Willems, Sophie Indestege en iedereen die onderzoek 
binnen LCRC mogelijk maakt. Ik kon jullie altijd laagdrempelig bereiken in verband met mijn 
vele vragen rond contracten en joint PhD. Sorry dat ik ook steeds jullie allen in cc zette als 
ik niet wist naar wie ik de mail moest richten. Veronique Pousset en Len Cuppens bedankt 
voor de begeleiding tot aan mijn PhD verdediging. 
Tevens wil ik alle MDL en Medische Microbiologie collega’s van het MUMC+ bedanken 
bestaande uit de artsen, arts-assistenten en (arts-)onderzoekers. Bedankt voor de prettige 
samenwerking. Ook hartelijk dank aan de gastro-enterologen binnen ZOL Genk en aan alle 
collega’s (doctoraatstudenten en onderzoekers) van het LCRC in de kelder van ZOL Genk. 
Aangezien ik afwisselend werkte in Maastricht en Genk was ik niet altijd mee met het 
gebeuren in de kelder en zorgde ik soms voor awkward late felicitaties.  
Verder wil ik uiteraard mijn familie bedanken. Anne, sana teşekkür ediyorum çünkü 
“karşılıksız, koşulsuz, şartsız sevmek” nedir bana öğreten ve yaşatan sensin. Senin için 
bulabileceğim en iyi kelimeler, seni tüm kalbimle sevdiğim! Canım babam. Ilk öğretmenim. 
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İyi bir yaşam sürmek için gereken her şeyi senden öğrendim. Her zaman orada olduğun için 
teşekkür ederim baba. Abla, ik ben geen slijmbal zoals Baris maar ik meende het toen ik op 
facebook zei dat jij de beste zus in de wereld bent. Baris, mijn eeneiige tweelingbroer. Al 
van in moeders buik zijn we onafscheidelijk. Nu ook in Maastricht UMC+. Ik ben enorm fier 
om te zeggen dat mijn tweelingbroer naast zijn opleiding tot specialist ook nog heel wat 
onderzoek doet. We moeten ook eens een onderzoek samen publiceren. Het wordt alleen 
lastig om een onderwerp te vinden dat past bij zowel Maag-Darm-Leverziekten en 
Orthopedie.  
Zonder ontspanning ook geen inspanning, dus dan ook maar eens bedankt aan alle 
vrienden! Hier hoeft geen verdere uitleg bij! 
Tenslotte, mijn askim, mijn Kübra the Explorer. Jij vult mij geweldig aan. Ik heb niet het 
geduld om een 3-weekse reis in extreme detail als jou uit te werken. Je bent een zeer goede 
reisplanner en reispartner. Wel voel ik me veiliger als ikzelf autorijd op drukke wegen of 
navigeer tijdens de ooooo zo lange wandelingen. Ik vind het ook geweldig hoe jij mij hebt 
kunnen transformeren in een instagram husband. Alhoewel ik in het begin van de relatie 
tegenstribbelde om foto’s van jou te nemen tijdens onze buitenlandse avonturen, geef ik nu 
zelfs advies om beter te poseren. Van de vele reisbestemmingen, vind ik echter het uitzicht 
op jou het mooist. I love all your perfect imperfections! 
 
